4th Schizophrenia International Research Society Conference

Fostering Collaboration in Schizophrenia Research

FLORENCE, ITALY
05 - 09 APRIL 2014

This meeting is jointly sponsored by the Vanderbilt University School of Medicine and the Schizophrenia International Research Society
Dear Attendees,

It is our great pleasure to welcome you to the 4th Biennial Schizophrenia International Research Society (SIRS) Conference. SIRS is a non-profit organization dedicated to promoting research and communication about schizophrenia among research scientists, clinicians, drug developers, and policy makers internationally. We sincerely appreciate your interest in the Society and in our conference. The third congress in 2012 was a major success for the field attracting more than 1600 attendees from 53 countries. We anticipate an even higher attendance at this congress with most of the best investigators in the world in attendance.

SIRS was founded in 2005 with the goal of bringing together scientists from around the world to exchange the latest advances in biological and psychosocial research in schizophrenia. The Society is dedicated to facilitating international collaboration to discover the causes of, and better treatments for, schizophrenia and related disorders. Part of the mission of the Society is to promote educational programs in order to effectively disseminate new research findings and to expedite the publication of new research on schizophrenia. In addition to the Biennial Congress, the Society will host the second regional meeting in Buenos Aires, Argentina in December of 2014.

Under the outstanding leadership of Program Committee Chairs, Anissa Abi-Dargham and Jonathan Rabinowitz, we have an exciting scientific program planned for the 4th Biennial Conference. The Program Committee selected thirty-five outstanding symposia session in addition to seven evening workshops out of ninety-two submissions. Special sessions including the Family Forum, Italian Research and Family Day and the Pharmaceutical Pipeline session have been added to the conference schedule. The Program Committee also selected forty-eight superior oral presentations from more than 1000 abstracts submitted. Plan to visit the poster sessions during lunch on Sunday, Monday and Tuesday.

Please remember to complete an evaluation at the end of the conference so the Society can continue to improve its educational offerings. If you are not already a member, please stop by the registration desk and inquire about member benefits and how to join. We hope you enjoy this conference and in addition to learning about the latest, cutting edge research in the field, you will enjoy the beautiful city of Florence and its rich history.

Sincerely,

The Organizers
John Kane, M.D., President
René Kahn, M.D., Ph.D., President-Elect
Robin Murray, M.D., Past-President
Lynn E. DeLisi, M.D., Secretary
Anthony Grace, Ph.D., Treasurer
Anissa Abi-Dargham, M.D., Program Committee Chair
Jonathan Rabinowitz, Ph.D., Program Committee Chair
General Information

Disclosures

Disclosures for 2014 speakers, plenary, special session, symposia, workshop, oral presentations and poster presenters may be found online at www.SchizophreniaConference.org. A copy of the disclosures will be available at the registration desk.

Acknowledgements

The Schizophrenia International Research Society appreciates the generous support of the Society from our 2013-2014 Supporting Corporations.

Gold

Lilly

Silver

Pfizer  FORUM PHARMACEUTICALS  SUNOVION  Alkermes

Educational Grants:
The Sponsors express appreciation to the following companies for their support of this educational activity by providing unrestricted educational grants:

Otsuka America Pharmaceutical, Inc.

The Junior Travel Award Fellowship Program is sponsored by an R13 grant from the U.S. National Institute of Mental Health to Harvard Medical School (Lynn DeLisi, PI) (Grant ED: R13MH082446).

Additional Supporters:
The Bowman Family Foundation

OFFICERS

John Kane M.D.
President

René Kahn M.D., Ph.D.
President-Elect

Lynn E. DeLisi M.D.
Secretary

Anthony Grace Ph.D.
Treasurer

BOARD OF DIRECTORS (2013-2014)

Jean Addington  Canada
Celso Arango  Spain
Geraldo Busatto  Brazil
John McGrath  Australia
Stephen Marder  USA
Jun Soo Kwon  Korea
Patrick McGorry  Australia
Herbert Meltzer  USA
Cynthia Shannon-Weickert  Australia
Xin Yu  China
Alison Yung  Australia

INCOMING OFFICERS:

René Kahn  The Netherlands, President
Patrick McGorry  Australia, President-Elect
Cynthia Shannon-Weickert  Australia, Secretary
Til Wykes  United Kingdom, Treasurer
John Kane  USA, Past-President

The Schizophrenia International Research Society appreciates the generous support of the Society from our 2013-2014 Supporting Corporations.

Educational Grants:
The Sponsors express appreciation to the following companies for their support of this educational activity by providing unrestricted educational grants:

Otsuka America Pharmaceutical, Inc.

The Junior Travel Award Fellowship Program is sponsored by an R13 grant from the U.S. National Institute of Mental Health to Harvard Medical School (Lynn DeLisi, PI) (Grant ED: R13MH082446).

Additional Supporters:
The Bowman Family Foundation
## INTERNATIONAL ADVISORY COUNCIL

<table>
<thead>
<tr>
<th>Name</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mary Cannon</td>
<td>Ireland</td>
</tr>
<tr>
<td>William Carpenter</td>
<td>USA</td>
</tr>
<tr>
<td>David Castle</td>
<td>Australia</td>
</tr>
<tr>
<td>Eric Chen</td>
<td>China</td>
</tr>
<tr>
<td>Slow Ann Chong</td>
<td>Singapore</td>
</tr>
<tr>
<td>Christina Dalman</td>
<td>Sweden</td>
</tr>
<tr>
<td>Paola Dazzan</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Robin Emsley</td>
<td>South Africa</td>
</tr>
<tr>
<td>Peter Falkai</td>
<td>Germany</td>
</tr>
<tr>
<td>Wolfgang Fleischhaker</td>
<td>Australia</td>
</tr>
<tr>
<td>Wagner Gattaz</td>
<td>Brazil</td>
</tr>
<tr>
<td>Birte Glenthoj</td>
<td>Denmark</td>
</tr>
<tr>
<td>Michael Green</td>
<td>USA</td>
</tr>
<tr>
<td>Kyung Sue Hong</td>
<td>Korea</td>
</tr>
<tr>
<td>Matti Huttunen</td>
<td>Finland</td>
</tr>
<tr>
<td>Richard Keefe</td>
<td>USA</td>
</tr>
<tr>
<td>Mario Maj</td>
<td>Italy</td>
</tr>
<tr>
<td>Philip McGuire</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Paulo Menezes</td>
<td>Brazil</td>
</tr>
<tr>
<td>Preben Mortensen</td>
<td>Denmark</td>
</tr>
<tr>
<td>Dieter Naber</td>
<td>Germany</td>
</tr>
<tr>
<td>Michael Owen</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Christos Pantelis</td>
<td>Australia</td>
</tr>
<tr>
<td>Sibylle Schwab</td>
<td>Germany</td>
</tr>
<tr>
<td>Cynthia Shannon-Weickert</td>
<td>Australia</td>
</tr>
<tr>
<td>Iris Sommer</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>Masatoshi Takeda</td>
<td>Japan</td>
</tr>
<tr>
<td>Carol Tammenga</td>
<td>USA</td>
</tr>
<tr>
<td>Rangaswamy Thara</td>
<td>India</td>
</tr>
<tr>
<td>Si Tianmei</td>
<td>China</td>
</tr>
<tr>
<td>Jim van Os</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>Dawn Velligan</td>
<td>USA</td>
</tr>
<tr>
<td>Antonio Vita</td>
<td>Italy</td>
</tr>
<tr>
<td>John Waddington</td>
<td>Ireland</td>
</tr>
<tr>
<td>Mark Weiser</td>
<td>Israel</td>
</tr>
<tr>
<td>Til Wykes</td>
<td>United Kingdom</td>
</tr>
</tbody>
</table>

## 2014 Meetings Committees

### CONGRATULATIONS TO THE 2014 TRAVEL FELLOWS

<table>
<thead>
<tr>
<th>Name</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Olukayode Abayomi</td>
<td>Nigeria</td>
</tr>
<tr>
<td>Davide Amato</td>
<td>Germany</td>
</tr>
<tr>
<td>Candace Bailey</td>
<td>USA</td>
</tr>
<tr>
<td>Byron Bitanahirwe</td>
<td>Switzerland</td>
</tr>
<tr>
<td>Lynniece Bowen</td>
<td>USA</td>
</tr>
<tr>
<td>Shimon Burstein</td>
<td>Israel</td>
</tr>
<tr>
<td>Alexis Cullen</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Montserrat Fuste</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Ana Herrmann</td>
<td>Brazil</td>
</tr>
<tr>
<td>Babak Khodae</td>
<td>Iran</td>
</tr>
<tr>
<td>Sanja Kilian</td>
<td>South Africa</td>
</tr>
<tr>
<td>Qortni Lang</td>
<td>USA</td>
</tr>
<tr>
<td>Elizabeth Manning</td>
<td>Australia</td>
</tr>
<tr>
<td>Raffael Massuda</td>
<td>Brazil</td>
</tr>
<tr>
<td>Roy Mathew</td>
<td>India</td>
</tr>
<tr>
<td>Yuya Mizuno</td>
<td>Japan</td>
</tr>
<tr>
<td>Milawiyya Nurjono</td>
<td>Singapore</td>
</tr>
<tr>
<td>Sarosh Sadiq</td>
<td>Pakistan</td>
</tr>
<tr>
<td>Tamara Sheinbaum</td>
<td>Spain</td>
</tr>
<tr>
<td>Venkataram Shivakumar</td>
<td>India</td>
</tr>
<tr>
<td>Nicholas Simon</td>
<td>USA</td>
</tr>
<tr>
<td>Anneliese Sperli-Staines</td>
<td>Australia</td>
</tr>
<tr>
<td>Srijit Suttajit</td>
<td>Thailand</td>
</tr>
<tr>
<td>Rafael Tapias</td>
<td>USA</td>
</tr>
<tr>
<td>Yi Wang</td>
<td>China</td>
</tr>
<tr>
<td>Sunali Wadhera</td>
<td>USA</td>
</tr>
<tr>
<td>Rebekah Wighton</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Sergey Yagoda</td>
<td>Russia</td>
</tr>
<tr>
<td>Yulia Zaytseva</td>
<td>Russia</td>
</tr>
</tbody>
</table>

### 2014 PROGRAM COMMITTEE

<table>
<thead>
<tr>
<th>Name</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lynn DeLisi</td>
<td>USA, CHAIR</td>
</tr>
<tr>
<td>Robin Emsley</td>
<td>South Africa</td>
</tr>
<tr>
<td>Dieter Naber</td>
<td>Germany</td>
</tr>
<tr>
<td>Larry Seidman</td>
<td>USA</td>
</tr>
<tr>
<td>Sibylle Schwab</td>
<td>Australia</td>
</tr>
<tr>
<td>Cynthia Shannon-Weickert</td>
<td>Australia</td>
</tr>
</tbody>
</table>

### 2014 PROGRAM COMMITTEE

<table>
<thead>
<tr>
<th>Name</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anissa Abi-Dargham</td>
<td>USA, CHAIR</td>
</tr>
<tr>
<td>Jonathan Rabinowitz</td>
<td>Israel</td>
</tr>
<tr>
<td>Dolores Malaspina</td>
<td>USA</td>
</tr>
<tr>
<td>Stephen Marder</td>
<td>USA</td>
</tr>
<tr>
<td>John McGrath</td>
<td>Australia</td>
</tr>
<tr>
<td>Igor Nenadic</td>
<td>Germany</td>
</tr>
<tr>
<td>Merete Nordentoft</td>
<td>Denmark</td>
</tr>
<tr>
<td>Maxine Patel</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Dan Rujescu</td>
<td>Germany</td>
</tr>
<tr>
<td>Patricio O’Donnell</td>
<td>USA</td>
</tr>
<tr>
<td>Marco Michael Picchioni</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Avi Reichenberg</td>
<td>USA</td>
</tr>
<tr>
<td>Nina Schooler</td>
<td>USA</td>
</tr>
<tr>
<td>Martha Shenton</td>
<td>USA</td>
</tr>
<tr>
<td>Iris Sommer</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>Daniel Umbricht</td>
<td>Switzerland</td>
</tr>
<tr>
<td>Sophia Vinogradov</td>
<td>USA</td>
</tr>
<tr>
<td>Neeltje E.M. Van Haren</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>Thomas Weickert</td>
<td>Australia</td>
</tr>
<tr>
<td>Mark Weiser</td>
<td>Israel</td>
</tr>
<tr>
<td>Robert Zipursky</td>
<td>Canada</td>
</tr>
</tbody>
</table>
General Information

The 4th Biennial Schizophrenia International Research Society Conference has been granted 24 European CME credits (ECMEC) by the European Accreditation Council for Continuing Medical Education (EACCME). Italian Ministry of Health Credits: The 4th Biennial Schizophrenia Research Conference has been accredited at the Italian Ministry of Health with ID Number 110-86354 for the following specialties: physicians (Psychiatry, Neurology, Pediatric Neuropsychiatry, Psychotherapy), Technicians for Psychiatric Rehabilitation, Psychology.

Conference Evaluation:
All conference attendees are urged to complete an evaluation of the meeting. Attendees who are requesting CME (ACME, EACCME) credit for the meeting are required to complete the evaluation. This form is available online only. You may complete the evaluation in the Computer Center or on-line at www.SchizophreniaConference.org. All evaluations must be completed by 9 May, 2014.

Videotaping Sessions:
Attendees may not videotape, audiotape, or photograph (camera or camera phone) presentations at the conference without prior permission from the session chair.

COURSE OBJECTIVES
After participating in the CME Activity, Clinicians should be able to describe and discuss:

- Strategies for determining an approach to manage patients with schizophrenia
- The status of genetic findings, and how they can be incorporated into strategies for managing patients with schizophrenia
- The use of brain imaging data about pathophysiology and disease progression to revise or continue a strategy for managing patients with schizophrenia
- The implications of basic neuroscience findings for managing patients with schizophrenia

After participating in the CME Activity, Researchers should be able to describe and discuss:

- Approaches to develop novel treatments for schizophrenia
- Strategies for translating basic neuroscience into knowledge that can be used in clinical practice
- Differences in schizophrenia research across diverse cultures and geographic areas
- Novel intervention studies that will promote the development of advanced knowledge about schizophrenia
- Methods to advance the clinical application of genetic research in schizophrenia

Disclosures:
It is the policy of Vanderbilt University School of Medicine and Schizophrenia International Research Society to require disclosure of financial relationships from individuals in a position to control the content of a CME activity, to identify and resolve conflicts of interest related to those relationships; and to make disclosure information available to the audience prior to the CME activity. Presenters are required to disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentations. Disclosures for 2014 speakers, plenary, special session, symposia, workshop, oral presentations and poster presenters may be found online at www.SchizophreniaConference.org. A copy of the disclosures will be available at the registration desk.

REGISTRATION
Registration for the 4th Biennial Schizophrenia International Research Society Conference is located at the Main Entrance of Firenze Fiera Congress Center, Piazza Adua.

DATE
Saturday, 05 April
Sunday, 06 April
Monday, 07 April
Tuesday, 08 April
Wednesday, 09 April

TIME
11:00 AM – 7:30 PM
8:00 AM – 6:30 PM
8:00 AM – 7:00 PM
8:00 AM – 8:30 PM
8:00 AM – 4:00 PM
REGISTRATION TYPES
Delegate: Scientific Attendee
Student: Full-time graduate students, medical students, or students in the first two years of a post-doctoral fellowship program at a university in a field relevant to schizophrenia research. A letter from the student’s immediate supervisor verifying his/her student status and relevant field will be required for registration.
Accompanying Guest: Non-scientific attendee who only attends social functions.

REGISTRATION TIME FRAMES
Regular: Register August 2013 – 12 March 2014
Late: Register 13 March 2014 – onsite

REGISTRATION FEES
Category Up to 12 March 2014 13 March or later
SIRS 2013 and 2014 Member 400.00€ 450.00€
SIRS 2014 New Member 440.00€ 490.00€
SIRS 2013 and 2014 Student Member 150.00€ 190.00€
SIRS 2014 New Student Member 190.00€ 240.00€
Non-Member Delegate 650.00€ 700.00€
Non-Member Student 230.00€ 280.00€
Accompanying Other 200.00€ 200.00€

ABSTRACTS
Abstracts for all presentations are available online at www.SchizophreniaConference.org.
Abstracts will be published electronically by Schizophrenia Research and will be available as an electronic flipbook and as a PDF document.

OPENING RECEPTION TICKET
60.00 €
Saturday, 05 April 07:00 PM - 09:00 PM

HONORIFIC AWARDS
The Awards Committee and Board of Directors of the Schizophrenia International Research Society are pleased to announce the Society’s Honorary Award Winners.

OUTSTANDING BASIC RESEARCH
Akira Sawa, M.D., Ph.D.
Dr. Sawa is a psychiatrist and neuroscientist. He is currently the Director of Johns Hopkins Schizophrenia Center and a Professor of Psychiatry, Mental Health, Neuroscience, and Institute of Genetic Medicine at Johns Hopkins Schools of Medicine and Public Health. The Johns Hopkins Schizophrenia Center aims better care and cure for schizophrenia and adult-onset major mental illness by organizing academic efforts on patient care, research, professional education, and public outreach in a good balanced manner. He also led NIH designated P50 Silvo O. Conte center grant at Johns Hopkins, which takes a multifaceted translational approach on the development and maturation of the cerebral cortex in association with the pathological trajectory of schizophrenia. In addition to these administrative leaderships, Dr. Sawa also runs his own research program on mental illness (Molecular Psychiatry Program at Johns Hopkins). The overall emphasis of Dr. Sawa’s academic activity is on how new discoveries can be efficiently delivered to the clinical setting and patient care from the global health viewpoint.

OUTSTANDING CLINICAL/COMMUNITY RESEARCH
Michael Foster Green, Ph.D.
Dr. Green is a Professor-in-Residence in the Department of Psychiatry and Biobehavioral Sciences and the Semel Institute for Neuroscience and Human Behavior at the Geffen School of Medicine at UCLA. He is Director of the Treatment Unit of the VA Desert Pacific Mental Illness Research, Education, and Clinical Center (MIRECC). Dr. Green obtained his B.A. in psychobiology at Oberlin College, his doctorate in neuropsychology at Cornell University, and his postdoctoral training in neuropsychology at UCLA. He is an associate editor for Schizophrenia Bulletin, on the editorial boards of several journals, including Cognitive Neuropsychiatry and Schizophrenia Research, and has authored over 250 journal articles. He has received numerous grants from the National Institute of Mental Health, the VA, and private foundations. His laboratory (greenlab.npjh.ucla.edu) has explored the relationship between cognitive impairments in schizophrenia and activities of daily living, as well as the neural mechanisms of cognitive and social cognitive dysfunction. Ongoing studies are evaluating social cognitive retraining and novel pharmacological interventions to improve cognitive impairment. He has written two books: Schizophrenia from a Neurocognitive Perspective: Probing the Impenetrable Darkness (1998), and Schizophrenia Revealed: From Neurons to Social Interactions (2001). Dr. Green has had leadership roles in several NIMH treatment development initiatives: he was Co-PI of the MATRICS Initiative, PI of the MATRICS-Psychometric and Standardization Study, and PI of the MATRICS-CT Validation of Intermediate Measures Study. He is a Fellow in the American College of Neuropsychopharmacology, a member of the work group for Psychotic Disorders for the 11th edition of the International Classification of Diseases (ICD), and past-president of the Society for Research in Psychopathology.
Oliver Howes, BM, BCh, MA, MRCPsych, PhD, DM

Oliver Howes is Group Head/Reader at the Institute of Psychiatry, London, and the MRC CSC Psychiatric Imaging Group, Imperial College, Hammersmith Hospital. His clinical work is as Consultant Psychiatrist at The Maudsley Hospital where, amongst other things, he runs a service for refractory psychoses. His research interests centre on the causes and treatment of psychosis. His recent work has focussed on characterising the dopaminergic system in the psychotic prodrome, the effects of antipsychotic drugs on the endocrine system, & the causes of cognitive impairment in schizophrenia. This work has been recognised through a number of awards including the European Psychiatric Association Biological Psychiatry Prize (2012), the Royal Society of Medicine Psychiatry Prize (2010), Royal College of Psychiatrists research prize (2005), the British Association of Psychopharmacology Clinical Psychopharmacology Prize (2007) and awards at the International Conference of Schizophrenia Research (2006), the European College of Neuropsychopharmacology (2008). He was made an honorary associate of the European College of Neuropsychopharmacology in 2006. Other career highlights include a stint as junior potato scrubber on a farm.

Distinguished Service Awards

LYNN E. DELISI, M.D.

Lynn E. DeLisi, MD, is currently an Attending Psychiatrist in the VA Boston Healthcare System and Professor of Psychiatry at Harvard Medical School. In addition, she is editor-in-chief and co-founder of the Elsevier journal, Schizophrenia Research. She was secretary, as well as co-founder, of two professional organizations: The Schizophrenia International Research Society (SIRS) and The International Society of Psychiatric Genetics (ISPG). She is also an active fellow of the American College of Neuropsychopharmacology. Her undergraduate degree is in zoology from The University of Wisconsin, Madison, Wisconsin. She obtained her M.D. degree from the Medical College of Pennsylvania and went on from there to do 3 years of general practice work with the migrant Chile farmers of Northern New Mexico. She completed a residency in psychiatry at Saint Elizabeth’s Hospital, Washington DC, and then went on to complete a post-doctoral fellowship and then remain as a full-time staff research psychiatrist in the NIMH intramural research program, at both St. Elizabeth’s Hospital and in Bethesda, Maryland. In 1987, she left NIMH to assume a professorship at The State University of New York at Stony Brook where she set up several research programs on the longitudinal biological outcome of schizophrenia, emphasizing both brain imaging and genetic studies. During this time, she was the first to conduct a longitudinal controlled MRI study that showed progressive brain change in schizophrenia and was a pioneer in developing an international collaboration for ascertainment of families with multiple members having schizophrenia to be used in molecular genetic studies. From 2001 through 2008, she was professor at New York University School of Medicine and Associate Director of the brain imaging division at The Nathan Kline Institute for Psychiatric Research where she contributed several studies on anomalies of language processing in people high risk for schizophrenia. She moved to her current position in the Boston area in January 2009 where she continues to focus her research on biological markers for high risk for schizophrenia.

HENRY A. NASRALLAH, M.D.

Dr. Henry Nasrallah is an internationally recognized neuropsychiatrist, educator and researcher. He received his BS and MD degrees at the American University of Beirut (AUB) whose Board of Trustees is located in New York. Following his psychiatric residency at the University of Rochester and post-residency neuropsychiatry fellowship at NIH, he served as a faculty member at the University of California at San Diego and the University of Iowa before assuming the chair of the Ohio State University Department of Psychiatry for twelve years. In 2003, following a research sabatical, he joined the University of Cincinnati College of Medicine as Associate Dean for Faculty Development and Professor of Psychiatry and Neurosciences, and also served as Vice-Chair for Education and Training in the Department of Psychiatry and behavioral neuroscience, overseeing 3 residencies, 4 fellowships, medical students education and the Neuroscience PhD Graduate Program. In October 2013, he joined Saint Louis University as the Sydney W. Souers Endowed Chair and Professor of Neurology and Psychiatry.

Dr. Nasrallah’s main research focus is the neurobiology and psychopharmacology of schizophrenia and related psychoses. He has published over 380 scientific articles, 440 abstracts, 135 editorials as well as 12 books. He is Editor-In-Chief of two peer-reviewed journals (Schizophrenia Research and Current Psychiatry) and is the co-founder, with Lynn Delisi, of the Schizophrenia International Research Society (SIRS) whose biannual meetings are now attended by over 1400 international researchers. He is board-certified in adult psychiatry. He is a Fellow of the American College of Neuropsychopharmacology (ACNP), Fellow of the American College of Psychiatrists (ACP), distinguished life Fellow of the American Psychiatric Association (APA), past President of the Cincinnati Psychiatric Society (CPS) and past president of the American Academy of Clinical Psychiatrists (AACP), and has served as the President of the Ohio Psychiatric Physicians Association / Education and Research Foundation (OPPA-ERF). He was elected President of the University of Cincinnati College of Medicine Faculty [comprised of over 1500 faculty members], Twice received the NAMI Exemplary Psychiatrist Award and was recognized as the U.S. Teacher of the Year by The Psychiatric Times. He also received the Golden Apple Teaching Excellence Award from the psychiatric residents at several universities. He received the highest research honor at Ohio State (Distinguished Scholar Award). He has received over 85 research grants from federal, industry and private foundations, and is listed in all editions of the book “Best Doctors in America”.

She has edited and authored over 300 books and manuscripts and aside from editing her own journal, serves on the editorial board of several other journals. Her book, 100 Questions and Answers about Schizophrenia: Painful Minds, about to be revised in a 3rd edition, has been circulated widely among families of people with schizophrenia and medical students internationally and has been translated into Japanese and Spanish, as well as other languages besides English. In her non-professional life she contributes to her local community of Lincoln, Massachusetts as a member of its Planning Board, and as an amateur photographer, and spends time with her partner, 2 adult children and 4 grandchildren.
General Information

**4th Schizophrenia International Research Society Conference**
Fostering Collaboration in Schizophrenia Research

**FINAL PROGRAM**
FLORENCE, ITALY
05 - 09 APRIL 2014

**AWARD COMMITTEE MEMBERS**

Philip Harvey  
USA, Chair

John Waddington  
Ireland, Co-Chair

Alessandro Bertolino  
Italy

Donald Linszen  
The Netherlands

Mary Cannon  
Ireland

Anthony David  
United Kingdom

Tilo T.J. Kircher  
Germany

Maxine Patel  
United Kingdom

Nina Schooler  
USA

Nadia Solowij  
Australia

**POSTER AWARDS**

_Cognitive Neuropsychiatry, Schizophrenia Bulletin, Schizophrenia Research_ will award poster prizes during the Closing Session on Wednesday, 09 April at 4:00 PM. The SIRS Awards Committee will collaborate with journal editors to select the awards recipients. All three journals require that researchers be less than 40 years of age at the time of the conference for consideration.

**NEW INVESTIGATOR ORIENTATION**

Saturday, 05 April, 3:45 PM – 5:45 PM  
Auditorium

All attendees are welcome to attend. Travel Awardees are required to attend.

3:45 - 4:45

_How To Successfully Publish Papers Panel_

Peter Buckley, Will Carpenter, Lynn DeLisi

4:45 - 5:45

_How To Successfully Obtain Funding Support Panel_

Robert McCarley (in USA) and Jim van Os (in Europe)

**Scientific Sessions**

Saturday, 05 April, 3:45 PM – 5:45 PM  
Auditorium

**How To Successfully Publish Papers Panel**

Peter Buckley, Will Carpenter, Lynn DeLisi

**How To Successfully Obtain Funding Support Panel**

Robert McCarley (in USA) and Jim van Os (in Europe)

**KEYNOTE LECTURE**

Saturday, 05 April, 6:00 PM – 7:00 PM  
Auditorium

_Road to Damascus: A Scientific Journey_

Huda Akil, Ph.D., is the Gardner Quarton Distinguished University Professor of Neuroscience and Psychiatry and the co-Director of the Molecular & Behavioral Neuroscience Institute (MBNI) at the University of Michigan. Dr. Akil together with Dr. Stanley J. Watson and their colleagues have made seminal contributions to the understanding of the brain biology of emotions, including pain, anxiety, depression and substance abuse. She and her collaborators provided the first physiological evidence for a role of endorphins in the brain, and showed that endorphins are activated by stress and cause pain inhibition.

Dr. Akil’s current research investigates the genetic, molecular and neural mechanisms underlying stress, addiction and mood disorders. Along with Dr. Watson, she is the Michigan Site Director of the Pritzker Consortium, which is engaged in large-scale studies to discover new genes and proteins that cause vulnerability to major depression and bipolar illness. She is the author of over 500 original scientific papers, and has been recognized as one of the most highly cited neuroscientists by the ISI Citation Index.

Dr. Akil’s scientific contributions have been recognized with numerous honors and awards. These include the Pacesetter Award from the National Institute on Drug Abuse in 1993 and the Pasarow Award (with S.J. Watson) for Neuroscience Research in 1994. In 1998, she received the Sachar Award from Columbia University, and the Bristol Myers Squibb Unrestricted Research Funds Award. She is also the recipient of the Society for Neuroscience Mika Salpeter Lifetime Achievement Award and the NARSAD Patricia Goldman-Rakic Prize for Cognitive Neuroscience (2007), the Koch Award from the American College of Neuropsychopharmacology (2010). She has shared with Dr. Stanley Watson the Thomas William Salmon Award in 2010, and the Institute of Medicine Sarnat Award in 2012. In 2013, she received Association of American Medical Colleges (AAMC) Award for Distinguished Research in the Biomedical Sciences.

In 1994, Dr. Akil was elected to the membership of the Institute of Medicine (IOM) of the National Academy of Science. She was elected as a Fellow of the American Association for the Advancement of Science in 2000. In 2004, she was elected to the American Academy of Arts and Sciences. In 2011, she was elected to the National Academy of Sciences.

Dr. Akil service includes membership of numerous boards and scientific councils. She has served on several national and international organizations to promote scientific and brain health awareness nationally and globally. She is the past President of the American College of Neuropsychopharmacology (1998) and the past President of the Society for Neuroscience (2004) the largest neuroscience organization in the world. She has co-chaired the Neuroscience Steering Committee for Biomarkers Development at the Foundation for the National Institute of Health; she has served two terms on the Council of the Institute of Medicine of the US National Academy of Sciences, and currently serves on the National Research Council (NRC) review board.
PLENARY SESSIONS

There will be four plenary sessions covering topics including new approaches on schizophrenia research, drug development, an update on therapeutics, and the clinical challenges of comorbid disorders.

Sunday, 06 April
Auditorium
8:30 AM – 12:00 PM

Impact of Genomics and Connectomics Approaches on Schizophrenia Research
Chairs: Lynn DeLisi and René Kahn

Genomics Panel
Pat Sullivan, University of North Carolina, Chapel Hill, USA
Jonathan Sebat, Cold Spring Harbor Laboratory, USA
Tiina Paunio, National Public Health Institute, Finland
Francis McMahon, National Institute of Mental Health, USA

Connectomics Panel
Ed Bullmore, University of Cambridge, United Kingdom
Deanna Barch, Washington University, USA
Holly Moore, Columbia University, USA

Monday, 07 April
Auditorium
8:30 AM – 12:00 PM

Behavioral and Imaging Translational Paradigms in Drug Development
Chair: Holly Moore

Novel Drug Targets and Translating Results from Animal Models into Humans: Insights Using the MAM Development Model
Anthony Grace

Negative Symptoms in Schizophrenia as a Target for Translation Research
Jim Gold

A Central Role of the Dopamine D2 Receptor in the Modulation of Motivation
Pierre Trifilieff

Translating Social Cognition and Social Neuroscience for Schizophrenia Research
Michael Green

Translational Paradigms for Social Cognition in Rodents and Non–Human Primates
Karen Bales

Neural Substrates of Abnormal Predictions and Rewards: Clinical and Preclinical fMRI Studies of Incentives and Surprises in Psychiatric Illness
Graham Murray

Tuesday, 08 April
Auditorium
8:30 AM – 12:00 PM

Update on Therapeutics: Improving the Clinical Yield
Chairs: John Kane and Richard Keefe

Sharpening the Signal in Cognitive Enhancement Trials
Richard Keefe

Preclinical and Clinical Evaluation of PDE10A Inhibition as a Treatment for Schizophrenia
Chris Schmidt

The Development of Pomaglumetad Methionil as a Glutamate-based Pharmacotherapy for Schizophrenia: Lesson Learned
Bruce Kinon

Challenges and Potential Solutions in Negative Symptom Trials
Daniel Umbricht

Power of Collaborations and Big Data in Advancing Drug Development: NewMeds and Beyond
Jonathan Rabinowitz
Wednesday, 09 April
Auditorium
8:30 AM – 12:00 PM

The Clinical Challenges of Comorbidity with Addiction and Somatic Disease
Chairs: Nick Stefanis and Mary Cannon (Substance Abuse)
Chairs: Robin Murray and John McGrath (Physical Disease)

Dopaminergic Dysfunction in Schizophrenia Comorbid with Substance Dependence
Anissa Abi-Dargham

Why is Treatment of People with Cannabis-Induced Psychosis so Unsuccessful?
Robin Murray

Methamphetamine Use and Schizophrenia:
A Population-Based Cohort Study in California
Russell Callaghan

Family-Based Study Examining Moderation of Familial Correlation in Psychotic Experiences by the Environment
Jim van Os

Obesity and Cardiovascular Disease in Schizophrenia
Christoph Correll

Epidemiological Studies of Somatic Co-Morbidity in Schizophrenia
Preben Mortensen

Understanding the Widening Gap in Schizophrenia Mortality through Electronic Medical Record Databases.
Rob Stewart

IMPaCTing Lifestyle Choice and Cardiovascular Risk in Psychosis
Fiona Gaughran

SPECIAL SESSIONS
Special sessions have been included in the conference program:

• The Italian Research and Family Day
  Saturday, 05 April, 10:00 AM – 5:15 PM, Sala Verde
  The day will be in English and is open and free to all attendees at the SIRS meeting and the general public (Italian and non-Italian alike). Those with experience of psychosis and their relatives are very welcome.

• Voices in My Head: Dom’s Story
  A video and discussion session about Dom’s schizophrenia diagnosis at age 10.
    Sunday, 06 April 1:00 PM - 2:00 PM
    Monday, 07 April 1:00 PM - 2:00 PM
    Tuesday, 08 April 1:00 PM - 2:00 PM

SYMPOSIA SESSIONS
The title and location of each symposium is indicated in the program. The presentations in each session are scheduled at approximately 20 – 25 minute intervals. A general discussion period is scheduled after the last presenter in each session.

Symposia are scheduled:

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday, 06 April</td>
<td>2:00 PM – 4:00 PM</td>
</tr>
<tr>
<td></td>
<td>4:15 PM – 6:15 PM</td>
</tr>
<tr>
<td>Monday, 07 April</td>
<td>2:00 PM – 4:00 PM</td>
</tr>
<tr>
<td></td>
<td>4:15 PM – 6:15 PM</td>
</tr>
<tr>
<td>Tuesday, 08 April</td>
<td>2:00 PM – 4:00 PM</td>
</tr>
<tr>
<td>Wednesday, 09 April</td>
<td>1:30 PM – 3:30 PM</td>
</tr>
</tbody>
</table>
WORKSHOPS
Six workshops have been scheduled on Tuesday evening from 6:30 PM – 8:30 PM. The title and location of each workshop is indicated in the program. The presentations within each session are scheduled at approximately 20 – 25 minute intervals. A general discussion period is scheduled after the last presentation within each workshop.

ORAL PRESENTATIONS
Six concurrent oral presentation session are scheduled on Tuesday, 08 April from 4:15 PM – 6:15 PM. Within the concurrent sessions, there are 8 individual presentations. Oral sessions scheduled:

Advances in Imaging in Schizophrenia I
Chair: Sophia Vinogradov

Advances in Imaging in Schizophrenia II
Chair: Alessandro Bertolino

Biomarkers
Chair: Cynthia Shannon-Weickert

Therapeutics
Chair: Robert Zipursky

Genetics and Epidemiology
Chair: Dan Rujescu

High Risk Research
Chair: Nina Schoeler

POSTERS
Three poster sessions have been scheduled. Presenters should put their poster up by 9:30 AM and remove the poster at 5:00 PM on the day it is scheduled. Poster presentations are grouped by general topic when possible. All three poster sessions are located in the Cavaniglia. Lunch will be served each day with the poster session. Poster viewing will be open until 5:00 PM. E-Posters are available for viewing online at www.SchizophreniaConference.org.

<table>
<thead>
<tr>
<th>Date</th>
<th>Session</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday, 06 April</td>
<td>Poster Session I</td>
<td>12:00 PM – 2:00 PM</td>
</tr>
<tr>
<td>Monday, 07 April</td>
<td>Poster Session II</td>
<td>12:00 PM – 2:00 PM</td>
</tr>
<tr>
<td>Tuesday, 08 April</td>
<td>Poster Session III</td>
<td>12:00 PM – 2:00 PM</td>
</tr>
</tbody>
</table>

FINAL PROGRAM
FLORENCE, ITALY
05 - 09 APRIL 2014

COMPUTER ACCESS
Complimentary wireless internet is available in the conference center. To access the wireless internet, input “SIRSCongress” as the username and “SIRS2014” as the password. Conference attendees may also use the Computer Center located in Limonaia.

The Computer Center is provided this year for the convenience of meeting attendees who wish not to bring a laptop. The Computer Center will be open the following hours:

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, 05 April</td>
<td>9:00 AM – 7:00 PM</td>
</tr>
<tr>
<td>Sunday, 06 April</td>
<td>7:30 AM – 6:30 PM</td>
</tr>
<tr>
<td>Monday, 07 April</td>
<td>7:30 AM – 6:30 PM</td>
</tr>
<tr>
<td>Tuesday, 08 April</td>
<td>7:30 AM – 6:30 PM</td>
</tr>
<tr>
<td>Wednesday, 09 April</td>
<td>7:30 AM – 4:30 PM</td>
</tr>
</tbody>
</table>

SPEAKER READY ROOM
A speaker ready room is available in Sala 103 in the Palazzo Congressi. All presenters are required to come to the speaker ready room to upload your presentation, preferably 24-hours prior to the presentation. Presentations from individual computers are not permitted. Below are the hours for the Speaker Ready Room:

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, 05 April</td>
<td>8:00 AM – 7:00 PM</td>
</tr>
<tr>
<td>Sunday, 06 April</td>
<td>7:30 AM – 7:00 PM</td>
</tr>
<tr>
<td>Monday, 07 April</td>
<td>7:30 AM – 7:00 PM</td>
</tr>
<tr>
<td>Tuesday, 08 April</td>
<td>7:30 AM – 8:00 PM</td>
</tr>
<tr>
<td>Wednesday, 09 April</td>
<td>7:30 AM – 3:30 PM</td>
</tr>
</tbody>
</table>

REFRESHMENT BREAKS
All registered individuals are invited. Coffee and light pastries are available Sunday through Wednesday mornings at 8:00 AM. The morning break will be located in the Passi Perduti, located outside the Auditorium.

Afternoon coffee/tea breaks will be available Saturday – Wednesday outside the Palazzo Affari meeting rooms, the Auditorium and the Sala Verde.

LUNCHEONS
Buffet lunch will be served Sunday through Tuesday from 12:00 PM – 2:00 PM in the Cavaniglia, Lower Floor during the poster sessions. Buffet lunch will be served on Wednesday from 12:00 PM – 1:30 PM in the Passi Perduti, located outside the Auditorium.
Concurrent Symposia, Oral Presentations and Special Sessions will be held on the Lower Level, Ground Level, First Level, Second Level of the Palazzo degli Affari.

The Computer Center will be located in the Limonaia building just between the Palazzo Degli Affari and the Villa Vittoria.

Poster Sessions and lunches will be held at the Fortezza da Basso in the Cavaniglia. This is a short 3 to 5 minute walk from the Palazzo de Congressi.
Keynote, Plenary Sessions and some Special Sessions, Symposia and Oral Presentations will be held in the Auditorium.

The Speaker Ready Room (Sala 103) and other small meeting rooms and committee meetings will be in the Villa Vittoria Building on the 1st Floor. The Villa Vittoria building is connected to the Auditorium. The Sala Verde room is on the 2nd floor of the Villa Vittoria building.

The Italian Research and Family Day, Symposia and Oral Presentations will be held in the Sala Verde.
### Scientific Sessions

**ABSTRACT:**
This satellite meeting builds on a very successful similar day at the last SIRS meeting. It provides the opportunity to all attendees, and to all those interested in mental illness, to hear the best of Italian Research into Schizophrenia, both from those Italian research scientists now working in other countries and those carrying out research in major Italian Centres.

We will hear of how the incidence of schizophrenia appears surprisingly low in different centres in Italy, of the relative importance in Italy and elsewhere of risk factors for schizophrenia such as child abuse, immigration and drug abuse (including novel internet drugs). We will also hear how imaging can predict outcome of psychosis and how it reflects genetic predisposition.

The afternoon will include sessions on the ways in which relatives are involved in care of people with psychosis in Italy. The day will close with a panel of very distinguished clinicians from across the globe discussing the merits and demerits of the care offered to people with schizophrenia in their respective countries.

The day will be in English and is open and free to all attendees at the SIRS meeting and the general public (Italian and non-Italian alike). Those with experience of psychosis and their relatives are very welcome.

### THE CONTRIBUTION OF THE ITALIAN DIASPORA TO RESEARCH ON PSYCHOSIS

**Chairs:** Robin Murray and Jim van Os

**COFFEE BREAK**

**THE STATE OF THE ART: ITALIAN RESEARCH ON PSYCHOSIS – I**

**Chairs:** John McGrath and Anita Reicher-Rossler

**LUNCH**
THE STATE OF THE ART: ITALIAN RESEARCH ON PSYCHOSIS – II 1:45 PM - 2:45 PM
Chairs: Mirella Ruggeri and Robin Murray

COFFEE BREAK 2:45 PM - 3:15 PM

THE VIEW OF FAMILIES AND PATIENTS 3:15 PM - 4:00 PM
Chairs: Silvana Galderisi and Jean-Paul Selten

IS IT BETTER TO HAVE SCHIZOPHRENIA IN ITALY, UK, USA, AUSTRALIA OR BRAZIL? 4:05 PM - 5:15 PM
Chairs: Lynn Delisi and John Kane

SPECIAL SESSION – New Investigator Orientation 3:45 PM - 5:45 PM
Location: Auditorium
Travel Awardees are required to attend

HOW TO SUCCESSFULLY PUBLISH PAPERS 3:45 PM - 4:45 PM
Peter Buckley, Lynn DeLisi

HOW TO SUCCESSFULLY OBTAIN FUNDING SUPPORT 4:45 PM - 5:45 PM
Robert McCarley (in USA) and Jim van Os (in Europe)

KEYNOTE LECTURE - The Road from Damascus: A Scientific Journey 6:00 PM - 7:00 PM
Location: Auditorium
Akil Huda, Ph.D.

In this talk, Dr. Akil will share her transition from Syria to the USA to become a scientist, witnessing the discovery of Endorphins, her current interests in neuroscience, and lessons she learned along the way about how to keep her love of science alive.
OVERALL ABSTRACT

Wikipedia defines “Omics” as an informal suffix that implies “the collective characterization and quantification of pools of biological molecules that translate into the structure, function, and dynamics of an organism or organisms.” Thus, “genomics” describes all that is known about the multiple aspects of the genetic architecture of an organism or its disorders and “connectomics” describes the complex cerebral architecture that is uniquely human and can develop in deviant ways in schizophrenia. In this session we thus aim to review the most up-to-date knowledge in the fields of both genomics and connectomics as they relate to improving our understanding about schizophrenia. Research findings are accumulating so rapidly now that even the latest published literature cannot keep up with the pace of progress in these fields.

In the genomics session, Dr. Patrick Sullivan will cover the latest Genome-Wide Association Study (GWAS) findings of common alleles with increased risk for schizophrenia from the large international collaborative effort, The Psychiatric Genomics Consortium (PGC). He will be followed by Dr. Jonathan Sebat who will discuss how rare genetic variants, such as Copy Number Variants (CNVs) can play a role in risk for schizophrenia. This will be followed by a discussion of environmental-gene interaction as led by Dr. Tiina Paunio. All panelists will then discuss the field of Next-Generation Sequencing and how it will be effective in finding genes for schizophrenia. We will end this session with a discussion of controversial ethical issues that the field of psychiatric genetics is now faced with, including commercial direct-to-consumer genome testing availability. This will be led by Dr. Francis McMahon, president of The International Society of Psychiatric Genetics. General audience participation will be encouraged.

The second half of this plenary will be devoted to “Connectomics” in the human brain and how connectivity is influenced by genetics. It will include Drs. Ed Bullmore and Deanna Barch. All of these researchers have developed innovative methods for viewing how the brain communicates and functions through its connectivity and how genes influence the variation that exists in human brain connections. Some of the latter variation may be relevant to neurodevelopmental disorders, such as schizophrenia. They will then lead a panel discussion session with audience participation to conclude this session.
PRESENTERS
Genomics Panel
Pat Sullivan, University of North Carolina, Chapel Hill, USA
Jonathan Sebat, Cold Spring Harbor Laboratory, USA
Tiina Paunio, National Public Health Institute, Finland
Francis McMahon, National Institute of Mental Health, USA

Connectomics
Ed Bullmore, University of Cambridge, United Kingdom
Deanna Barch, Washington University, USA
Holly Moore, Columbia University, USA

TRAVEL FELLOW AND MENTOR LUNCH 12:00 PM - 2:00 PM
Location: Scherma, Fortezza de Basso

POSTER SESSION I AND LUNCH 12:00 PM - 2:00 PM
Location: Cavaniglia
Buffet lunch will be served daily at the poster sessions
Please see page 70 for a complete listing of posters.

SPECIAL SESSION - VOICES IN MY HEAD: DOM’S STORY 1:00 PM - 2:00 PM
Location: Sala Verde

COFFEE BREAK 10:15 AM - 10:30 AM
Location: Palazzo Entrance

CONCURRENT SYMPOSIA
DEVELOPMENTAL STRESS IN SCHIZOPHRENIA:
EPIGENOMICS AND POSSIBLE MECHANISMS 2:00 PM - 4:00 PM
Location: Affari, Ground Level
Chair: James Koenig
Co-Chair: Preben Bo Mortensen

Epidemiological Evidence for a Role of Developmental Stress in Schizophrenia
Preben Bo Mortensen

Transient Neuroinflammation is a Key Mechanism Mediating the Neuropathological Interactions between Prenatal Immune Challenge and Peripubertal Stress
Urs Meyer

Epigenetic Profiling of Prenatal Stress and Long-Term Psychopathological Implications
Marco A. Riva

Adolescent Stress-Induced Epigenetic Control of Neuronal Networks
Akira Sawa

Discussant: James Koenig

NEGATIVE SYMPTOMS AND SOCIAL COGNITION IN SCHIZOPHRENIA: NEURAL CIRCUITRY, FUNCTIONAL OUTCOMES, AND TREATMENT INNOVATION 2:00 PM - 4:00 PM
Location: Auditorium
Chair: Aristotle Voineskos

Behavioral and Neural System Effects of Computerized Social Cognitive Training Exercises in Schizophrenia
Sophia Vinogradov

Network Topology in Deficit Schizophrenia, Nondeficit Schizophrenia, and Bipolar Disorder: From Circuits to Functional Outcome
Aristotle Voineskos

Neuroscientific Explorations of Two Levels of Social Cognition in Schizophrenia
Michael Green

The Neural Circuitry of Social Impairments in Schizophrenia Spectrum Disorders
Robert W. Buchanan

Identification of Neuroimaging Biomarkers for Negative Symptoms in Schizophrenia
Anil K. Malhotra

Discussant: Celso Arango
NEW VISTAS IN Dopamine Receptor Research: ImPlications FOR NOVEL Therapies IN Schizophrenia

Location: Affari, Lower Level
Chair: Larry J. Siever

- Mutant Mouse Models to Explore D1-Glutamate Interactions and Cortical vs Subcortical D1 Dopamine Receptor Function. Schizophrenia-Related Phenotypic Effects
  John L. Waddington
- Chemical, Molecular, and Cellular Factors Influencing the Discovery and Development of Dopamine D1 Agonists
  Richard B. Mailman
- Dopamine Receptors as Targets for Cognitive Deficits in Schizophrenia: Lessons from Animal Models
  Patricio O’Donnell
- The D1 Receptor and Cognition and Trial of a Novel D1 Agonist in the Schizophrenia Spectrum
  Larry J. Siever

Discussant: René S. Kahn

Oligodendrocytes as a Target for Treatment in Schizophrenia

Location: Affari, Second Level
Chair: Johann Steiner
Co-Chair: Natalya Uranova

- Ultrastructural Abnormalities and Deficit of Oligodendrocytes in Schizophrenia: Clinical-pathological Correlates
  Natalya Uranova
- Oligodendrocyte-targeted Proteomics: Insights about Schizophrenia
  Daniel Martins-de-Souza
- Animal Experiment Data Regarding the Effect of Antipsychotic Drugs on Oligodendrocyte Turnover
  Lan Xiao
- A Systems Biology Approach toward Understanding Schizophrenia
  Vahram Haroutunian

Discussant: Andrea Schmitt

Suicide and Psychosis: The Context and Meaning of Early Risk

Location: Sala Verde
Chair: Stephen Wood

- Suicide-related Behaviour in Young People: Rates, Risk Factors and Intervention
  Jo Robinson
- Psychotic Experiences as a Predictor of the Natural Course of Suicidal Ideation: A Swedish Cohort Study
  Ian Kelleher
- Depression and Suicidality in First Episode Psychosis: Subordination and Shame
  Rachel Upthegrove
- The Long-term Risk of Suicide Following First Onset Psychosis and Potential Early Risk Factors
  Rina Dutta

Discussant: Stephen Wood

No Smoke Without Fire: Could Tobacco Smoking Have a Causal Role in Psychosis?

Location: Affari, First Level
Chair: James H. MacCabe
Co-Chair: Robin M. Murray

- Tobacco Use and Psychotic Experiences in UK Teenagers – Evidence from the ALSPAC Longitudinal Study
  Suzanne H. Gage
- Systematic Review and Meta-analysis on Associations between Tobacco Smoking and Both the Diagnosis and the Clinical Symptoms of Psychosis?
  Pedro Gurillo Muñoz
- Another Good Reason to Stop Smoking: A Case-Control Study of the Association between Tobacco Use and First Episode Psychosis
  Marta Di Forti
- Cigarette Smoking is Equally Strongly Associated with Psychotic-like Experiences as Cannabis Use
  Marco P.M. Boks

Discussant: John J. McGrath

COFFEE BREAK

Location: Passi Perduti – Adjacent to the Auditorium; Palazzo Affari Foyers; Sala Verde
**PHARMACEUTICAL PIPELINE SESSION**

**Location:** Auditorium  
**Chair:** John Kane

**Efficacy and Safety of Adjunctive Bitopertin versus Placebo in Subjects with Persistent Predominant Negative Symptoms of Schizophrenia Treated with Antipsychotics - Update from the Searchlyte Programme**  
Dragana Bugarski-Kirola

**Randomized, Double-blind, Active-controlled, Phase 2/3 Study to Determine the Short-term (6-week) and Long-term (6 month) Cognitive and Anti-psychotic Efficacy, Safety and Tolerability of CYP-1020 Compared to Risperidone**  
Jonathan Rabinowitz

**ITI-007, a New Approach to the Treatment of Schizophrenia**  
Kimberly E. Vanover

**Results of a Phase 2B Clinical Trial of TC-5619, a Selective Alpha 7 Neuronal Nicotinic Receptor (NNR) Agonist, in the Adjunctive Treatment of Negative Symptoms and Cognitive Dysfunction in Schizophrenia**  
David Hosford

**Dopamine-1 Receptor Stimulation in Schizophrenia: a Randomized, Clinical Trial**  
Ragy Girgis

**Early Clinical Results of the Phosphodiesterase 10 Inhibitor OMS643762 in Development for the Treatment of Schizophrenia and Huntington’s Disease**  
Albert Yu

**Efficacy and Safety of Novel Dopamine Serotonin Stabilizer RP 5063 in Acute Schizophrenia and Schizoaffective Disorder**  
Marc Cantillon

**ICOSR SYMPOSIUM: THE ADVANCES IN STRUCTURAL AND FUNCTIONAL BRAIN IMAGING IN SCHIZOPHRENI.A AND OTHER PSYCHOTIC DISORDERS**

**Location:** Affari, Ground Level  
**Chair:** S. Charles Schulz

**Guiding Neuromodulation with Neuroimaging**  
Kelvin Lim

**Structural and Functional Neuroimaging Findings in the BSNIP Psychosis Consortium**  
Godfrey D. Pearlson

**New Neuroscience Based Cognitive Paradigms for Biomarker Research in Schizophrenia**  
Deanna M. Barch

**Dynamics of Intrinsic Connectivity Networks in Schizophrenia**  
Vince Calhoun

**Discussant:** S. Charles Schulz

**SHOULD WE CONTINUE TO DO PLACEBO-CONTROLLED MEDICATION TRIALS IN SCHIZOPHRENI.A? AN ETHICO-CLINICAL DEBATE**

**Location:** Affari, Lower Level  
**Chair:** Anthony S. David

**The Use of Placebo in Randomized Controlled Trials in Schizophrenia: A Regulator’s View**  
Luca Pani

**The Ethics of Placebo-Controlled Trials in Schizophrenia: A View Informed by Working with Industry**  
Robert R. Conley

**Placebo Controlled Trials in Patients Suffering from Schizophrenia: Methodological Issues with an Indirect Effect on Ethical Considerations**  
W. Wolfgang Fleischhacker

**Ethics of Placebo Use in Schizophrenia Trials**  
Paul S. Appelbaum

**Discussant:** William T. Carpenter
THE LONG SEARCH FOR AN INFLAMMATORY COMPONENT IN SCHIZOPHRENIA

4:15 PM - 6:15 PM

Location: Sala Verde
Chair: Sabine Bahn
Co-Chair: Iris Sommer

Meta-analyses on Double-blind RCTs Adding Drugs with Anti-inflammatory Properties to Antipsychotic Medication
Iris Sommer

Serum Biomarkers for Psychiatric Disorders
Sabine Bahn

The Microbiome - The Missing Link in the Pathogenesis of Schizophrenia
Robert Yolken

Infections, Inflammatory Markers and Schizophrenia
Faith Dickerson

Neuroinflammation in Temporal Cortex of Patients with Recent Onset Schizophrenia
Bart van Berckel

Discussant: Cynthia Shannon-Weickert

USING NEUROIMAGING TO PREDICT OUTCOMES IN SUBJECTS AT HIGH RISK

4:15 PM - 6:15 PM

Location: Affari, First Level
Chair: Philip McGuire
Co-Chair: Tyrone Cannon

Identifying Biomarkers of Risk for and Progression to Psychosis Using High-Risk Strategies
Tyrone Cannon

Relationship between Brain Glutamate Concentrations and Functional Outcome in Individuals at Ultra High Risk of Psychosis
Alice Egerton

Clinical and Imaging Prediction of Schizophrenia in People at High Familial Risk
Stephen Lawrie

Outcome in Subjects at Ultra High Risk of Psychosis: Relationship to Dopaminergic Function
Oliver Howes

Discussant: Ed Bullmore

WHEN DOES THE TROUBLE START? OBESITY, DIABETES RISKS AND METABOLIC DISTURBANCES IN YOUNG PEOPLE WITH PSYCHOSIS

4:15 PM - 6:15 PM

Location: Affari, Second Level
Chair: Cherrie Galletly

Risk Factors for Death and Disability in Young People with Psychosis
Cherrie Galletly

Weight Gain and Metabolic Changes after Six Months of Treatment with Second-generation Antipsychotics in Antipsychotic-naïve Pediatric and Adult Patients
Celso Arango

Dysglycemic Signals in Children and Adolescents Treated with Antipsychotics for the First Time
Christoph Correll

Results from the NIMH-funded Metabolic Effects of Antipsychotics in Children (MEAC) Study
John W. Newcomer

Discussant: Benno G. Schimmelmann
4th Schizophrenia International Research Society Conference  
Fostering Collaboration in Schizophrenia Research  

**FINAL PROGRAM**  
**FLORENCE, ITALY**  
**05 - 09 APRIL 2014**

**POSTER SESSION II AND LUNCH**  
**Location:** Cavaniglia  
Buffet Lunch will be served daily at the poster sessions.  
*Please see page 96 for a complete listing of posters.*

**Special Session - Voices in My Head: Dom’s Story**  
**Location:** Sala Verde  
**1:00 PM - 2:00 PM**

**Coffee Available**  
**Locations:** Passi Perduti – Adjacent to the Auditorium  
Palazzo Affari Foyers  
Sala Verde  
**1:45 PM - 2:15 PM**

**CONCURRENT SYMPOSIA**

**DEBATE: ATTENUATED PSYCHOSIS SYNDROME IS A NEEDED DIAGNOSTIC CATEGORY**  
**Location:** Auditorium  
**Chair:** Robin M. Murray  
**2:00 PM - 4:00 PM**

**Attenuated Psychosis Syndrome = Common Mental Disorder with Subthreshold Psychosis**  
Jim van Os

_The Psychosis High Risk State: Is It Valid?_  
Paolo Fusar-Poli

_Debate: Attenuated Psychosis Syndrome Is a Needed Diagnostic Category_  
David J. Castle

_Debate: Attenuated Psychosis Syndrome: A New Diagnostic Class Is Needed_  
William T. Carpenter

**Discussant:** Robin M. Murray

**EXPOSURE TO INFECTION/INFLAMMATION DURING BRAIN DEVELOPMENT AND RISK FOR PSYCHOTIC DISORDERS**  
**Location:** Affari, Ground Level  
**Chair:** Christina Dalman  
**2:00 PM - 4:00 PM**

_Early-life Exposure to Epstein Barr Virus, Childhood IQ and the Risk of Psychotic Experiences in the ALSPAC Birth Cohort_  
Golam Khandaker

_Serologically Documented Maternal Influenza and Bipolar Disorder in Adult Offspring_  
Alan Brown

_Fetal and Childhood Infections and Later Risk of Developing Psychoses; in Search of Possible Underlying Mechanisms by Combining Different Research Disciplines_  
Åsa Blomström

_ Early Infection/Inflammation and Later Development of Psychoses: An Overview of the Research Area_  
Christina Dalman

_Manganese-Enhanced Magnetic Resonance Imaging Reveals Increased Hallucination-Like brain Activity in a Mouse Model of a Schizophrenia Risk Factor_  
Paul H. Patterson

**Discussant:** Robert Yolken

**NOVEL TREATMENT OPTIONS FOR IMPAIRED COGNITION IN SCHIZOPHRENIA: COMBINING DIFFERENT MODES OF COGNITIVE REMEDIATION**  
**Location:** Affari, Lower Level  
**Chair:** Peter Falkai  
**Co-Chair:** William Honer  
**2:00 PM - 4:00 PM**

_Combining Exercise and Cognitive Remediation_  
Peter Falkai

_Yoga Exercise for Cognitive Impairment in Psychotic Disorders_  
Eric Yu Hai Chen

_Understanding of Musical Impairment May Facilitate the Development of Insight for Cognitive Remediation_  
Ken Sawada

_Combining Cognitive and Social Cognitive Training for Individuals with Schizophrenia_  
Sophia Vinogradov

**Discussant:** William Honer
SCHIZOPHRENIA INTERNEURON PATHOLOGY: LOST IN MIGRATION  2:00 PM - 4:00 PM

Location: Affari, Second Level
Chair: Cindy Shannon-Weickert

Increased White Matter Neuron Density Is Related to High Neuroinflammation in People with Schizophrenia
Cindy Shannon-Weickert

Subcortical White Matter Neurons in Autism, Schizophrenia and Depression
Schahram Akbarian

Oxidative Stress in Parvalbumin Interneurons in a Developmental Rodent Model of Schizophrenia
Patricio O’Donnell

Patterns of Neuronal Migration from the Early Postnatal Subventricular Zone: Potential Relevance for Schizophrenia
Dragos Inta

Discussant: Bita Moghaddam

THE BIOLOGY OF SOCIAL DEFEAT  2:00 PM - 4:00 PM

Location: Affari, First Level
Chair: Jean-Paul Selten
Co-Chair: Andreas Meyer-Lindenberg

Abnormalities of Neural Social Stress Processing and Exposure to Environmental Risk Factors for Schizophrenia
Andreas Meyer-Lindenberg

Exaggerated Dopamine Release in Immigrants during Social Stress: A Risk Mechanism for Psychosis
Romina Mizrahi

ΔfosB in the Prefrontal Cortex, Susceptibility to Social Stress and Antipsychotic Treatment
Vincent Vialou

Social Exclusion and Sensitization of the Dopamine System: A [123I]IBZM-SPECT Study in Young Adults with Serious Hearing Impairment
Martin Gevonden

Discussant: Oliver Howes

VIOLENCE AND SCHIZOPHRENIA: RISK FACTORS AND MEDIATORS  2:00 PM - 4:00 PM

Location: Sala Verde
Chair: Seena Fazel

Risk Factors for Violence in Psychosis: Findings from a Meta-analysis
Seena Fazel

Delusions and Violence
Jeffrey Swanson

Systematic Review of the Prevalence and Risk Factors for Interpersonal Violence in Acute Psychiatric Units
Giovanni De Girolamo

Preventing Violence in Schizophrenia
Olav Nielsen

Discussant: John J. McGrath

COFFEE BREAK  4:00 PM - 4:15 PM

Location: Passi Perduti – Adjacent to the Auditorium
Palazzo Affari Foyers
Sala Verde
CONCURRENT SYMPOSIA

CANNABIS, SKUNK AND SPICE: THE EVOLVING RISK OF PSYCHOSIS  4:15 PM - 6:15 PM
Location: Affari, Second Level
Chair: Marta Di Forti

How Sinsemilla (Skunk) Use has Reshaped the Association between Cannabis and Psychosis
Marta Di Forti

Spicing Thing Up - What Can We Learn from Synthetic Cannabinoids about the Link between Cannabinoids and Psychosis
Deepak Cyril D’Souza

Epigenetic and Transcriptional Changes Associated with the Development of the Schizoaffective-like Phenotype Induced by Adolescent Exposure to THC in Rats
Tiziana Rubin

“The Good, the Bad, the Ugly”: Experimental Human Studies of CBD, THC, and THCV
Amir Englund

Discussant: Robin M. Murray

IS THE ASSOCIATIVE STRIATUM A LOCUS OF VULNERABILITY FOR TRANSITION TO PSYCHOSIS?  4:15 PM - 6:15 PM
Location: Affari, Ground Level
Chair: Anissa Abi-Dargham

Developmental and Dietary Sensitivity of Dopamine in Dorsal Striatum
Bita Moghaddam

Abnormalities of Frontostriatal Circuits in the Psychosis Prodrome
Tiziano Colibazzi

Striatal GABAergic and Glutamatergic Dysregulations as Potential Predictors of Conversion to Psychosis in Individuals at Ultra-High Risk
Camilo de la Fuente-Sandoval

Is the Associative Striatum a Locus of Vulnerability for Transition to Psychosis?
Oliver Howes

Discussant: Anissa Abi-Dargham

POTENTIAL ROLE OF NMDA-RECEPTOR ANTIBODIES IN SCHIZOPHRENIA: OVERLAP AND DISTINCTION FROM NMDA-RECEPTOR ENCEPHALITIS  4:15 PM - 6:15 PM
Location: Affari, Lower Level
Chair: Johann Steiner
Co-Chair: Hannelore Ehrenreich

Increased Prevalence of Diverse N-methyl-D-aspartate Glutamate Receptor Antibodies in Patients with an Initial Diagnosis of Schizophrenia
Johann Steiner

NMDA Receptor Antibodies in First Episode Psychosis: Prevalence and Clinical Phenotype
Belinda Lennox

Anti-NMDA-receptor Antibody Detected in Limbic Encephalitis, Schizophrenia and Narcolepsy with Psychotic Symptoms
Takashi Kanbayashi

Neuropsychiatric Disease Relevance of Circulating Anti-NMDA Receptor Autoantibodies Depends on Blood Brain Barrier Integrity
Hannelore Ehrenreich

Discussant: Souhel Najjar

RELAPSE - RISK AND PREVENTION  4:15 PM - 6:15 PM
Location: Sala Verde
Chair: Robert Zipursky
Co-Chair: Robin Emsley

Can the Ongoing Use of Placebo in Relapse-Prevention Clinical Trials in Schizophrenia be Justified?
Robin Emsley

Are There Clinically Useful Predictors and Early Warning Signs for Relapse in Schizophrenia?
Wolfgang Gaebel

Patterns of Response and the Neurobiology of Relapse in Schizophrenia
Ofer Agid

Risk of Symptom Recurrence with Medication Discontinuation in First-Episode Psychosis: A Systematic Review
Robert Zipursky

Discussant: S. Charles Schulz
REWARD PROCESSING, COGNITION AND PERCEPTION DURING ADOLESCENT BRAIN DEVELOPMENT AND VULNERABILITY FOR PSYCHOSIS

Location: Affari, First Level
Chair: Richard S.E. Keefe
Co-Chair: Bita Moghaddam

Effort, Motivation and Reward Learning in Schizophrenia: Relationships to Amotivation and Functional Impairment
Deanna M. Barch

Adapting Effort-Based Decision-making Paradigms for Schizophrenia: What Works and What Doesn’t
Michael Green

Dissecting Motivation in Animal Models of Dopamine Dysfunction
Eleanor H. Simpson

Isolating Poor Attention, Reward Learning, and Motivation in the Sp4 Hypomorphic Mouse Model of Schizophrenia: GLYT1 Inhibitors Treat Only Inattention
Jared W. Young

Discussant: Athina Markou

Coffee Available
Location: Passi Perduti – Adjacent to the Auditorium

SIRS Business Meeting and Award Presentations
Location: Auditorium

CONCURRENT SYMPOSIA

AT-RISK MENTAL STATE TREATMENT UPDATE 2:00 PM - 4:00 PM
Location: Affari, First Level
Chair: Dorien H. Nieman
Co-Chair: Mark van der Gaag

Subthreshold Intervention to Reduce the Impact of Emerging Psychosis and Risk for Stage Progression: Recent and Future Clinical Trials
Patrick McGorry

Internalised Stigma in Young People at High Risk of Developing Psychosis: findings from a Cognitive Therapy Trial
Anthony P. Morrison

Preventing a First Episode of Psychosis: A Meta-Analysis
Mark van der Gaag

Preventive Psychotherapy
Dorien H. Nieman

Discussant: Stephan Ruhrmann

COFFEE AVAILABLE 10:15 AM -10:30 AM
Location: Passi Perduti – Adjacent to the Auditorium

POSTER SESSION III
Location: Cavaniglia
Buffet Lunch will be served daily at the poster sessions.
Please see page 122 for a complete listing of posters.

SPECIAL SESSION - VOICES IN MY HEAD: DOM’S STORY 1:00 PM - 2:00 PM
Location: Sala Verde

COFFEE AVAILABLE 1:45 PM - 2:15 PM
Location: Passi Perduti – Adjacent to the Auditorium
Palazzo Affari Foyers
Sala Verde

CHILDHOOD TRAUMA AS RISK FACTOR IN PSYCHOTIC DISORDERS IN SEARCH OF MECHANISMS 2:00 PM - 4:00 PM
Location: Affari, Ground Level
Chair: Ingrid Melle

History of Trauma in the Ultra High Risk for Psychosis Population: Findings from the PACE Clinic
Barnaby Nelson

Childhood Trauma Influences the Clinical Expression of Bipolar Disorders
Bruno Etain

How Does Childhood Trauma Contribute to Psychosis Onset? A Focus on the Biological Stress Response
Valeria Mondelli

BDNF Val66Met Polymorphism Modulates Associations between Childhood Abuse–Neglect and Functional and Structural Abnormalities in Psychoses
Monica Aas

Discussant: Paola Dazzan

MODELING SCHIZOPHRENIA USING PATIENT DERIVED CELLS BUT WHICH ONES? 2:00 PM - 4:00 PM
Location: Auditorium
Chair: David Cotter
Co-Chair: Alan Mackay-Sim

Significant Down-regulation of EIF2 and Associated Ribosomal Proteins in ONS Cell Model of Schizophrenia
Jane A. English

Patient-derived Stem Cells and SZ: A Path to Aetiology?
Alan Mackay-Sim

Elucidating the Molecular Pathophysiology of Mental Illness with Olfactory Neuronal Cells and Induced Pluripotent Stem Cells
Akira Sawa

Modeling Predisposition to SZ Using hiPSCs
Kristen Brennand

Discussant: Paul Harrison
4th Schizophrenia International Research Society Conference
Fostering Collaboration in Schizophrenia Research

THE CANNABINOID DICHOTOMY IN SCHIZOPHRENIA: 2:00 PM - 4:00 PM
FROM RISK FACTOR TO THERAPY
Location: Affari, Second Level
Chair: Andrea Giuffrida
Co-Chair: Daniel Lodge

Endocannabinoid-enhancing Drugs Reverse Social Withdrawal in the PCP Rat Model of Schizophrenia
Andrea Giuffrida

Increasing Endocannabinoid Levels Restores Aberrant Dopamine System Function in the
PCP Model of Schizophrenia
Daniel Lodge

CB1 Receptor Signaling, Prefrontal GABAergic Transmission and Adolescence
Kuei Y. Tseng

Modulation of the Endocannabinoid System as a Potential New Target in the Treatment of Schizophrenia
F. Markus Leweke

Discussant: David Morilak

UNDERSTANDING PATHWAYS TO CARE AS A MEANS OF ADVANCING EARLY INTERVENTION: FINDINGS FROM AROUND THE WORLD 2:00 PM - 4:00 PM
Location: Sala Verde
Chair: Michael T. Compton

A Comparative Study of Pathways to First-Episode Care for Psychosis in Three Ethnic Groups in Ontario, Canada: The African, Caribbean, & European Project (ACE)
Kelly K. Anderson

The Use of Social Media in Early Psychosis
Michael L. Birnbaum

Reducing Duration of Untreated Psychosis: Care Pathways to Early Intervention in Psychosis Services
Max Birchwood

Help-seeking and Pathways to Care in the Early Stages of Psychosis: Results from the FePsy Study
Anita Riecher-Rössler

Discussant: John M. Kane

WHAT IS THE LONG TERM OUTCOME OF SCHIZOPHRENIA? 2:00 PM - 4:00 PM
Location: Affari, Lower Level
Chair: Michael Davidson

Ten-Year Outcomes of Psychotic Disorders: The ÆSOP-10 Study
Peter B. Jones

Outcomes of Schizophrenia from a Lifespan Perspective. The Northern Finland 1966 Birth Cohort Study (NFBC 1966)
Matti Isohanni

Long Term Outcome in Schizophrenia: A 6 Year Follow Up in over 1000 Patients
René S. Kahn

Nation-wide Employment Status in Patients with Schizophrenia and Bipolar Disorders
Mark Weiser

Discussant: Robin M. Murray

COFFEE AVAILABLE 3:45 PM - 4:15 PM
Location: Passi Perduti – Adjacent to the Auditorium
Palazzo Affari Foyers
Sala Verde
4th Schizophrenia International Research Society Conference  
Fostering Collaboration in Schizophrenia Research

Tuesday 08 April

4:15 PM - 6:15 PM
Location: Affari, Second Level
Chair: Alessandro Bertolino

**ADVANCES IN IMAGING IN SCHIZOPHRENIA II**

**4:15 PM**
Cortical Thickness in Individuals with Nonclinical and Clinical Psychosis  
Sanne Koops

**4:30 PM**
Differential Diagnostic Classification of Functional Psychoses Using MRI-based Pattern Recognition  
Nikolaos Koutsouleris

**4:45 PM**
Elevated Anterior Cingulate Cortex Glutamate Levels are Associated with Antipsychotic Treatment Resistance and Clinical Severity in Schizophrenia  
Elias Mouchlianitis

**5:00 PM**
Emerging Evidence of Affected Anatomical Rich Club Hub Structure in Schizophrenia Patients, their Healthy Siblings and their Non-affected Young Offspring  
Martijn van den Heuvel

**5:15 PM**
GABA and Glutamate in Schizophrenia: A 7T 1H-MRS Study  
Anouk Marsman

**5:30 PM**
Prefrontal Abnormalities in NAA and Glutamate Levels in Persons with a Psychotic Disorder or at Risk for a Psychosis: A Large H-MRS Study  
Edith Liemburg

**5:45 PM**
Reduced Microstructural White Matter Alterations in Psychotic Disorder; Stable or Progressive?  
Patrick A.E. Domen

**6:00 PM**
Topological Features of Structural Brain Networks in Sub-Clinical Psychosis Revealed by Graph Theoretical Analysis of Tractography Data  
Mark Drakesmith
4th Schizophrenia International Research Society Conference
Fostering Collaboration in Schizophrenia Research

FINAL PROGRAM
FLORENCE, ITALY
05 - 09 APRIL 2014

GENETICS AND EPIDEMIOLOGY
Location: Sala Verde
Chair: Dan Rujescu

4:15 PM  A Population-Based Longitudinal Study of Serum Interleukin-6 and C-reactive Protein in Childhood as Predictors of Psychosis and Depression in Young Adult Life
Golam Khandaker

4:30 PM  Anticipating and Experiencing Pleasure in Schizophrenia: A New Paradigm
Clementine Edwards

4:45 PM  Common and Rare Risk Variants Implicate PAK Signaling in the Molecular Etiology of Schizophrenia
Aiden Corvin

5:00 PM  Dopamine or Glutamate: Using Genetic Copy Number Variant Pathway Analysis and Treatment Resistance to Adjudicate Schizophrenia Hypotheses
James T.R. Walters

5:15 PM  Interaction of Maternal Infection and Adolescent Cannabinoid Exposure on miRNA Regulation of Gene Expression in the Adult Entorhinal Cortex
Sharon L. Hollins

5:30 PM  Premature Death is Higher in Persons with Psychotic Disorders but not with Psychotic Experiences: A Population-based Longitudinal Study
Nomi Werbeloff

5:45 PM  The Genetic Architecture of Schizophrenia: How do CNVs and Polygenic Scores Contribute to Disease Risk?
Sarah E. Bergen

6:00 PM  The Role of Imaging Genetics in Unanticipated Schizophrenia Risk Gene Discovery: TNIK and microRNA-137
Steven G. Potkin

BIOMARKERS
Location: Affari, Ground Level
Chair: Cynthia Shannon-Weickert

4:15 PM  Continuity of Externalising and Internalising Psychopathology as Predictors of Psychotic-like Experiences in a Longitudinal General Population Cohort of Teenagers
Alessandra Raudino

4:30 PM  Inflammatory Response in First-episode Psychosis
Jaana Suvisaari

4:45 PM  Premorbid and Current Cognitive Function in Schizophrenia associate with Treatment Resistance and EGF 61 AA Genotype
Vaidy Swaminathan

5:00 PM  Real-time Detection of Cognitive Decline in Children at High Genetic Risk of Schizophrenia and Bipolar Disorder
Michel Maziade

5:15 PM  Risk of Diabetes in Pediatric Patients Exposed to Antipsychotics: A Nationwide 12-year Case-control Study
René E. Kondrup (Nielsen)

5:30 PM  RNA Sequencing of Choroid Plexus in Schizophrenia and Unaffected Control Subjects
Maree J. Webster

5:45 PM  The Neurobiology of Negative Symptoms and the Effect of Glycine Reuptake Inhibitors
Daniela Alberati

6:00 PM  The Role of Oligopeptidases in Schizophrenia – Translational Evidence from Human to Animal Research
Ary Gadelha
HIGH RISK RESEARCH 4:15 PM - 6:15 PM
Location: Affari, Lower Level
Chair: Nina Schooler

4:15 PM Altered Relationship between Medial Temporal Lobe Resting Cerebral Blood Flow and Striatal Dopamine Synthesis Capacity in People at Risk of Psychosis
Paul Allen

4:30 PM Childhood Sleep Disturbance and Risk of Psychotic Experiences in a Large UK Birth Cohort
Andrew Thompson

4:45 PM Difficulty in Making Contact with Others and Social Withdrawal as Early Signs of Psychosis in Adolescents – The Northern Finland Birth Cohort 1986
Juha Veijola

5:00 PM High Blood Cytokine Levels are Related to Decreased Verbal Fluency and Broca’s Area Volume Reduction in Schizophrenia
Thomas Weickert

5:15 PM Is Treatment Resistant Schizophrenia a ‘Type’ or a ‘Stage’ of Psychotic Illness?
Arsime Demjaha

5:30 PM Reward Processing in Unaffected Siblings of Schizophrenia Patients: An fMRI Study
Max de Leeuw

5:45 PM Salience Matters: Brain Potentials Distinguish Premorbid Attention Problems among Children At-Risk for Schizophrenia
Kristin R. Laurens

6:00 PM The Excess of Non-right-handedness in Schizophrenia is not the Result of Methodological Artifacts and Biases – A Meta-Analysis
Marco Hirnstein

THERAPEUTICS 4:15 PM - 6:15 PM
Location: Auditorium
Chair: Robert Zipursky

4:15 PM Antipsychotic Medication and Remission of Psychotic Symptoms. Long Term Development and Characteristics
Ditte R. Gottfredsen

4:30 PM Childhood Trauma and Psychosis in a Prospective Cohort Study: Cause, Effect and Directionality
Ian Kelleher

4:45 PM Intention-to-harm is the Key Component Linking Childhood Traumatic Experiences to Psychosis
Martine M. van Nierop

5:00 PM Negative Modulation of the Synaptic Vesicle Protein (SV2A): A New Pharmacological Target for Cognitive Deficit Associated with Schizophrenia
Marc Laruelle

5:15 PM Novel Genetic Risk Variants for Clozapine-associated Neutropenia
Sophie Legge

5:30 PM Recovery in Remitted First-Episode Psychosis at 7 Years of Follow-up of an Early Dose Reduction/Discontinuation or Maintenance Treatment Strategy
Lex Wunderink

5:45 PM Risk of Mortality in Offspring of Mothers with Psychosis: A Western Australian Whole-of-population Cohort Study
Sonal Shah

6:00 PM Social Support as an Effect Modifier or Mediator in the Relationship between Childhood Adversity and Psychosis?
Charlotte Gayer-Anderson

COFFEE AVAILABLE 5:45 PM - 6:30 PM
Location: Passi Perduti – Adjacent to the Auditorium
Palazzo Affari Foyers Sala Verde
### WORKSHOPS

**BIOLOGICAL AND PSYCHOPATHOLOGICAL DIMENSIONS OF PSYCHOTIC DISORDERS: THE ROAD FORWARD TO DECONSTRUCTION?**  
**Location:** Affari, Second Level  
**Chair:** Tilo Kircher  
**Co-Chair:** Werner Strik

- Thought and Language Disorders and their Neural Pathophysiology  
  Tilo Kircher
- The Brain Systems Underlying Hallucinations and Catatonia  
  Werner Strik

**Altered Transfer of Momentary Mental States (ATOMS) as the Basic Unit of Psychosis Liability in Interaction with Environment and Emotions**  
Jim van Os

- Neural Network Model Deconstruction of Psychosis  
  Sophia Frangou

**Discussant:** Wolfgang Gaebel

**NEUROADAPTATIONS TO CHRONIC ANTIPSYCHOTIC TREATMENT IN PRECLINICAL MODELS**  
**Location:** Affari, First Level  
**Chair:** Shitij Kapur

- Mechanisms of Antipsychotic Treatment Failure  
  Davide Amato
- Impact of Chronic Antipsychotic Drug Treatment on Brain Morphology: A Cause for Concern?  
  Anthony C. Vernon
- Clinical Insights Derived from Rodent Models of Antipsychotic-Induced Metabolic Perturbations  
  Margaret K. Hahn

**Dopamine D2 Receptors Regulate the Anatomical Balance of Basal Ganglia Circuitry**  
Christoph Kellendonk

**Discussant:** Shitij Kapur

### NEUROSTIMULATION FOR PSYCHOTIC SYMPTOMS

**Location:** Affari, Second Level  
**Chair:** Remko van Lutterveld  
**Co-Chair:** Iris Sommer

- Effects of Transcranial Direct Current Stimulation on Treatment-resistant Psychotic Symptoms and Brain Functional-connectivity in Patients with Schizophrenia  
  Jerome Brunelin
- From the Neurobiology of Origin and Treatment of Auditory Hallucinations  
  Philipp Homan
- A Pilot Case Series of Magnetic Seizure Therapy in Refractory Schizophrenia  
  Daniel M. Blumberger
- Theta-burst Repetitive Transcranial Magnetic Stimulation as Treatment for Auditory Verbal Hallucinations  
  Remko van Lutterveld

**Discussant:** Iris Sommer

### NEXT STEPS WITH GWAS AND GENE SEQUENCING: FUNCTIONAL MUTATIONS, GENE BY GENE INTERACTIONS AND PATHWAY ANALYSIS

**Location:** Affari, Lower Level  
**Chair:** Dick McCombie

- Epistasis and Empirical Pathways in Schizophrenia  
  Kristin K. Nicodemus
- PAK Signaling as a Molecular Risk Mechanism for Psychosis  
  Aiden Corvin
- Using High Through-put Sequencing of the DISC1 Locus to Understand the Genetic Complexity of Psychiatric Illness  
  Pippa A. Thomson

**Discussant:** David Porteous
RECENT ADVANCES IN COGNITIVE BEHAVIOUR THERAPY FOR PSYCHOSIS (CBTP) FOR COMPLEX AND TREATMENT RESISTANT GROUPS

Location: Auditorium
Chair: Emmanuelle Peters

The MRC COMMAND Trial: Results of a Multi-centre, Randomised Controlled Trial of Cognitive Therapy to Prevent Harmful Compliance with Command Hallucinations
Max Birchwood

Computer Assisted Therapy for Auditory Hallucinations: The AVATAR Clinical Trial
Tom Craig

Cognitive Therapy for People with Schizophrenia Spectrum Disorders not Taking Antipsychotic Medication: A Randomised Controlled Trial
Anthony P. Morrison

The Results of Eye Movement Desensitisation and Reprocessing and Prolonged Exposure in Patients with Posttraumatic Stress Disorder and Chronic Psychotic Disorder
Mark van der Gaag

Discussant: Til Wykes

TWENTY YEARS OF RESEARCH ON THE 22Q11.2 DELETION SYNDROME AND SCHIZOPHRENIA: WHAT HAVE WE LEARNED SO FAR?

Location: Sala Verde
Chair: Jacob A.S. Vorstman

The 22q11.2 Deletion Syndrome as a Model for Dementia Praecox
Jacob A.S. Vorstman

22q11.2 Deletion Syndrome as a Genetic Model for Schizophrenia
Anne S. Bassett

Neurocognitive Functioning in 22q11.2 Deletion Syndrome
Raquel E. Gur

Structural and Functional Neural Connectivity as a Predictor of Psychotic Symptom Expression in 22q11.2 Deletion Syndrome
Carrie E. Bearden

Insights into Schizophrenia from 22q11DS Mouse Models
Laurie R. Earls

Discussant: René Kahn
In this Plenary Session, four international experts on the field will present evidence from neuroimaging, neuropharmacology and population epidemiology perspectives highlighting how substance abuse/dependence may moderate the expression of psychosis. While neuroimaging studies have indicated that the major locus of dopaminergic dysfunction in schizophrenia is presynaptic, characterized by elevated dopamine synthesis and release capacity, Prof Abi-Dargham (Columbia University, USA) and Prof R. Murray (Institute of Psychiatry, UK) will tackle the apparent inconsistency that arises from recent studies showing that dopamine release in patients with schizophrenia and comorbid substance use is considerably blunted, comparable in magnitude to substance users, suggesting that oversensitivity of the D2 receptor or abnormality of the post-D2 signaling pathway may also be involved in substance use psychosis. Prof. Callaghan (University of Northern British Columbia, Canada) will present evidence from a large population-based cohort study in California that patients with methamphetamine-related conditions and cannabis use have a significantly higher risk of schizophrenia than matched control population or indeed than other substance use disorders. Finally Prof. van Os (Maastricht University, The Netherlands) will present evidence from a large family based cohort including patients, their siblings and parents, that familiar correlation of psychosis varies considerably as a function of selective environmental exposures such as cannabis (but interestingly not childhood trauma) indicating the importance of selective gene-environment interactions in psychosis susceptibility.
CONCURRENT SYMPOSIA

CLINICAL STAGING IN SEVERE MENTAL DISORDERS: TOWARDS STAGE SPECIFIC TREATMENTS IN PSYCHOSIS 1:30 PM - 3:30 PM
Location: Sala Verde
Chair: Marta Rapado-Castro
Co-Chair: Seetal Dodd

Duration of the Illness and Response to Treatment
Marta Rapado-Castro

Staging and Neuroprotection
Seetal Dodd

Brain Imaging Markers of Psychosis Relapse. Is There Evidence for a Psychosis Relapse Signature?
Christos Pantelis

Fatty Acid Markers of Psychosis Progression and Treatment Response
Paul Amminger

Discussant: Peter Buckley

DRUG REPURPOSING AND EMERGING ADJUNCTIVE TREATMENTS FOR SCHIZOPHRENIA 1:30 PM - 3:30 PM
Location: Auditorium
Chair: Vicki L. Ellingrod
Co-Chair: Joshua Roffman

Positive Symptoms Respond to Add-on Aspirin in Schizophrenia Patients with High Sera CRP Levels: A Post-hoc Analysis of an RCT
Mark Weiser

Adjunctive Minocycline in Clozapine Treated Schizophrenia Patients
Deanna L. Kelly

The Use of Sodium Nitroprusside for the Treatment of Schizophrenia
Jaime Hallak

Effects of Folic Acid and Vitamin B12 Supplementation on Negative Symptoms and Related MRI Indices
Joshua Roffman

Discussant: Peter Buckley
OXYTOCIN, SOCIAL COGNITION, AND SCHIZOPHRENIA 1:30 PM - 3:30 PM

Location: Affari, Second Level
Chair: Robert W. Buchanan

Preclinical Assessment of Oxytocin’s Ability to Modulate Social Behavior
James Koenig

Associations between Peripheral Oxytocin Levels and Impaired Social Cognition in Schizophrenia
Gregory Strauss

Impact of Prosocial Neuropeptides on Human Brain Function and Structure: Implications for Schizophrenia
Andreas Meyer-Lindenberg

Oxytocin and Social Cognition Training
Stephen R. Marder

Discussant: Shitij Kapur

SCHIZOPHRENIA RESEARCH: THE CHALLENGE OF MEASUREMENT VARIABILITY 1:30 PM - 3:30 PM

Location: Affari, First Level
Chair: Janet B.W. Williams
Co-Chair: John M. Kane

Multi-site PET Imaging: Considerations for Appropriate Standardization
Ilan Rabiner

Standardization of Magnetic Resonance Imaging Approaches in Neuropsychiatric Illness: Challenges and Opportunities
Alan Anticevic

Clinician-based Assessment of Psychiatric Diagnosis and Symptom Severity
Janet B.W. Williams

Sleep EEG Studies in Schizophrenia: Methodological Considerations
Matcheri Keshavan

Discussant: René S. Kahn
POSTERS, SUNDAY 06 APRIL

12:00 PM - 2:00 PM

Location: Cavaniglia

1. Further Evidence of the Effects of Childhood Abuse in First-episode Psychosis and Subclinical Psychosis
   Silvia Alemany, Rosa Ayesa-Arriola, Bárbara Arias, Mar Fatjó-Vilas, Manuel I. Ibáñez, Generós Ortel, Benedicto Crespo-Facorro, Lourdes Fañanás

2. Cardiometabolic Adverse Effects of Second-generation Antipsychotics in Drug Naïve Children and Adolescents in Acute Care
   Marco Armando, Luigi Mazzone, Valeria Lucarelli, Valentina Postorino, Maria Laura Pucciariini, Nella Lo Cascio, Stefano Vicari

3. Antipsychotic induced Movement Disorders in Long-stay Psychiatric Patients: A Prospective Study
   PR. Bakker, Izaäk W. de Groot, Jim van Os, Peter N. van Harten

4. Two Candidate Gene-Based Association Studies of Antipsychotic-induced Movement Disorders in Long-Stay Psychiatric Patients: Prospective Studies
   PR. Bakker, Egbert Bakker, Asmar F.Y. Al Hadithy, Najaf Amin, Cornelia M. van Duijn, Jim van Os, Peter N. van Harten

5. Gender Differences in the Effect of Childhood Trauma Experiences on Prodromal Symptoms and Personality Disorder Traits in Young Adults at High-risk for Psychosis
   Neus Barrantes-Vidal, Tecceli Dominguez-Martínez, Paula Cristobal, Tamara Sheinbaum, Thomas R. Kwapił

6. Childhood Trauma Mediates the Association between Ethnic Minority Status and More Severe Hallucinations in Psychotic Disorder
   Akiah A.O. Berg, Monica Aas, Ole A. Andreassen, Ingrid Melle

7. Meta-analysis of Changes in Brain Structure in Healthy Individuals with a History of Childhood Adversity
   Maria Calem, Matthew Kempton

8. Glucometabolic Hormones and Cardiovascular Risk Markers in Antipsychotic-treated Patients
   Bjørn H. Ebdrup, Filip K Knop, Anna Madsen, Henrik B. Mortensen, Birgitte Søgaard, Jens J. Holst, Pal B. Szecsi, Henrik Lublin

   Thierry Q. Mentzel, Charlie Mentzel, Ritsaert Lieverse, Hein Daanen, Peter van Harten

10. Polypharmacy to Counteract Antipsychotic-induced Weight Gain and Metabolic Adverse Effects in Schizophrenia: A Systematic Review and Meta-analysis
    Yuuya Mizuno, Takefumi Suzuki, Atsuo Nakagawa, Kazunari Yoshida, Masaru Mimura, W. Wolfgang Fleischhacker, Hiroyuki Uchida

11. The Joint Effect of Social Adversity in Childhood and in Adulthood on Predicting Psychosis
    Simona A. Stilo, Marta Di Forti, Charlotte Gayer-Anderson, Kathryn Hubbard, Ulrich Reininghaus, Antonella Trotta, Stephanie Beards, Helen Fisher, Valeria Mondelli, Robin M. Murray, Craig Morgan

12. Increased Pre-synaptic Striatal Uptake of Dopamine as a Potential Mechanism of Antipsychotic Failure
    Davide Amato

13. DNA Methylation and GABAergic Pathology of Schizophrenia
    Helene Aparecida Fachim, Umarat Srisawat, Michael Harte, Gavin Reynolds, Caroline Dalton

14. Prenatal Immune Activation Impairs Synaptic Development in the Absence of Overt Glial Pathology
    Sandra Giovaneli, Urs Meyer

15. A Mouse Model of 22q11 Deletion Syndrome Exhibits Deficits in Behaviors Relevant to the Core Domains of Schizophrenia
    Zoe A. Hughes, Radka Graf, Ashley Hanks, Susan Lotarski, Alexander I. More, Stacey Sukoff Rizzo, Liam Scott, Polina Stolyar

16. Comparison of Phencyclidine-induced Deficits in Morris Water Maze Task and its Reversal by Sertindole between Wistar and Lister Hooded Rats
    Jouni Ihalainen, Katja Savolainen, Jarlko Hiltunen, Markus M. Forsberg

17. Are Dopamine Partial Agonist Antipsychotics Similar? Preclinical Comparison of Aripiprazole, Bifeprunox and Cariprazine
    Béla Kiss, István Gyertyán, Zsolt Némethy, Katalin Ságly, Judit Laszy, Károly Fazekas, Sándor Kolok, Zoltán Kapui

18. Advanced Paternal Age as a Risk Factor for Schizophrenia: A Translational Study in Humans and Rats
    Axel Krug, Dominik Seffer, Henrike Rippberger, Bruno Dietsche, Heidelore Backes, Henriette Schneider-Halßlof, Rainer Schwarting, Tilo Kircher, Markus Wöhr

19. Peripubertal High Fat Diet Exposure Leads to a Dopamine-dependent Disruption of Sensorimotor Gating in Adulthood
    Marie A. Labouesse, Ulrike Stadlbauer, Wolfgang Langhans, Urs Meyer
20. Spreading Depression Mimics the Behavioral Features of Schizophrenia
Mahmoud Loftinia

21. Characterization of a Mouse Model of the 1q21.1 Microdeletion Syndrome
Jacob Nielsen, K.W. Fejgin, Sotty Florence, J.B. Lauridsen, V. Nielsen, D. Clausen, P.H. Larsen, I.V. Klewe, C.T. Christoffersen, M. Didriksen

22. The anti-anhedonic properties of Lurasidone in the Chronic Mild Stress Model are associated with synaptic and neuroplastic changes in the rat Prefrontal Cortex
Marco A. Riva, Flavia Macchi, Andrea C. Rossetti, Mariusz Papp, Raffaella Molteni

23. Upregulation of striatal Dopamine D2 Receptors Results in Persistent Alterations in Pre-synaptic Dopamine Function
Eleanor H. Simpson, Sabine Krabbe, Johanna Duda, Eric Kandel, Birgit Liss, Jochen Roeper

24. Abnormal stress responsiveness in a rodent developmental disruption model of schizophrenia
Eric C. Zimmerman, Mark Bellaire, Samuel Ewing, Anthony Grace

25. Aberrant A-I RNA Editing Profile in the Brains of Schizophrenia Patients
Ran Barzilay, Khen Khermesh, Tali Ben-Zur, Abraham Weizman, Erez Levanon, Daniel Offen

26. White blood cell levels are related to poor social functioning and reduced insula, amygdala, and nucleus accumbens volumes in a subgroup of people with schizophrenia
Stu G. Fillman, Rhoshel Lenroot, Jason Bruggemann, Stanley Catts, Maryanne O’Donnell, Cynthia Shannon-Weickert, Thomas Weickert

27. The Inflammation Paradox: A Longitudinal Study Monitoring Biomarkers of Immune Function from Before Birth to After Diagnosis in Non-affective Psychosis Cases and Matched Controls
Renee M. Gardner, Christina Dalman, Susanne Wicks, Brian Lee, Hakan Karlsson

28. Immune Response to Stress in Postpartum Psychosis
Annalisa Giordano, Astrid M. Pauls, Katie M. Hazelgrove, Costanza Vecchio, Valeria Mondelli, Mitul A. Mehta, Carmine M. Pariente, Susan Pawlby, Paola Dazzan

29. Cerebrospinal Fluid Biomarkers for Schizophrenia Revealed by a cICAT Proteomic Analyses
Kotaro Hattori, Yuichi Goto, Sumiko Yoshida, Daimei Sasayama, Toshi Komurasaki, Shigeyuki Chaki, Yasuyuki Fujii, Takao Yoshimizu, Hiroshi Kunugi

30. Reverse-translating Biological Markers for DISC1-Associated Behavioral Disorders to Human Patients
Laura Hecher, Svenja Trossbach, Verian Bader, Caroline Chwiesko, Magdalena Sauvage, Carsten Korth

31. Neutrophin Brain-derived Neurotrophic Factor (BDNF) in Psychiatric Systemic Lupus Erythematosus
Paulo Louzada Junior, Leticia Tamashiro, Rene Oliveira, Elizabeth Comini Frota, Eduardo Donadi, Cristina Del-Bon, Antonio Teixeira

32. Peripheral BDNF: A Candidate Biomarker of Healthy Neural Activity during Learning Is Disrupted in Schizophrenia
Thomas Weickert, Ashley Skilliter, Ans Vercammen, Rhoshel Lenroot, Cynthia Weickert

33. Reduced Deactivation in Medial Prefrontal Cortex during an Inner Speech Task in Schizophrenia Patients with Auditory Verbal Hallucinations
Leonie Bais, Ans Vercammen, Henderikus Knegtering, André Rieck

34. Impoverished High-Frequency Oscillatory Activity in Frontal Cortex in Individuals with Schizophrenia during Implicit Sequence Learning
Bruno Bagiante, Leighton Hinkley, Srikanth Nagarajan, Sophia Vinogradov

35. Affective Theory of Mind and Its Relationship with Impaired Insight in Patients with Schizophrenia: An fMRI Study
Annerieke de Vos, Marieke Pijnenburg, Daouia Larabi, Christine Hooker, Lisette van der Meer, André Rieck

36. Simultaneous EEG-fMRI Study of Chronic Schizophrenic Patients with Auditory Hallucinations
Beatriz Dionisio, Gracián García, Nicolás Peñaranda, Conrado J. Calvo, Francisco Olucha, Luis Martí-Bonmatí, Julio Sanjuán

37. Self-reflection in Schizophrenia: A Preliminary Activation-likelihood Estimation Meta-analysis
Clara S. Humpston, Anthony S. David, Ian Ellison-Wright

38. Language-related lateralization before and after antipsychotic treatment in prodromal or first-episode psychosis: An fMRI study
Tzung-Jeng Hwang, Chia-Ta Chen, Tai-Li Chou, Chih-Min Liu, Shen-Chung Liu, Ming H. Hsieh, Yi-Ling Chien, Hai-Gwo Hwu

39. Endogenous testosterone levels are associated with neural activity in men with schizophrenia during a facial emotion processing task
Ellen K., Cynthia Shannon-Weickert, Ans Vercammen, Ashley Skilliter, Rhoshel Lenroot, Thomas Weickert

40. Apathy-related resting state connectivity in patients with schizophrenia
Nicky Klæsens, Edith Liemborg, Leonie Bais, Ans Vercammen, Jozarni Dlabac-de Lange, Marte Swart, Lisette van der Meer, Esther Opmeer, André Rieck
41. Heritability of Brain Activity during Explicit Emotion Processing: A Study in Twins
Daniela Marvulli, Tiziana Quarto, Raffaella Romano, Marina Mancin, Annamaria Porcelli, Barbara Gelaio, Paolo Taurisano, Leonardo Fazio, Silvestro Trizio, Giuseppe Blasi, Alessandro Bertolino

42. Comparison of Large-scale Human Brain Functional and Anatomical Networks in Schizophrenia
Brent G. Nelson, Danielle Bassett, Jazmin Camchong, S. Charles Schulz, Kelvin Lim

43. Brain’s Functional Alterations in High Performance Schizophrenic Patients
Fabrizio Parente, Alessia Mirigliani, Marianna Frascarelli, Annalisa Giordano, Fabio Di Fabio, Antonio Buzzanca, Francesca Caramia, Mariana Gallo, Giuseppe Blasi, Maria Chiara Torti, Massimo Biondi

44. The Interaction between Variation in DRD2 and HTR2A Genes Predicts Prefrontal Function During Working Memory
Pierluigi Selvaggi, Raffaella Romano, Leonardo Fazio, Paolo Taurisano, Antonio Rampino, Annabella Di Giorgio, Grazia Caforio, Teresa Popolizio, Giuseppe Blasi, Alessandro Bertolino

45. Development of Novel PET Ligands (PF-04831704 and PF-06327104) for PDE10A
Karen M. Ward, Laigao Chen, Lei Zhang, Deborah Smith, Tom Chappie, Christopher Schmidt, Sarah Grimwood, Rebecca O’Connor, Stacey Rizzo, Klaas Schildknecht

46. White Matter Perfusion Fraction in Schizophrenia and Deficits in Processing Speed
Susan N. Wright, Joshua Chiappelli, Katie Nugent, Florian Muellerklein, Hemalatha Sampath, Pan Jiang, Laura Rowland, Danny J.J. Wang, Kavita Thangavelu, L. Elliott Hong, Peter Kochunov

47. Brain Activation during Self-reflection in Schizophrenia Compared to Bipolar Disorder
Li Wen Zhang, Esther Opmeer, Henricus Ruhe, Willem Nolen, André Aleman, Lisette van der Meer

48. The Reproducibility of 1H-MRS Glutamate Concentration Estimates at 3 Tesla, Implications for Glutamate Imaging in Schizophrenia
Kate S. Merritt, James M. Stone, Gareth J. Barker, Christopher A. Chaddock, Philip K. McGuire, Alice Egerton

49. An Initial Report on Metabolic Defects in Recent Onset Schizophrenia with a 7 Tesla MRI Scanner: Link to Changes in Brain Temperature and Cognition
Sotiris Posporelis, Mark Varvaris, Anouk Marsman, Jennifer Marie Coughlin, Susanne Bonekamp, Pearl Kim, Richard Edden, David J. Schretlen, Nicola Cascella, Peter B. Barker, Akira Sawa

50. Effects of Glutamatergic Function on Membrane Lipid Turnover and Energy Metabolism – A Combined 1H- and 31P-MR Spectroscopic Imaging Study in Healthy Individuals
Stefan Smesny, Alexander Gussew, Natalie Joan Biesel, Heinrich Sauer, Juergen Reichenbach

51. Suicidality and Cortical Structure in Schizophrenia - Effects on Cortical Thickness and Folding
Bianca Besther, Claudia Schachtzabel, Gerd Wagner, Jürgen Reichenbach, Ralf Schlösser, Heinrich Sauer, C. Christoph Schultz

52. Does Season of Birth Influence Cortical Thickness Correlates of Psychotic Experiences? A Genetically Informative MRI Study
Aldo Cordova-Palomera, Silvia Alemany, Carles Falcón, Nuria Bargalló, Ximena Goldberg, Benedicto Crespo-Facorro, Igor Nenadic, Lourdes Fañanás

53. Medial Frontal Gyrus Alterations in Schizophrenia: Relationship with Duration of Illness and Executive Dysfunction
Marianna Frascarelli, Stefania Tognin, Alessia Mirigliani, Fabrizio Parente, Buzzanca Antonino, Maria Chiara Torti, Caramia Francesca, Fabio Di Fabio, Massimo Biondi, Paolo Fusar-Poli

54. Brain Structural Abnormalities in Postpartum Psychosis: An MRI Study
Montserrat Fusté, Astrid Pauls, Simone Reinders, Mitul Mehta, Andy Simmons, Steve Williams, Josep Maria Haro, Carmine Pariante, Paola Dazzan

55. Prefrontal Cortex Volume in Patients with Schizophrenia is Correlated with Verbal Memory Performance
Clarissa S. Gama, Leticia Czeplelewski, Mariana Pedrini, Juliana Sartori, Marina Londero, Sandra Polita, Juliana Duarte, Pedro Goi, Mireia Vianna-Sulzbach, Paulo Belmonte-de-Abreu, Raffa Massuda

56. Thalamic Volume Abnormalities Associated with Negative Symptoms Predating the Onset of Psychosis
Fabienne Harrisherger, Renata Smieskova, André Schmidt, Stefan Borgwardt

57. Emotion Recognition and Theory of Mind Are Related to Gray Matter Volume of the Prefrontal Cortex in Schizophrenia
Arija Maat, Nelteije E.M. van Haren, Cali Bartholomeusz, René Kahn, Wiepke Cahn

58. Serum Levels of Inmate Immune Response Markers CCL22, CXCL1 and Apolipoprotein A1 Altered in First-episode Psychosis Associate with White Matter Volume and Integrity
Teemu J.S. Mäntylä, Outi Mantere, Tuukka T. Raji, Tuula Kieseppä, Hanna Laitinen, Jaana Leiviskä, Minna Torniainen, Outi Vaarala, Jaana Suvisaari

59. Decreased Grey Matter Volume as the Expression of Differential Sensitivity to Environmental Risk Exposure in Psychotic Disorder
Machteld Marcelis, Aleida Frissen, Petra Habets, Ed Gronenschild, Jim van Os

60. White Matter Alterations and Structural Connectivity in First-episode Antipsychotic-naïve Schizophrenia Patients
Jayachandra Mitra Raghava, Bjørn H. Ebrdrup, Mette Ødegaard Nielsen, Sanne Wulff, Egill Rostrup, Birte Glenthøj

61. Heterogeneity of Brain Structural Changes across Subgroups of Schizophrenia: Cortical Thickness and Cortical Complexity Analyses
Igor Nenadic, Rachel Yotter, Heinrich Sauer, Christian Gaser
62. Schizotypal Traits and Psychosis Proneness Differentially Affect Brain Structure in Healthy Persons  
Igor Nenadic, Carsten Lorenz, Kerstin Langbein, Maren Dietzek, Rakha Maityra, Stefan Smesny, Heinrich Sauer, Christian Gaser

63. Reduced Hippocampal Volume in Male but Not Female Patients with First Episode Psychosis: Relationship to Cortisol Levels and Symptoms  
Marita Pruessner, Martin Lepage, Louis Collins, Ridha Joober, Jens C. Pruessner, Ashok K. Malia

64. Neuroanatomical Predictors of Functional Outcome in the At-risk Mental State  
Renate L. Reniers, Ashleigh Lin, Alison Yung, Nikolaos Koutsourlieris, Barnaby Nelson, Dennis Velakoulis, Christos Pantelis, Stephen Wood

65. Classification of Twins Discordant for Schizophrenia and Healthy Twins Based on Their Structural MRI Scans  
Hugo G. Schnack, Mireille Nieuwenhuis, Neeltje E.M. van Haren, Wiepke Cahn, René Kahn, Hilleke Hulshoff Pol

66. The Polymorphism of YWHAE, a Gene Encoding 14-3-3epsilon, and Orbitofrontal Sulcogyral Pattern in Schizophrenia and Healthy Subjects  
Michio Suzuki, Yumiko Nakamura, Yukako Nakamura, Branko Aleksic, Yoichiro Takayanagi, Atsushi Furuchi, Mikio Kido, Kyo Noguchi, Koro Kabuchi, Norio Ozaki, Tsutomu Takahashi

67. In Vivo Characterization of the PDE10A PET tracer [18F]MNI-659  
Gilles D. Tamagnan, Olivier Barret, Caroline Papin, David Alagille, David Thoma, Ronald Baldwin, Kenneth Marek, John F. Seibyl

68. Grey Matter Volume Alterations in Patients with Schizophrenia and Unaffected Siblings Show Region-specific Effects of Genetic Risk and Disease-related Factors  
Silvestro Trizio, Giulio Pergola, Annabella Di Giorgio, Enrico Dambrosio, Ileana Andriola, Barbara Gela, Daniela Marvulli, Paolo Taurisano, Leonardo Fazio, Giuseppe Blasi, Alessandro Bertolino

69. Structural Brain Abnormalities, Psychosocial Functioning, and Genetic Vulnerability for Schizophrenia  
Wanda Truong, Michael J. Spilka, Vina Goghai

70. Is Gray Matter Volume a Structural Endophenotype for Schizophrenia?  
Jorien van der Velde, Paula Gromann, Marte Swart, Liesuwe de Haan, Richard Bruggeman, Durk Wiersma, Lydia Krabbendam, Andre Aleman

71. Change in Intelligence Is Associated with Progressive Gray Matter Loss in the Early Years of Schizophrenia  
Neeltje E.M. van Haren, Sander Haijma, Wiepke Cahn, René Kahn

72. Associations between Cortical Thickness and Trait Physical and Social Anhedonia in Non-clinical College Students  
Yi Wang, Yi Deng, Germaine Fung, Wen-hua Liu, Xin-hua Wei, Xin-qing Jiang, Eric Cheung, Raymond C. K. Chan

73. Treatment and Outcome of Youth with Early-phase Schizophrenia-spectrum Disorders and Psychosis NOS: 12-Week Results from a Naturalistic Cohort Study  
Diitie Lammers Vernal, Sandeep Kapoor, Aseel Al-Jadiri, Yehonatan Borenstein, Marta Hauser, Eva Sheridan, Irmgard Borner, Maren Carbon, Christoph Correll

74. Increased Risk of Schizophrenia Spectrum Disorders after all Childhood Psychiatric Disorders - Nationwide Study  
Cecilie F. Malling, Michael Eriksen Benros, Perete Nordenfelt, Soren Dalsgaard, Carsten Bocker Pedersen

75. Coping, Psychotic Symptoms and Functioning in Adolescents with Mental Illness  
Johanna Wigman, Nina Devlin, Ian Kelleher, Aileen Murtagh, Michelle Harley, Anne Kehoe, Carol Fitzpatrick, Mary Cannon

76. A Randomized Trial Administering Raloxifene vs Placebo as Add-on to Antipsychotics in Post-menopausal Female Patients with Schizophrenia or Schizoaffective Disorder  
Shimon Burshtein, Michael Davidson, Mark Weiser

77. Risk-based Monitoring for Aberrant Rating Patterns and Patient Selection Anomalies in Global Schizophrenia Trials  
David G. Daniel, Alan Kott

78. The Novel Pharmacology of ITI-007 Is Enhanced and Extended by Its Metabolic Back Conversion from IC200131  
Robert E. Davis, Joseph Hendrick, Lei Zhang, Wei Yao, Lawrence P. Wennogle, Hongwen Zhu, Gretchen L. Snyder, Kimberly Vanover, Sharon Mates

79. Effectiveness of Integrated Cognitive Remediation Therapy for Schizophrenia Outpatients: Early Versus Long-term Course of Illness - Results from an International RCT  
Daniel R. Müller, Valentin J. Benzing, Volker Roder

80. Understanding Social Situations (USS): Development of a New Social Cognitive Intervention for Individuals with Psychosis  
David L. Roberts, Laura Diggins, Lori Parente, Joanna Fiszdon

81. Randomized Trial of Clozapine vs. Risperidone in Treatment-Naïve First-Episode Schizophrenia: Preliminary Results  
Francisco Javier Sanz-Fuentenebro, Diana Taboada, Vicente Molina
82. Failures in the Facial Emotion Recognition in Patients with Schizophrenia, Siblings, and Control Subjects
   Ricardo Saracco-Alvarez, Ana Fresan, Raul Escamilla

83. Paliperidone ER Treatment and the Improvement of Social and Cognitive Function in Patients with Schizophrenia - A 24-Week, Single Arm, Open-Label Study
   Chuan Shi, Xin Yu, Lan Kang, Shuqiao Yao, Xirong Tang, Yifeng Xu, Daihui Peng, Jianguo Shi, Huali Lin, Xiufeng Xu, Fang Liu, Congpei Zhang, Xijin Wang

84. The Effect of Lifestyle Interventions on Psychosocial Functioning and Well-Being in Patients with Severe Mental Illness
   A.P.M. Stiekema, Anne Looijmans, Lisette van der Meer, Marian Dethmers, Robert Schoevers, Richard Bruggeman, Eva Corpeleijn, Frederike Jörg

85. Ability to Shift to Voluntary Attention Strategies Affects Performance on a Covert Detection Task in Schizophrenia but Not for Comparison Participants
   Elizabeth Bryant, Mohammed M. Al-Uzri, Maria Dale, Vesna Acovski, Timothy Millward, Chris Stowers, Steven S. Shimozaki

86. Metabolic Syndrome in Young Patients with Schizophrenia Is Associated with Poor Cognitive Performance
   Wiepke Cahn, Jessica de Nijs, Milou Pet, GROUP Investigators

87. Attentional Bias for Self-stigmatizing Stimuli in People with Schizophrenia Experiencing Habitual Self-stigma: Evidence from the Emotional Stroop Task
   Kevin K.S. Chan, Winnie W.S. Mak

88. Prospective Memory Impairments in Patients with First-episode Schizophrenia: A 1-year Follow-up Study
   Raymond C.K. Chan, Simon S.Y. Lui, Ya Wang, Tian-xiao Yang, Yi Wang, Eric Cheung, David Shum

89. Time Perception Networks and Cognitive Dysfunction in Schizophrenia: A Meta-Analysis
   Felipe Ortuño, Jose Gómez, Natalia Ojeda, Francisco Guillen-Grima, Joaquim Radua

   Hugo Geerts, Athan Spiros, Patrick Roberts

91. Affective Prosody in Psychosis: Recent Evidence and Future Directions
   Susan Rossell, Tamsyn Van Rheenen, Chris Groot

92. Limited Literacy among People with Serious Mental Illness in the US and Australia: A Natural Experiment?
   Cherrie Galletly, Alisa Lincoln, Cassandra Burton, Tammi Arford, Christopher Prener, Dennis Liu

93. AMPA-Receptor Modulators as Cognitive Enhancers in Schizophrenia: Why Are They So Difficult to Develop?
   Hugo Geerts, Athan Spiros, Patrick Roberts

94. C-reactive Protein Levels are Inversely Associated with Neurocognitive Performance in Acutely Admitted Patients with Psychosis
   Erik Johnsen, Farivar Fathian, Rolf Gjestad, Hugo A. Jorgensen, Rune A. Kroken, Else-Marie Loberg

95. Are Speech Illusions in a Healthy Sample Associated with Psychometric Risk for Schizophrenia?
   Richard J. Linscott, Max Nicolson, Sarah Morton, Jaimee Maha

96. Neurocognition, Social Cognition and Three-year Follow-up Social Functioning in Recent Versus Non-Recent Onset Psychosis
   Claudia Simons, Agna Bartels-Velthuis, Gerdina Pijnenborg

97. The Association between Thought Disorder and Memory Impairments in First-episode Psychosis
   Mustafa Dursun, Cen保 Aydind, Ahmet Ayer, Berna Yilmaz, Berna Binnur Akdede, Koksal Alptekin

98. Insight into Illness, Cognitive Reasoning and Uncooperativeness in Chronic Schizophrenia
   Richard J. Linscott, Max Nicolson, Sarah Morton, Jaimee Maha

   Gilles Martinez, Celia Mam-Lam-Fook, Patrica Garel, Marie-Odile Krebs, Isabelle Amado

100. The Association between Thought Disorder and Memory Impairments in First-episode Psychosis
    Arndis Simonsen, Vibeke Bliksted, Oddbjorg Johansen, Marjun Biskopst, Andreas Roepstorff, Daniel Campbell-Meiklejohn, Ole Mors, Riccardo Fusaroli

101. Insight into Illness, Cognitive Reasoning and Uncooperativeness in Chronic Schizophrenia
    Cynthia Siu, Ofer Agid, Mary Waye, Carla Brambilla, Wing-Kit Choi, Gary Remington, Philip D. Harvey

102. The Association between Thought Disorder and Memory Impairments in First-episode Psychosis
    Arndis Simonsen, Vibeke Bliksted, Oddbjorg Johansen, Marjun Biskopst, Andreas Roepstorff, Daniel Campbell-Meiklejohn, Ole Mors, Riccardo Fusaroli
103. High Educational Performance is a Distinct Feature of Bipolar Disorder compared to Schizophrenia
   Annabel Vreeker, Lucija Abramovic, Annet van Bergen, Sanne Verkooijen, BIG Investigators, GROUP Investigators, Aniël Orl, Yoon Jung, Roel Ophoff, Marco Boks

104. Childhood Trauma and Cognitive Impairments in Patients with Schizophrenia
    Seunghee Won, Do Hoon Kim, Jiwoo Kim, Taehoon Koo

105. Disappearance of the Unmasking Effect of Temporally Pre-Presented Lipreading Cues on Speech Recognition in People with Chronic Schizophrenia
    Chao Wu, Liang Li, Chuan-Yue Wang

106. The Relationship of Attitudinal Beliefs to Negative Symptoms, Neurocognition, and Daily Functioning in Recent-onset Schizophrenia
    Joseph Ventura, Kenneth L. Subotnik, Arielle Ered, Denise Gretchen-Dooral, Gerhard S. Hellemann, Anja Vaskinn, Keith H. Nuechterlein

107. Dimensions of Delusions and Self-serving Bias along the Continuum of Psychosis
    Suzanne H. So, Venus Tang, Patrick Wing-leung Leung

108. Instruments Evaluating Emotional Blunting in Schizophrenia Patients with Negative Symptoms: A Systematic Review
    Sanja Kilian, Anneke Goosen, Robin Emsley

109. The Basel Interview for Psychosis: Structure, Reliability and Validity
    Anita Riecher-Rössler, Tamara Ackermann, Martina Uttinger, Sarah Ittg, Susan Kornay, Charlotte Rapp, Ilial Bugra, Jacqueline Aston, Rolf-Dieter Stieglitz, Erich Studerus

110. Redefining Schizophrenia Subtypes and Dimensions with Structural Brain Imaging: Unsupervised and Multivariate Learning Algorithms Applied to Diagnostic Nosology in Schizophrenia
    Geoffrey C. Tan, Carissa Nadia Kuswanto, Lye Yin Poon, Min Yi Sum, Guoliang Yang, Wieslaw Nowinski, Yi Yian Sitoh, John Ashburner, Swapan Verma, Kang Sim

111. Characterizing Schizophrenia using Semantic Judgments and Body Quotients
    Bellon Thibaut

112. Clinical Staging in People Diagnosed with Schizophrenia or a Related Disorder
    Eva Vethorst, Amy Tedja, Carin Meijer, Lieuwe de Haan, GROUP investigators

113. A Novel Kc3 Positive Modulator Augments Gamma Frequency Oscillations in the Mammalian Neocortex In vitro
    Faiza Ben-Mabrouk, Giuseppe Alvaro, Charles Large, Fiona Lebeau, Mark Cunningham

114. Pleiotropic Effect of Disrupted in Schizophrenia 1 Gene: Analysis of Event-related Potentials and Brain Structure
    Vincenzo de Luca, Gianfranco Spalletta

115. Effects of Blocking D2 Receptors on Mismatch Negativity of Antipsychotic Naïve, First Episode Schizophrenia Patients
    Signe W. During, Bob Oranje, Birte Gøntshoej

116. Increasing Glutamate Release in a Genetic Model of Cognitive Deficits
    Antonieta Lavin, Darius Becker-Krail

117. The Effect of Cognitive Training on Event-related Potentials in Schizophrenia
    Bernhard W. Müller, Daniela Kariofi, Christian Kärger, Jens Wiltfang, Gudrun Sartory

118. The Effect of Different Definitions of Schizophrenia
    Janne Tidselbaek Larsen, Holger Jelling Sørensen, Liselotte Petersen, Ole Mors, Preben Bo Mortensen

119. The Psychosis Recent Onset GRoningen Survey (PROGR-S): Defining Dimensions and Improving Outcome in Early Psychosis
    Edith Liemborg, Stynke Castelein, Ellen Visser, Dick Smid, Erna Van’t Hag, Frank Van Es, Anne Neelje Scholte, Gerard Van de Willige, Richard Bruggeman, Henderikus Kneetering

120. Help-seeking Behaviour and At-risk Criteria of Psychosis in the General Population: Preliminary Results from a Telephone Survey
    Chantal Michel, Benno G. Schimmelmann, Frauke Schultze-Lutter

121. Mental Health Literacy: Is Psychosis as Well Recognized as Depression?
    Chantal Michel, Benno G. Schimmelmann, Frauke Schultze-Lutter

122. Association between Epilepsy and Psychotic Disorders in the Northern Finland 1966 Birth Cohort Study
    Jouko Miettunen, Tanja Nordström, Emmi Keskinen, Johanna Uusimaa, Ina Rissanen, Matti Isohanni, Erika Jääskeläinen

123. Sex Differences in Prevalence and Comorbid Substance Use Disorders among Patients with Schizophrenia and Bipolar Disorder: A Five-year Population-based Study
    Ragnar Nesvang, Gun Peggy Knudsen, Inger Johanne Bakken, Anne Høy, Eivind Ystrom, Pål Surén, Anne Reneflot, Camilla Stoltenberg, Ted Reichborn-Kjennerud

124. Delay in Routinely Neonatal Blood Screening is Associated with Increased Risk of Schizophrenia
    Merete Nordentoft, Janne Larsen, Liselotte Petersen, Holger Sørensen, Mads Hollegaard, Preben Bo Mortensen, Carsten B. Pedersen
125. Social Class and Psychosis
Brian O’Donoghue, Felicity Fanning, John Lyne, Laoise Renwick, Kevin Madigan, Anthony Kinsella, Abbie Lane, Niall Turner, Eadbhard O’Callaghan, Mary Clarke

126. Mental Health Literacy: Design of and Response to an Add-on Questionnaire Study to a Population Survey
Frauke Schultze-Lutter, Chantal Michel, Benno G. Schimmelmann

127. Prevalence of At-risk Criteria of Psychosis in Children and Adolescents, and in Young Adults: Results from Two Swiss Community Samples
Frauke Schultze-Lutter, Chantal Michel, Benno G. Schimmelmann

128. Risk of Schizophrenia Spectrum and Affective Disorders Associated with Small for Gestational Age Birth and Height in Adulthood
Yoichi Takayanagi, Liselotte Petersen, Thomas Laursen, Nicola Cascella, Akira Sawa, Preben Bo Mortensen, William Eaton

129. Evidence for a Shared Etiological Mechanism of Psychotic Symptoms and Obsessive Compulsive Symptoms in Patients with Psychotic Disorders and Their Siblings
Frank Van Dael, Marije Swets, Lieuwe de Haan, Jim van Os, Inez Myin-Germeys

130. Premature Death is Higher in Persons with Psychotic Disorders but not with Psychotic Experiences: A Population-based Longitudinal Study
Nomí Werbeloff, Bruce Dohrenwend, Izhak Levav, Rina Yaffe, Ziona Haklai, Mark Weiser

131. Use and Abuse: The Role of Community Treatment Orders in an Intensive Outreach Team
Carol Silberberg

132. Copy Number Variant Analysis on 401 Cases of Schizophrenia: A Search for Causal Genes Finds Disruption in the Neurogenesis Regulator Jagged 2
Joshua R. Atkins, Jing Qin Wu, Paul A. Tooney, Rodney J. Scott, Vaughan J. Carr, Murray J. Cairns

133. Association of a Risk Allele of ANK3 with Cognitive Performance and Cortical Thickness in Patients with First-episode Psychosis
Clifford M. Cassidy, Lisa Bucyi, Michael Bodnar, Jennifer Delécluse, Zia Choudhry, Sarojini Sengupta, Rebecca Fox, Srividya Iyer, Ashok Mallu, Martin Lepage, Ridha Joober

134. Impact of the Schizophrenia Candidate Gene RGS4 on Psychosis-proneness
Marta de Castro-Català, Neus Barrantes-Vidal, Elionora Peña, Thomas R. Kwapil, Paula Cristóbal-Narváez, Arcadii Rosa

135. Analysis of Neurtin1 Gene in Schizophrenia-spectrum and Bipolar Disorders: Its Influence on Age at Onset and Cognitive Functioning
Mar Fatjó-Vilas, Claudia Prats, Edith Pomarol-Clotet, Luisa Lázaro, Carmen Moreno, Mara Parellada, Ana María González-Pinto, Generós Ortet, Peter McKenna, Lourdes Fañanás

136. Relation of RGS4 Gene with Schizophrenia
Emre Guler, Çağdem Ereş Yapıcı, Sefa Kızıldag, Banu Dergirmencioglu, Serhat Taslı, Koksal Alptekin

137. Genetic Variations in Prefrontal Dopamine: Influences on Schizotypy and Cognition
Caroline Gurvich, Erica Neill, Tamssyn Van Rheenan, Stephanie Louise, Kiymet Bozaoğlu, Susan Rossell

138. Spatio-temporal Protein Interaction Network Dynamics of 16p11.2 Genes
Lilia M. Iakoucheva, Nick Guan Lin, Roser Corominas, Xinping Yang, Tong Hao, David Hill, Marc Vidal

139. PLA2 Gene Expression in First Episode Drug Naïve Patients
Daniel S. Kerr, Mauricio Serpa, Leda L. Talib, Martinus Theodorus Van de Bilt, Juliana Alcantara, Tiffany Chaim, Geraldo Busatto, Marcus Zanetti, Wagner Gattaz

140. The Influence of AHI1 Variants on the Diagnosis and Treatment Outcome in Schizophrenia
Jung Jin Kim, Jung Seo Yi, Seung Hyun Kim, Chi Un Pae

141. Associations between Polygenic Risk Scores for Type 2 Diabetes Mellitus and Co-morbid Diabetes in a Sample of Subjects with Schizophrenia, Schizoaffective, or Bipolar I Disorders
Jaya Padmanabhan, Neeraj Tandon, Chiara Haller, Ian Mathew, Gualberto Ruan, Andreas Windemuth, Brett Clementz, John Sweeney, Godfrey D. Pearlson, Carol Tamminga, Matcheri Keshavan

142. Genetic Association Studies of Schizophrenia Risk Genes with Cognitive and Neuroimaging Traits in the GENUS Consortium Collection
Tracey Petryshen, Gabriella Blokland, GENUS Consortium

143. Interactive Effects of FKBP5 and Childhood Trauma on Cognition in Schizophrenia
Alessandra Raudino, Vaughan J. Carr, Murray J. Cairns, Chris Oldmeadow, Paul A. Tooney, Rodney J. Scott, Melissa J. Green

144. Neurodevelopment Genes Are Differentially Expressed in Blood of Subjects with Ultra High Risk (UHR) to Psychosis Compared to Controls and First Episode of Psychosis (FEP) Patients
Marcos L. Santoro, Ary Gadelha, Vanessa Ota, Gracciele Cunha, Elson Azevedo, Cristiano Noto, Pedro Pan, Quirino Cordeiro, Elisa Brietzke, Rodrigo Bressan, Sintia Belanger

145. Health-related Quality of Life Outcomes among Patients with Schizophrenia: Results from a Long-term Naturalistic Trial of Patients Switching to Lurasidone from Other Antipsychotics
Kritika Rajagopalan, Mariam Hassan, A. George Awad, Jay Hsu, Andrei Pikalov, Antony Loebel

146. Copy Number Variation Analysis of 401 Cases of Schizophrenia: A Search for Causal Genes Finds Disruption in the Neurogenesis Regulator Jagged 2
Joshua R. Atkins, Jing Qin Wu, Paul A. Tooney, Rodney J. Scott, Vaughan J. Carr, Murray J. Cairns

147. Association of a Risk Allele of ANK3 with Cognitive Performance and Cortical Thickness in Patients with First-episode Psychosis
Clifford M. Cassidy, Lisa Bucyi, Michael Bodnar, Jennifer Delécluse, Zia Choudhry, Sarojini Sengupta, Rebecca Fox, Srividya Iyer, Ashok Mallu, Martin Lepage, Ridha Joober

148. Impact of the Schizophrenia Candidate Gene RGS4 on Psychosis-proneness
Marta de Castro-Català, Neus Barrantes-Vidal, Elionora Peña, Thomas R. Kwapil, Paula Cristóbal-Narváez, Arcadii Rosa

149. Analysis of Neurtin1 Gene in Schizophrenia-spectrum and Bipolar Disorders: Its Influence on Age at Onset and Cognitive Functioning
Mar Fatjó-Vilas, Claudia Prats, Edith Pomarol-Clotet, Luisa Lázaro, Carmen Moreno, Mara Parellada, Ana María González-Pinto, Generós Ortet, Peter McKenna, Lourdes Fañanás
Fostering Collaboration in Schizophrenia Research

146. Alexithymia and Emotion Regulation Strategies in First-degree Relatives of Schizophrenia Patients
André Aleman, Jorien van der Velde, Paula Gromann, Marte Swart, Lieuwe de Haan, Durk Wiersma, Lydia Krabbe, Richard Bruggeman

147. Eye Movement Abnormalities in Adults with an At-risk Mental State for Psychosis
Sabine Bosch, Erich Studerus, Martina Papmeyer, Anita Riecher-Rössler

Camilla Austa Jerlang Christiani, Jens Richardt Jepsen, Anne A. E. Thorup, Nicoline Hemager, Aja Greve, Ditte L. Gantriis, Ditte L. Ellersgaard, Mette Skjærbæk, Ole Mors, Kerstin J. Plessen, Merete Nordentoft

149. Dysfunctional Emotion Regulation as a Vulnerability Marker for Psychosis: The Twinscan China Study
Francesca A. Cotier, Lu Hua Chen, Winifred Mark, Phoebe Kong, Shelly Leung, Cecilia N.W. Leung, Emma Li, Jim van Os, Timothea Touloupoulou


151. Neurocognitive Profiles in 7-year Old Offspring of Parents with Schizophrenia or Bipolar Disorder. Part of the High Risk and Resilience Study - VIA 7
Nicoline Hemager, Jens Richardt Møllegaard Jepsen, Anne Amalie Elgaard Thorup, Camilla Austa Jerlang Christiani, Aja Neergaard Greve, Ditte Lou Gantriis, Ditte Vestbjerg Ellersgaard, Ole Mors, Merete Nordentoft, Kerstin J. Plessen

152. Psychosis Risk in Adolescence: Clinical Baseline Differences between Prodromal and Familial High Risk Samples
Daniel Izarbe, Gisela Sugranyes, Inmaculada Baeza, Elena De la Serna, Soledad Romero, Vanessa Sanchez-Gistau, Montserrat Dolz, Josefin Castro Fornieles

153. Clinical and Functional Course of Youths at Ultra-high Risk for Psychosis: Outcomes of Non-converters in Japan
Masahiro Katsura, Noriyuki Ohmuro, Chika Obara, Tatsuo Kikuchi, Yumiko Hamaie, Emi Sunakawa, Fumiaki Ito, Tetsuo Miyakoshi, Atsushi Sakuma, Hiroo Matsuoka, Kazunori Matsumoto

154. Emotional Dysregulation, Attributional Bias, Neurocognitive Impairment in Ultra-high Risk for Psychosis and Schizophrenia: It’s Association with Paranoia
Namwook Kim, Jin Young Park, Yun Young Song, Seo Yeon Baek, Jee In Kang, Eun Lee, Suk Kyoon An

155. Prediction of Psychopathology and Functional Impairment by Positive and Negative Schizotypy in the Chapmans' Ten-year Longitudinal Study
Thomas R. Kwapil, Georgina Gross, Paul Silvia, Neus Barrantes-Vidal

156. Speech Illusion, Perceived Social Standing and Self-esteem in Psychosis Proneness: The TwinsScan China Study
Cecilia N.W. Leung, Emma Li, Francesca Cotier, Winifred Mark, Lu Hua Chen, Jim van Os, Timothea Touloupoulou

157. The Course of Neurocognitive Functioning in Helpseeking Individuals: Comparison of Risk for Psychosis and Bipolar Disorder Criteria
Sibylle Metzler, Diane N. Dvorsky, Christine Wyss, Mario Müller, Nina Traber-Walker, Susanne Walitza, Anastasia Theodoridou, Wulf Rössler, Karsten Heekeren

158. Cannabis Use and Neuropsychological Functioning in Ultra-high Risk for Developing Psychosis in Child and Adolescent Patients and Healthy Controls
Marta Pardo, Anna Sintes, Olga Puig, Clara Espelt, Elena De la Serna, Marta Rodriguez, Marta Espadas, Marta Carulla, Inmaculada Baeza, Montserrat Dolz

159. Functional Impairment in Children and Adolescents with Psychosis Risk Syndrome: Social and Role Functioning Compared with Controls and Relationships to Prodromal Symptoms
Olga Puig, Inmaculada Baeza, Elena De la Serna, Anna Sintes, Clara Espelt, Jordina Tor, Gisela Sugranyes, Vanessa Sanchez-Gistau, Mireia Rosa, Marta Pardo, Montserrat Dolz

160. Review of False Negatives with the Comprehensive Assessment of At-risk Mental State (CAARMS) Screening
Suiattha Rao, Lay Kew Lim, Lye Yin Poon, Spencer Yuen, Santha Pariyasami, Sarah Ann Tay, Swapna Verma

161. A Joint Latent Class Modelling Approach for the Prediction of Psychosis by Basic Symptom and Ultra-high Risk Criteria
Stefanie J. Schmidt, Stephan Ruhrmann, Benno G. Schimmelmann, Joachim Klosterkötter, Frauke Schultze-Lutter

162. Deficits in Fine Motor Skills in Emerging Psychosis
Fabienne S. Soguel-dit-Piquard, Erich Studerus, Martina Papmeyer, Ittig Sarah, Uttinger Martina, Avisnash Ramyead, Susan Koranyi, Anita Riecher-Rössler

163. What Happens in the Brain When Psychosis Proneness Subject Undergoes Psychiatric Treatment for 2 Years?
Je-Yeon Yun, Tae Young Lee, Sung Nyun Kim, Joon Hwan Jang, Do-Hyung Kang, Jun Soo Kwon

164. Duration of Untreated Psychosis and Negative Symptoms; A Systematic Review and Meta-analysis of Individual Patient Data
Nynke Boonstra, Rianne Klaassen, Lex Wunderink, Sjoerd Sytema, Max Marshall, Lieuwe de Haan, Durk Wiersma
165. **Apathy but not Diminished Expression in Schizophrenia is Associated with Discounting of Monetary Rewards by Physical Effort**  
Matthias N. Hartmann, Oliver M. Hager, Anna V. Reimann, Matthias Kirschner, Justin R. Chumbley, Philippe N. Tobler, Stefan Kaiser

166. **Is Quality of Life Related to Cognitive Performance or Negative Symptoms in Patients with Schizophrenia? Results from a Double-Blind, Active-Controlled, Lurasidone Continuation Study**  
Philip D. Harvey, Antony Loebel, Josephine Cucchiara, Debra Phillips, Cynthia Siu

167. **Negative Symptoms: Review from a Life Course Approach**  
John Paul Lyng, Mary Clarke

168. **Spanish Adaptation and Validation of the Brief Negative Syndrome Scale**  
Anna Mane Santacana, Clemente Garcia-Rizo, Daniel Berge, Mari Paz Garcia-Portilla, Leticia Garcia, Gisela Sugranyes, Miguel Bernardo, Julio Bobes, Emilio Fernandez-Egea

169. **Verbal Memory, but not Working Memory as Cognitive Marker of Negative Symptoms in Patients with First Episode of Psychosis**  
Gisela Mezquida, Bibiana Cabrera, Miquel Bioque, Clemente Garcia-Rizo, Cristina Oliveira, Ana Meseguer, Miguel Bernardo

170. **Identifying Negative Symptoms in Schizophrenia and Association with Clinical Outcomes Using Natural Language Processing**  
Rashmi Patel, Nishamali Jayatilleke, Richard Jackson, Hitesh Shetty, Robert Stewart, Philip McGuire

171. **Dissociation of Anticipatory and Consummatory Pleasure in Schizophrenia**  
Chao Yan, Qi-feng Yin, Simon S.Y. Lui, Lai-quan Zou, Fu-chun Zhou, Raymond C.K. Chan

172. **Alteration of the Expression Balance of hnRNP C1 and C2 Changes the Expression of Myelination- and Schizophrenia-related Genes in the Human Oligodendrocytic Cell Line**  
Keiko Iwata, Hideo Matsuzaki, Takayuki Manabe, Daniel Martins-de-Souza, Nori Takei

173. **Metabotropic Glutamate Receptor 5 Dysregulation in Schizophrenia**  
Kelly Newell, Natalie Matosin, Francesca Fernandez-Enright, Xu-Feng Huang

174. **Stress, Cortisol and Pituitary Volume during Psychosis**  
Dorte Nordholm, Merete Nordentoft, Lasse Randers, Valeria Mondelli, Mette Ø Nielsen, Sanne Wulff, Kristine Krakauer, Paola Dazzan, Henrik Norbak-Emig, Egil Rostrup, Birte Glenthøj

175. **The Erythrocyte Membrane Lipid Abnormalities Observed in Schizophrenia Patients Support the Oxidative Stress Hypothesis in Schizophrenia**  
Philippe Nuss, Cédric Tessier, Haifa Bergaoui, Ariel Fragerman, Antonin Lamaziere, Marc De Hert

176. **Uniquely Targeted Molecular Therapeutic for Schizophrenia: Characterization of ITI-007 in Vitro and in Vivo Animal Models**  
Lawrence P. Wennogle, Gretchen L. Snyder, Robert E. Davis, Kimberly Vanover, Joseph Hendrick, Peng Li

177. **Proteomic and Genomic Analyses Implicate the Postsynaptic Density in Schizophrenia**  
Melanie Foecking, Lorna M. Lopez, Jane English, Patrick Dicker, Gerard Cagney, David Cotter

178. **Left Parietal Lobe Arachnoid Cyst in a Patient with Psychosis: Case Report**  
Arnab K. Ghosh, Richard Cuthbert Mellor

179. **Gene Expression throughout Human Postnatal Development in Single Cell Populations in the Prefrontal Cortex**  
Tsung-Ung W. Woo, Emily A. Kohlbrenner, Sarah A. Mauney

180. **Dynamic Causal Modelling of Abnormal Frontal Evoked Gamma Band Activity in Patients with Schizophrenia**  
Alvaro Dieg, Siri M. Ranlund, Harriet Brown, Rick A. Adams, Muriel Walshe, Robin M. Murray, Karl Friston, Dimitris Pinotis, Elvira Bramone

181. **Greater Leftward Frontal Alpha Activation during Criticism is Associated with Schizotypal Traits and Anxiety**  
Preethi Premkumar, Miguel Espirito-Santo, Juliana Onwumere, Veena Kumari, Maddie Groom, Elizabeth Kuipers

182. **The Effect of Reboxetine and Haloperidol on Sensory Gating in Healthy Humans and Rats**  
Louise M. Witten, Birte Glenthøj, Jesper Bastlund, Arne Mørk, Björn Steiniger-Brach, Bob Oranje

183. **Chronic Social Defeat Stress Induces Increased Expression of D2-dimer in the Prefrontal Cortex of Mice**  
Tarique R. Bagalkot, Hong-Mei Jin, Yin Cui

Joseph Bisoglio, Josh Mervis, Jimmy Choi

185. **Attribution of Mental States during Conversation in Schizophrenia: Profile of Poor Mentalisers Maud Champagne-Lavau, Hélène Wilquin, Catherine Faget, Florence Vaillant, Stéphane Rauzy, Laurent Boyer, Christophe Lançon**

186. **Cognitive Performances of Juvenile Offenders with Severe Psychiatric Disorders**  
Stéphanie Charles, Gaëlle Grajek, Nelson Provost, Audrey Pauwels, Anu Raevuori, Laurent Servais
187. At-risk States in Psychosis: Schizophrenia Proneness Instrument (SPI-A / SPI-CY) and its Neuropsychological Correlates
Diane N. Dvorsky, Sibylle Metzler, Mario Müller, Christine Wyss, Karsten Heekeren, Susanne Walitza, Wulf Roessler, Anastasia Theodoridou

188. The Role of Cognitive Reserve in Predicting Neuropsychological Outcome in Schizophrenia
Wanping Huang, Jimmy Lee, Max Lam, Attilio Rapisarda, Michael Kraus, Richard S.E. Keefe

189. Neuropsychometric Functioning of Subjects with Putative Pre-psychotic States and Early Psychosis: Baseline Assessment and 1-year Follow-up
Chen-Chung Liu, Mau-Sun Hua, Hai-Gwo Hwu

190. Screening for Cognitive Impairment in Chronic Schizophrenia using the Cognigram Cognitive Assessment System
Paul Maruff, Peter Snyder, Judy Jaeger

Rinaldi Romina, Lefebvre Laurent

192. Examining the Impact of Neurocognitive and Language Impairments on Formal Thought Disorder in Schizophrenia
Eric Tan, Gregory Yelland, Susan Rossell

193. Social Cognition Training for People with Schizophrenia: A Randomised Study
Matteo Cella, Rumina Taylor, Emese Csipke, Charles Heriot-Maitland, Til Wykes

194. Roll-out and Impacts of DJ's Choices Workshops
Marie-France Demers, Julie Bourbeau, Julie Bouchard, Claudia Lévesque, Lysanne Gauthier, Marc-André Roy

195. Prevention of Weight Gain in Early Psychosis: A Randomized Controlled Clinical Trial of 16-Week Stepped Behavioral Intervention
Rohan Ganguli, Sabrina Hassan, Mehran Bhamani, Todd Jenking

196. Community-based Skills Training Helps Psychotic Clients of Varying Ages, Educational Level, and Work Experience Make Functional Gains
Alice Medalia, William Jock, Alicia Ventresca, Tiffany Herlands

197. Enhancing Cognitive Training through Aerobic Exercise after a First Schizophrenia Episode: Theoretical Conception and Pilot Study
Keith H. Nuechterlein, Joseph Ventura, Denise Gretchen-Doorly, Sarah C. McEwen, Sophia Vinogradov, Kenneth L. Subotnik

198. Is Cortical Thickness Associated to Responsiveness to Cognitive Remediation Therapy in Schizophrenia?
Rafael Penadés, Rosa Catalán, Núria Pujol, Clemente García-Rizo, Guillem Massana, Carme Junqué, Miquel Bernardo

199. REFLEX: A Metacognitive Group Treatment to Improve Insight in Psychosis
Gerdina Piienenborg, Annerieke De Vos, Liset Van der Meer, Esther Sportel, Claudi Bockting, Mark van der Gaag, Andre Aleman

200. A Three Month Follow Up Study Evaluating Clinical Change and Attitudes towards Involuntary Admission in Individuals Detained under the Mental Health Act 2001
Emma Bainbridge, Brian Hallahan, David McGuinness, Agnes Higgins, Kathy Murphy, Colm McDonald

201. Stability of Retrospective Self-reports of Childhood Trauma in Early Psychosis
Sarah Bendall, Samantha Simpson, Gennady Baksheev, Belinda Garner, Christina Phassouliotis, Lisa Phillips

202. Characterization of a Number of Atypical Antipsychotics in-vitro
Claus T. Christoffersen, K. Holm, A. Ruskov-Nielsen, J. Nielsen

203. Increased Autonomic Arousal: Is it a Vulnerability Factor and Specific for Psychosis?
Annika Clamor, Maike Hartmann, Ulf Köther, Christian Otte, Steffen Moritz, Tania Lincoln

204. Non Psychotic Pregnancy Denial: A Case Report
Ester di Giacomo, Tommaso Tabacchi, Fabrizia Colmegna, Susan Pawlhy, Barbara Pucci, Patrizia Vergani

205. Examining and Contrasting the Social Stereotype of Schizophrenia and Depression
Ross G.M. Norman, Elizabeth Hampson, Richard Sorrentino, Yang Ye, Yxian Li

206. Vitamin D Deficiency in Dutch Outpatients with Bipolar Disorder, Schizoaffective Disorder or Schizophrenia
Peter F. J. Schulte, Remco Boerman, Dan Cohen

207. Accumulated Environmental but not Genetic GWAS-derived Risk Determines Schizophrenia Onset
Beata Stepiak, Sergi Papiol, Christian Hammer, Martin Begemann, Anna Ramin, Sarah Everts, Lena Hennig, Hannalore Ehrenreich

208. Beliefs about the Concept of Schizophrenia in the Argentinian Population
Laura N. Vanadia, Noelia Johanna Benchart, Raimundo Juan Muscellini
209. Effects of Object Size and Distance on Reach-to-grasp Movement in Patients with Schizophrenia and Healthy Controls

Shu-Mei Wang, Li-Chieh Kuo, Wen-Chen Ouyang, Hsiao-Man Hsu, Hui-Ing Ma

210. Maori Patients with Schizophrenia: How to Improve their Rehabilitation and Recovery

Nicoleta Clementi, Alison Brown, Ellen Norman

211. Treatment Outcomes, Insight and Recovery in First-episode Schizophrenia

Ofer Agid, Cynthia Siu, Philip D. Harvey, Robert Zipursky, Gagan Fervaha, George Foussias, Krysta McDonald, Gary Remington

212. Sexual and Physical Trauma and the Social and Vocational Functioning in First-episode Psychosis Patients

Luis Alameda, Carina Ferrari, Philipp Baumann, Margot Fournier, Hélène Moser, Mehdi Mohammad Gholam-Razae, Kim Q. Do, Philippe Conus

213. Perfectionism and Working Alliance in a Cognitive-behavioral Intervention for Weight Loss in Psychotic Illness

Sabrina Hassan, Rohan Gangafuli, Gordon Flett, Amanda Suleiman, Paul Hewitt

214. Remission Criteria and Functional Outcome in Schizophrenia Patients, a Longitudinal Study

Henriette Heering, Mayke Janssens, Lindy Boyette, Neeltje E.M. van Haren, GROUP authors

215. Effects of Cannabis Use on Clinical and Psychosocial Outcomes in First-episode Psychosis

Anna Kolliakou, Hannah Sallis, Antonella Trotta, Jennifer O’Connor, Marta Di Forti, Anthony S. David, Robin M. Murray

216. Vitamin D as a Predictor of Illness Severity at One Year in First Episode Psychosis

John Lally, Poomam Gardner-Sood, Oliver Howes, Stefania Bonaccorso, Shubulade Smith, Marta Di Forti, Robin M. Murray, Fiona Gaughran

217. Comparison of Characteristics of Psychosis Patients with and without Hospitalization at First Episode

Edwin Lee, Christy L.M. Hui, W.C. Chang, Sherry K.W. Chan, Eric Y.H. Chen

218. Meta-analysis shows that the Level of Cannabis Use Determines the Risk of Psychosis

Marta Di Forti, Arianna Marconi, Robin M. Murray, Cathryn Lewis, Evangelos Vassos

219. The Relationship between Neurocognition and Real Life Functioning in First-episode Schizophrenia: Results from the 2-year Follow-up in the Oslo Longitudinal Recovery Study

Anne-Kari Torgalsboen, Christine Mohn, Nikolai Czajkowski, Bjørn Rishovd Rund

220. Premorbid Cannabis Use and Earlier Age at Onset of Psychosis: Findings from Two Studies in the U.S.

Michael T. Compton, Mary Kelley, Beth Broussard, Claire Ramsay Wan

221. Suicidality in Schizophrenia Spectrum Disorders: Relation to Hallucinations and Persecutory Delusions

Eirik Kjelby, Igne Sinkeviciute, Rolf Gjestad, Rune Andreas Kroken, Else-Marie Løberg, Hugo A. Jørgensen, Erik Johnsen

222. Disturbed Bodily Experiences in Patients with First-episode Schizophrenia

Lene Nyboe, Poul Videbech

223. Association between Subtle Dyskinesia and Schizotypy in Subjects with Auditory Verbal Hallucinations and Healthy Controls

Anne F. Willems, Diedrik Tenbøn, Jeroen Koning, Peter Van Haren

224. Cortisol Levels in Early Psychosis: Systematic Review and Meta-analysis

Boris Chaumette, Oussama Kebir, Thérèse Jay, Marie-Odile Krebs

225. Predicting Psychosis in a General Adolescent Psychiatric Sample

Maja Lindgren, Marko Manninen, Hely Kalska, Ulla Mustonen, Taina Laajasalo, Kari Moilanen, Matti Huttunen, Tyrone D. Cannon, Jaana Suvisaari, Sebastian Therman

226. Neural Networks Involved in Self-referential Processing and Perspective Taking in Healthy People: Its Association with Theory of Mind Ability and Anomalous Self Experience

Kyoungri Park, Hye Yoon Park, Minji Bang, Suk Kyoon An


Lasse Randers, Birgitte Fagerlund, Jens R.M. Jepsen, Dorte Nordholm, Kristine Krakauer, Birte Y. Glenthøj, Merete Nordentoft

228. The Association between Reported Childhood Trauma, Perceived Parenting and Psychopathological Risk

Attilio Rapisarda, Guo Quan Ryan Nah, Vidhya Renjan, Max Lam, Jimmy Lee

229. Dosing and Clinical Strategies of Paliperidone ER in Acutely Exacerbated Schizophrenia: An Expert Consensus in Taiwan

Ya Mei Bai, Yao Hung, Chia Yi Liu, Y.C. Yen, M.W. Huang, S.W. Wu, C.C. Chiu, M.H. Hsieh, W.T. Kao, Y.S. Lee

230. Natural Medicines in Schizophrenia: A Systematic Review

Agna A. Bartels-Velthuis, Rogier Hoenders, Nina Vollbehr, Richard Bruggeman, Rikus Knegcnering, Joop de Jong

231. Treatment of Violent Dissocial Personality Disorder Patients with Clozapine Requires Lower Dose and Therapeutic Levels than in Schizophrenia

Darcy Brown, Fintan Larkin, Samrat Sengupta, Jose Romero, Callum Ross, Morris Vinestock, Mrigendra Das
232. Efficacy of Second-versus First-generation Antipsychotic Drugs for Treatment-resistant Schizophrenia: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Markus Dold, Stefan Leucht

233. All-cause Discontinuation and Safety of Aripiprazole Once-monthly for the Treatment of Schizophrenia: A Pooled Analysis of Two Double-blind, Randomized, Controlled Trials
Anna Eramo, W. Wolfgang Fleischhacker, Raymond Sanchez, Lan-Feng Tsai, Timothy S. Peters-Strickland, Ross A. Baker, Dusan Kostic, John M. Kane

234. Resting Cerebral Blood Flow (rCBF) in First Episode Psychosis and Changes Induced by Antipsychotic Medication
Rhianna M. Goozee, Fernando Zelaya, Rocio Perez-Iglesias, Alice Egerton, Kyra Verena Sendt, Simone Reinders, Philip McGuire, Paola Dazzan

235. Correlation between Expected and Effective Plasma Concentrations of Antipsychotics and Changes in Psychopathology in Patients with Schizophrenia
Anna E. Ordóñez, David I. Driver, Mark Orloff, Jerry Overman, Deanna Greenstein, Diane Dillard-Broadnax, Judith Rapoport, Nitin Gogtay

236. Changes in Psychopathology in Patients with Schizophrenia
Peter B. Jones, Matti Isohanni, Hannu Koponen, Jouko Miettunen, Erika Jääskeläinen

237. Simulation of Dopamine D2 Receptor Occupancy by Aripiprazole in Steady State: Based on PK-PD Modeling
Euitae Kim, Bo-Hyung Kim, In-Jin Jang, Jae Min Jeong, Jun Soo Kwon

238. Pharmacological Modulation of Kv3 Potassium Channels on Parvalbumin-positive Fast-spiking Interneurons – A Novel Approach to the Treatment of Schizophrenia
Charles Large, Marcelo Rosato-Siri, Caterina Virgino, Erica Zambello, Chiara Mutinelli, Giuseppe Alvaro

239. AZD8529, A Positive Allosteric Modulator at the mGluR2 Receptor, Does Not Improve Symptoms in Schizophrenia: A Proof of Principle Study
Robert E. Litman, Mark A. Smith, Jim Doherty, Alan Cross, Shaine Raines, Stephen Zukin

240. Oxytocin and Psychosis: Exploratory Meta Analysis of Randomized Controlled Trials
Angus M. MacBeth, Andrew Gumley, Christine Braehler

241. The Position of Blonanserin as a Treatment for Schizophrenia: Evidence from Meta-analysis of Randomized, Placebo-controlled Trials
Yuki Matsuda, Taro Kishi

242. The Subjective Treatment Satisfaction of Switching Antipsychotics in Japanese Patients with Schizophrenia; J-BETA (Japan-broad Effectiveness Trial of Aripiprazole)
Masatsugu Moriwaki, Nakao Iwata

243. Clozapine Treatment in Pediatric Onset Schizophrenia: Lessons from the NIMH Experience
Anna E. Ordóñez, David I. Driver, Mark Orloff, Jerry Overman, Deanna Greenstein, Diane Dillard-Broadnax, Judith Rapoport, Nitin Gogtay

244. Consultant Psychiatrists’ Perspectives Regarding Antipsychotic Dose Choice and Plasma Concentration Therapeutic Drug Monitoring
Maxine X. Patel, Suzanne Law, Lauren A. Best-Shaw, Maria Gudbrandsen, Nusrat Husain, Imran B. Chaudhry, Richard Drake, Anthony S. David, Peter M. Haddad

245. Long-term Safety and Effectiveness of Lurasidone in Schizophrenia: Results of a 22 Month, Open-label Extension Study
Andrei Pikalov, Christoph Correll, Josephine Cucchiario, Robert Silva, Jay Hsu, Antony Loebel

246. Effects of Duration of Illness on Therapeutic Response to Adjunctive Treatment with N-acetyl Cysteine in Schizophrenia
Marta Rapado-Castro, Michael Berk, Kamlesh Venugopal, Ashley Ian Bush, Seetal Dood, Olivia M Dean

247. A Randomized, Active-controlled Rater-bound 2-year Study of Paliperidone Palmitate Versus Investigators’ Choice of Oral Antipsychotic Monotherapy in Patients with Schizophrenia (PROSIPAL)
Andreas Schreiner, Kaire Aadamsoo, Carlo Altamura, Manuel Franco, Philip Gorwood, Nikolay G. Neznanov, Juan Schronen, Alp Úçok, Mathias Zink, Marjolein Lahaye, Ludger Hargarter

248. Flexibly Dosed Paliperidone Palmitate in Non-acute Patients with Schizophrenia Previously Unsuccessfully Treated with Conventional Depot Antipsychotics
Andreas Schreiner, Ludger Hargarter, Pierre-Michel Llorca, Behcet Cosar, Antonino Petralia, Paul Bergmans, Pierre Cherubin

249. Is Once Daily Dosing of Perphenazine Clinically Feasible?
Hiroyoshi Takeuchi, Gagan Fervaha, Hiroyuki Uchida, Takefumi Suzuki, Robert Bies, David Grönte, Gary Remington

250. Prescription Patterns Prior to Clozapine Initiation in First-episode Psychosis
Charmaine Tang, Swapna Verma, Mythily Subramaniam, Boon Tat Ng, EdIMSnyah Abdin, Lye Yin Poon

251. Prognostic Factors for Treatment Resistance in Schizophrenia
Theresa Wimberley, Henrik Størving, James H. MacCabe, Holger Sørensen, Christiane Gasse
252. Objective Measurement of Compliance and Attitude toward Treatment in Patients with Schizophrenia
Nursen Yalcin-Siedentopf, Maria Rettenbacher, Alexandra Kaufmann, Susanne Baumgartner, Falko Biedermann, Monika Edlinger, Georg Kemmler, Christian G. Widenschwendter, Wolfgang W. Fleischhacker, Alex Hofer

253. Show Me the Money Revisited: Monetary Reinforcement versus Intrinsic Reward for Learning in Schizophrenia
Jimmy Choi, Joanna Fiszdon, Steven Silverstein, Deanna M. Barch

254. Infancy-to-adolescence Functional Deterioration in Early Onset Psychosis: Are There Differences Between Schizophrenia and Affective Psychosis?
Angel Del Rey-Mejias, David Fragas, Josefina Castro-Fornieles, Inmaculada Baeza, Elena De la Serna, Marta Rapado-Castro, Laura Pina-Camacho, Celso Arango, Mara Parellada

255. Comparative Study of Schizophrenia Patients According to Their Functionality
Irvin Garay, Raul Escamilla, Yehu Garfias, Ricardo Saracco-Alvarez, Tania Morales

256. Longitudinal Follow-up of Criticism and Depression among Families of First Episode Psychosis Patients
Yumiko Hamai, Noriyuki Ohmuro, Masahiro Katsura, Chika Obara, Tatsuo Kikuchi, Emi Sunakawa, Fumiaki Ito, Tetsuo Miyakoshi, Hiroo Matsuoka, Kazunori Matsumoto

257. Touching by Hand: How Psychotic Features Translate into Worse Life Conditions: The Relation of Key Psychosocial Issues with Clinical Variables in Non-psychotic, Psychotic Responder, and Psychotic Non-responder Patients
Felice Iasevoli, Sara Giordano, Raffaele Balletta, Livia Avvisati, Gianmarco Latte, Emi Sunakawa, Mariavittoria Formato, Emiliano Prinzivalli, Rodolfo Rossi, Andrea de Bartolomèis

258. Teaching and Learning the Discourse of Schizophrenia: Development of a Standardized Patient Training Program
Luka Lucić, Anzalee Khan, Christian Yavorsky, Brian Rothman

259. FFM Personality Traits and Adult Attachment Styles in Patients with Psychosis, Their Siblings and Healthy Controls
Carin Meijer, L.N. Boyette, N. Korver

260. Addressing Defeatist Beliefs in Work Rehabilitation
Josh Mervis, Paul Lysaker, Joanna Fiszdon, Joseph Bisoglio, Jimmy Choi

261. Sleep Disorders and Schizophrenia
Hannah Newall, Cherrie Galletly, Dennis Liu, Campbell Thompson

262. Impact of Obesity on Quality of Life in Patients with Schizophrenia
Milaway Nurjono, Nan Luo, Natasha Mitter, Vidhya Renjan, Jimmy Lee

263. Does Routine Outcome Monitoring in Schizophrenia Improve the Implementation of Evidence Based Care?
Stynke Castelein, Marte Swart, Gert Wolters, Richard Bruggeman, Henderikus Knegtering

264. Evaluation of a Community Case-management Program for Patients with Schizophrenia-Spectrum Disorder: A Prospective 1-year Case-control Study

265. The Association between Working Alliance and Clinical and Functional Outcome in a Cohort of 400 Patients with First Episode Psychosis: A Cross-sectional Study
Marianne Melau, Susanne Harder, Pia Jeppesen, Carsten Hjorthøj, Jens Richard Jepsen, Anne A.E. Thorup, Merete Nordentoft

266. Virtual Reality Job Interview Training
Matthew J. Smith, Emily Ginger, Michael Wright, Katherine Wright, Morris Bell, Michael Fleming

267. Improving Somatic Health of Outpatients with Severe Mental Illness
Fenneke M. van Hasselt, Marian J.T. Oud, Paul F.M. Krabbe, Maarten J. Postma, Anton J.M. Loonen

268. Decreased Brain Cannabinoid Receptor (CB1R) Availability in Cannabis Dependence Rapidly Normalizes with Abstinence
Deepak Cyril D’Souza, Jose Cortes, Mohini Ranganathan, Halle Thurnauer, Beata Planeta, Rajiv Radhakrishnan, Yiyoung Huang, Richard Carson, Patrick Skosnik

269. Dextromethorphan and Psychiatric Morbidity: A Singapore Perspective
Rajesh Jacob, Hui Leng Khoo, Arnab Kumar Ghosh

270. Does Substance Abuse Increase the Risk of Psychiatric Illness?
Nanna G. Toftdahl, Carsten Rygaard Hjorthøj, Merete Nordentoft

271. Schizophrenia and Disordered Gambling: Qualitative Features of Dual Diagnosis
Igor Yakovenko, Cameron M. Clark, David C. Hodgins, Vina M. Goghiari
1. Childhood Maltreatment, the BDNF-Val66Met Polymorphism and Hippocampal Volume: Further Evidence from a MRI-twin Study
Silvia Alemany, Aldo Córdova-Palomera, Carles Falcón, Mar Fatjó-Vilas, Ximena Goldberg, Bárbara Arias, Núria Bargalló, Benedetto Crespo-Facorro, Igor Nenadic, Lourdes Pañanás

2. Investigation of the Role of Allelic Variants of Multidrug Resistance Gene (MDR1) on Clozapine Related Leukopenia/Agranulocytosis
A. Elif Anıl Yağıboğlu, Gökhan Yoca, R. Özgür Karaca, Lokman Çevik, Melih O. Babaoğlu, Yavuz Ayhan, Nurhayat Eni, M. Kazım Yazıcı, Atilla Bozkurt, Clozapine Related Leukopenia/Agranulocytosis Study Group (CRLA-SG)

3. Prediction of Suicidal Behaviours in Young People Presenting with First-episode Psychosis in Hong Kong: A 3-year Follow-up Study

4. Treatment of Clozapine-induced Hypersalivation with Amisulpride: A Systematic Review

Yuka S. Kikuchi, Wataru Sato, Keiichiro Ataka, Kiwamu Yagisawa, Yuki Omori, Takashi Kanbayashi, Tetsuo Shimizu

6. Cardiometabolic Risks of Blonanserin and Perospirone in the Management of Schizophrenia: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Taro Kishi, Yuki Matsuda, Nakao Iwata

7. Negative Self and Other Schemas and Insecure Attachment Mediate the Association between Childhood Interpersonal Adversity and the Nonclinical Psychosis Phenotype
Tamara Sheinbaum, Thomas R. Kwapiel, Sergi Ballespí, Carles Falcón

8. Positive Allosteric Modulation of mGluR5 Reverses the Akt Signaling Deficits in Serine Racemase Knockout Mice, a Genetic Model of Schizophrenia Due to NMDA Receptor Hypofunction
Darrick T. Balu, Shunsuke Takagi, Jose Bartolomé, Thomas Steckler, Carrie Jones, P. Jeffrey Conn, Joseph Coyle

9. Disc1 Mutation Induced Alterations in Cerebral Metabolism and in the Response to Acute Subanesthetic Ketamine: A Comparison of Three Different Disc1 Mutations
Neil Dawson, Catherine Winchester, Allan McVie, David Thomson, Zoe Hughes, John Dunlop, Nicholas Brandon, Brian Morris, Judith Pratt

10. A New “Double Hit” Schizophrenia Model in Rat Shows Structural and Neurochemical Alterations of the Medial Prefrontal Cortex and the Hippocampus
Javier Gilabert-Juan, Maria Belles, Hector Carceller, Ana Rosa Saez, Rocio Gonzalez-Martinez, Sara Zamarbide-Fores, Maria Dolores Motlo, Juan Nácher

11. Long-term Effects of Neonatal MK-801 Treatment on Protein Translation Signal Pathway in the Rat Frontal Cortex
Yong Sik Kim, Se Hyun Kim, Hong Geun Park

12. Reward Deficits in the Maternal Immune Activation Model
Marie A. Labouesse, Wolfgang Langhans, Urs Meyer

13. Characterization of a ‘Two-Hit’ Mouse Model of Methamphetamine-induced Psychosis: Effects of Brain-derived Neurotrophic Factor (BDNF) Deficiency and Relevance to Schizophrenia
Elizabeth F. Manning, Maarten van den Buuse

14. Use of Folate to Prevent Schizophrenia in Animal Model of Ketamine Induce Schizophrenia in Rats
Flavio Augusto Pereira, Felipe Damazio, Alexandra Yugno

15. Pre-synaptic Localization of PDE2 Enzyme and Pharmacological Characterization of the PDE2 Inhibitor PF-999 in Models Related to Cognitive Symptoms of Schizophrenia
Holger Rosenbrock, Katja S. Kroker, Barbara Bertani, Birgit Stierstorfer, Cornelia Dorner-Ciossek, Roberto Arban

16. Effects of a Nitric Oxide Synthase Inhibitor on an Animal Model for the Study of Schizophrenia Based on the Neurodevelopmental Hypothesis
Cristiane Salum, Michelle Brosco, Oderci Messias-Filho, Angela Rodrigues

17. The Mechanism of Action of Antipsychotics and Intracortical Myelination in Schizophrenia
George Bartozkis, Po Lu, Chandra Kirkpatrick, Meghan Pyle, Erika Raven, Jim Mintz, Joseph Ventura, Laurie Casaus, John Luo, Kenneth Subotnik, Keith H. Nuechterlein

18.olfactory Identification Deficits as a Marker of Impaired Brain Development: A Cross-sectional Study in Patients with Schizophrenia and Healthy Controls
Jessica de Nijs, Julia Meijer

19. Shared Brain Dysfunction in Subtypes of Schizophrenia and Bipolar Disorder Defined by Poor Working Memory
Melissa J. Green, Yann Quide, Alana Shepherd, Jesseca Rowland, Philip Mitchell, Vaughan Carr

20. Increased Glycogen Synthase Kinase-3B (GSK-3B) Expression in Platelets of First Onset Psychosis Non-affective Patients
Helena PG Joaquim, Leda L. Talib, Marcus Zanetti, Martinus van de Bilt, Geraldo Busatto, Mauricio Serpa, Wagner Gattaz
21. Predictive Validity of Combined Minor Physical Anomalies and Neurological Soft Signs in Patients with Schizophrenia and their Nonpsychotic First-degree Relatives
Sheng-Hsiang Lin, Shu-Ting Gan, Ming-Kun Lu, Jin-Jia Lin

22. Classification of People with Treatment-resistant and Ultra-treatment-resistant Schizophrenia using Personalised Computer Modelling and EEG Data
Carolyn McNabb, Reggio Hartono, Meghan Mcilwain, Valerie Anderson, Nikola Kasabov, Rob Kydd, Bruce Russell

23. Antipsychotic Treatment Decreased iPLA2 Activity in First Episode Drug Naïve Patients with Schizophrenia
Leda L. Talib, Helena Joaquim, Mauricio Serpa, Geraldo Busatto, Martinus van de Bilt, Marcus Zanetti, Wagner Gattaz

24. Alterations in the Amplitude of Low Frequency Fluctuations in Refractory Schizophrenia Patients with Auditory Verbal Hallucinations

25. Spontaneous Brain Activity as a Biomarker for Schizophrenia
Simon J. Anhøj, Kirsten Ford, Peter Williamson, Birte Glenthøj, Egill Rostrup

26. Association of Schizophrenia with Independent Components of Brain Connectivity During Attentional Control
Linda A. Antonucci, Paolo Taurisano, Leonardo Fazio, Rosa Vitale, Tiziana Quarto, Raffaella Romano, Annabella Di Giorgio, Grazia Cafforio, Antonio Rampino, Giuseppe Blasi, Alessandro Bertolino

27. Serious Obstetric Complications Contribute to Risk for Hippocampal Dysfunction during Recognition Memory
Aurora Bonvino, Maria Antonieta Nettis, Annamaria Porcelli, Raffaella Romano, Enrico Dambrosio, Paolo Taurisano, Leonardo Fazio, Giuseppe Blasi, Annabella Di Giorgio, Alessandro Bertolino

28. Brain Activation Induced by Mental Stress in Patients with Schizophrenia
Mariana N. Castro, Mirta F. Villarreal, Natasha Bolotinsky, Eliana Papávero, Nicolás Deschle, Fernando Binder, Lucas Drucaroff, Elsa Y. Costanzo, Delfina de Achaival, Karl-Jürgen Bär, Salvador M. Guinjoan

29. Brain Hardware and Software for Self-reflection Associated with Insight in Patients with Schizophrenia
Branislava Ćurčić-Blake, Lisette van der Meer, Marieke G.H. Pijneborg, Anthony S. David, André Aleman

30. Presynaptic Dopamine Modulates Goal-directed Behavior and Interacts with Prefrontal and Striatal Glutamate
Lorenz Deserno, Andreas Heinz, Florian Schlagenhaus

31. Relationship between Cortical Activation during Working Memory and Functional Outcomes in Individuals at High Risk for Psychosis
Irina Falkenberg, Isabel Valli, Marie Raffin, Marco M. Picchioni, Philip McGuire

32. Imaging Endophenotypic Biomarkers for Schizophrenic and Affective Psychoses in Key Neural Circuits
Oliver Gruber, Henning Vieker, Sarah Trost, Anna Fanelli, Kathrin Jakob, David Zilles

33. Salience Network in Young People with Familial Risk for Psychosis the Oulu Brain and Mind Study
Tuomas Jukuri, Vesa Kiviniemi, Juha Nikkinen, Jouko Miettunen, Pirjo H. Mäki, Jenni Koivukangas, Tanja Nordström, Jennifer Barnett, Peter Jones, Graham Murray, Juha Veijola

34. Functional Dysconnection in the First Episode of Schizophrenia and in Remission
Tomas Kasparek, Jozef Zubor, Radovan Prikryl, Hana Prikrylova, Jiri Vanicek, Eva Ceskova

35. Disruptions in Small-world Cortical Functional Connectivity Network during an Auditory Oddball Paradigm Task in Patients with Schizophrenia
Seung-Hwan Lee, Miseon Lim, Jung Seo Yi, Dowon Kim, Chang-Hwan Im

36. Decreased Activation in Superior Frontal Gyrus in Patients with Schizophrenia Exposed to Curse Words: fMRI Study
Fan-jin Na, Jong-Il Park, Tariq Rajasheb Bagalkot, Hong-Mei Jin, Yin Cui, Young-Chul Chung

37. Working Memory and Brain Activation in Schizophrenia vs. Psychotic Bipolar I Disorder Assessed with Functional MRI
Igor Nemadic, Kerstin Langbein, Maren Dietzek, Raka Maitra, Gianluca Mingoia, Stefan Smesny, Gerd Wagner, Ralf Schloesser, Christian Gaser, Heinrich Sauer

38. Neural Correlates of Self-reference Processing and Aberrant Salience Attribution – Implications for Psychosis
Anne Pankow, Teresa Kathagen, Sarah Diner, Henrik Walter, Andreas Heinz, Florian Schlagenhaus

39. Semi-metric Analysis of the Functional Human Brain Network: Relationship with Familial Risk for Psychotic Disorder
Sanne Peeters, Tiago Simas, John Suckling, Ed Gronenschild, Petra Habets, Jim van Os, Machteld Marcelis
40. The Relation of Abnormal Brain Connectivity and Psychiatric Symptom Expression in Subjects at High-risk for Psychosis
André Schmidt, Renata Smieskova, Paul Allen, Paolo Fusar-Poli, Philip McGuire, Undine Lang, Marc Walter, Ernst-Wilhelm Radue, Anita Riecher-Rössler, Stefan Borgwardt

41. High Resolution Basal State Functional Imaging Reveals a Subcortical-cortical Spreading Pattern of Functional Abnormality in Clinical High-risk Patients Who Progress to Psychosis
Scott Schobel, Ragy Girgis, Cheryl Corcoran, Jeffrey Lieberman, Scott Small

42. A Functional Neuroimaging Family Study of Facial Emotion Perception in Schizophrenia
Michael J. Spilka, Aiden E. Arnold, Vina M. Goghari

43. Cerebral Blood Flow Changes in Late-onset Schizophrenia Using SPECT with the Easy Z-score Imaging System
Naohisa Tsujino, Sunao Mizumura, Yoko Baba, Naoyuki Katagiri, Taijyu Yamaguchi, Takahiro Nemoto, Nobuyuki Shiraga, Masafumi Mizuno

44. Interaction between Diagnosis of Schizophrenia and Drd2 Genetic Variation on Amygdala Activity during Explicit Emotion Processing
Giovanna Viscanti, Tiziana Quarto, Paolo Taurisano, Leonardo Fazio, Barbara Gelao, Rita Masellis, Mariateresa Attrotto, Grazia Caforio, Annabella Di Giorgio, Giuseppe Blasi, Alessandro Bertolino

45. GABA, Glutamate and Intellectual Ability
Anouk Marsman, Rene Mandl, Dennis Klomp, Vincent Boer, Anna Andreychenko, Wiepke Cahn, René Kahn, Peter Luijten, Hilleke Hulshoff Pol

46. Are the Glutamatergic Dysfunction and Membrane Lipid Hypothesis Linked? A Combined 1H/31P-MR-Spectroscopy Study in Never Treated Acute Onset Schizophrenia
Stefan Smesny, Alexander Gussew, Igor Nenadic, Natalie Joan Biesel, Carl Christoph Schultz, Paul Amminger, Heinrich Sauer

47. White Matter Integrity as a Candidate Endophenotype for Schizophrenia
Marc Bohlen, René Mandl, Rachel Brouwer, René Kahn, Hilleke Hulshoff Pol

48. Childhood Trauma Affects the Hypothalamic-pituitary-adrenal Axis Activity in Individuals at First Episode Psychosis and Healthy Controls Differently
Simone Ciufolini, Valeria Mondelli, Matthew Kempton, Tiago Reis-Marques, Craig Morgan, Simone Reinders, Anthony S. David, Robin M. Murray, Carmine Pariante, Paola Dazzan

49. Functional and Gray Matter Asymmetries in Patients with Schizophrenia and Bipolar Disorders
Sonia Dollfus, Nicolas Delcroix, Elise Leroux, Mathieu Alary, Annick Razafimandimbry, Perrine Brazo, Pascal Delamilleure

50. Structural Grey Matter and White Matter Differences in Individuals with Psychotic like Signs from an Epidemiological Cohort
Mark Drakesmith, Anirban Dutt, Glyn Lewis, Anthony S. David, Derek K. Jones

51. Temporal Lobe White Matter Alterations in Schizophrenia: A Diffusion Tensor Imaging Tractometry Family Study
Vina Goghari, Thibo Billiet, Stefan Sunaert, Louise Emsell

52. Neurological Soft Signs and Brain Morphology in Patients with Chronic Schizophrenia
Christina J. Herold, Marc M. Lässer, Lena A. Schmid, Ulrich Seidl, Marco Essig, Philipp A. Thomann, Johannes Schröder

Joseph Kambeitz, Lana Kambeitz-Ilankovic, Leucht Stefan, Steven Wood, Christos Davatzikos, Berend Malchw, Peter Falkai, Nikolaos Koutsouleris

54. The Role of a FOXP2 Variant on Brain Structure and Speech Production – a DTI Study
Axel Krug, Davide Laneri, Bruno Dietsche, Heidelore Backes, Stephanie Witt, Marcella Rietschel, Jens Sommer, Tilo Kircher, Arne Nagels

55. Duration of Illness Associated with Cortical Thickness Change in Schizophrenia: A Longitudinal MRI Study
Manabu Kubota, Neelje E.M. van Haren, Wiepke Cahn, René Kahn

56. Shared White Matter Dysconnectivity in Schizophrenia and Bipolar Disorder with Psychosis
Iyothika Kumar, Sarina Iwabuchi, Shunyu Oowise, Vijender Balain, Lena Palaniyappan, Peter Liddle

57. Left Fronto-temporal Disconnectivity within the Language Network in Schizophrenia: An fMRI and DTI Study
Elise Leroux, Sonia Dollfus, Nicolas Delcroix

58. Brain Structure Changes in First-episode Psychosis Patients with Persistent Apathy
Lynn March-Johnsen, Ragnar Nesvig, Ann Faerden, Unn Kristin Haukvik, Kjetil Nordbo Jørgensen, Elisabeth Hefermehl Lange, Ingrid Melle, Ole Andreas Andreassen, Ingrid Agartz

59. The “Fibre” Path to Psychosis? Can Advanced Diffusion Imaging Capture White Matter Brain Anomalies in Adolescents Experiencing Psychotic Symptoms?
Erik O’Hanlon, Alexander Leemans, Mary C. Clarke, Ian Kelleher, Francesco Amico, Thomas Frodl, Mary Cannon
60. Modelling Genetic and Environmental Influences on Brain Volume in Twins with Schizophrenia
Marco M. Picchioni, Timothea Toulopoulou, Christopher Chaddock, James Cole, Ulrich Ettinger, Robin M. Murray, Philip McGuire

61. Auditory Hallucinations in First Episode Psychosis: A Longitudinal DTI Study of the Arcuate Fasciculus
Tiago Reis Marques, Francisco Marques-Teixeira, Heather Taylor, Flavio Dell’Acqua, Aurora Falcone, Andy Simmons, Marta DiForti, Robin M. Murray, Anthony S. David, Paola Dazzan

62. White Matter Volume Reductions in First Episode Psychosis Are Associated with Cortisol Levels

63. Progressive Brain Structure Change Predicts Negative Symptoms in First Episode Psychosis at 3 Year Follow-up
Cathie Scannell, Shane McNerney, Stefani O’Donoghue, Liam Kilmartin, Heike Anderson-Schmidt, John McFarland, Mairead Waldron, Joanne Kenney, Srinath Ambati, Brian Hallahan, Dara Cannon, Colm McDonald

64. Continuing Grey Matter Changes in First-episode Schizophrenia and Affective Psychosis
Maristela S. Schaufelberger, Pedro Rosa, Marcus Zanetti, Fabio Duran, Luciana Santos, Paulo Menezes, Marcia Scazuca, Robin Murray, Geraldo Busatto

65. ZNF804A and Cortical Structure in Schizophrenia – In vivo and Postmortem Studies
Carl C. Schultz, Igor Nenadic, Brien Riley, Vladimir Vladimirov, Gerd Wagner, Thomas Mühlseisen, Markus Nöthen, Sven Cichon, Kathrin Koch, Ralf Schlösser, Heinrich Sauer

66. Reduced Regional Grey Matter Volumes in Offspring of Schizophrenia Patients Relative to Offspring of Bipolar Patients and Controls
Gisela Sugranyes, Elena De la Serna, Soledad Romero, Vanessa Sanchez-Gistau, Anna Calvo, Inmaculada Baeza, Dolores Moreno, Josefina Castro-Fornieles

67. Apathy in Schizophrenia: Are Structural Abnormalities in Primary Emotion Processing Areas Involved?
Marie-José van Tol, Edith Liemburg, Lisette van der Meer, Marieke Pijnenborg, Esther Opmeer, Richard Bruggeman, Henrikus Kneegtering, AndréAleman

68. Prevalence of SPEs in Child and Adolescents with Anxiety and Depressive Disorders and Correlation with General Functioning
Marco Armando, Nella Lo Cascio, Elena Monduccii, Maria Pontillo, Nicoletta Girardi, Claudia Battaglia, Martina Pataré, Giada Colafrancesco, Claudia Dario, Mauro Ferrara, Ignazio Ardizzone, Paolo Girardi, Stefano Vicari, Paolo Fiori Nastro

69. What Lies Beneath? A Thematic Content Analysis of Sub-cinical Psychotic Experiences among Children and Young Adolescents from the General Population in Ireland and the UK
Helen Coughlan, Ian Kelleher, Mary C. Clarke, Niamh Higgins, Kristin R. Laurens, Mary Cannon

70. Juvenile Offenders with Severe Psychiatric Disorders in a Forensic Unit: Risk Factors of Overt Aggressive Behaviors
Gaelle Graiek, Elsa Hoffmann, Nelson Provost, Gilles Vandekerckhove, Bruno Piccinin, Stephan De Smet, Ani Raevuori, Laurent Servais

71. Subclinical Psychotic Experiences are Associated with Anxiety, Daily Stressors and Family Functioning in an Adolescent General Population Sample
Ashleigh Lin, Tamara Woodall, Danielle Hallett, Renate Reniers, Stephen Wood

72. Differential Development of the Reward Network in Adolescent Offspring of Schizophrenia Patients
Matthijs Vink, Ruby Pouwels, Manon Hillegers, René Kahn

73. Thought Disorder in First-episode Psychosis
Ahmet Ayer, Esra Aydinli, Silay Sevilmit, Berna Yalnçetin, Berna Binnur Akdede, Köksal Alptekin

74. Problem-solving Based Bibliotherapy for First-time Primary Caregivers of Family Members with a First Episode of Psychosis: Randomized Controlled Trial
Terence McCann, Susan Cotton, John Gleeson, Kingsley Crisp, Brendan Murphy, Dan Lubman

75. The Effects of Modafinil on Cognitive Training: A Proof-of-concept Trial in Patients with Schizophrenia
Panayiota Michalopoulou, Shon Lewis, Richard Drake, Abraham Reichenberg, Richard Emsley, Anastasia Kalpakidou, Jane Lees, Eve Applegate, Til Wykes, Shitij Kapur

76. An Open-label, Flexible-dose Study of Paliperidone Extended Release in Chinese Patients with First-episode Psychosis
Tianmei Si, Wang Yang, Rui Qing, Tan QingRong, Zhang KeRang

77. How Does the NSA-4 Compare to the NSA-16?
Janet B. W. Williams, Lori Garzio, Douglas Osman

78. Effectiveness of Three Atypical Antipsychotic-initiated Treatments in Chinese First-episode Schizophrenia: An Open Randomized Clinical Trial
Yanbo Yuan, Fude Yang, Zheng Lu, Chuan Yue Wang, Hong Deng, Jingping Zhao, Xin Yu

79. Effects of Cognitive Remediation on Cognition in Young People at Clinical High Risk of Psychosis
Daniela Piskulic, Mariapaola Barbato, Lu Liu, Jean Addington
80. Schizotypy is Associated with a ‘Reversal Inference’ Deficit but no ‘Jumping to Conclusions’
Rick A. Adams, Timothée Devaux, Christoph Mathys, Karl Friston

81. How Framing of the Response and Metamemory Self-monitoring and Control Allow Patients with Schizophrenia to Improve their Memory Reporting for General Knowledge
Elisabeth Bacon, Marie Izaute, Elcin Akdogan

82. Link between Facial Emotion Perception and Schizophrenia towards a Clinical and Cognitive Study Among a Sample of 83 Schizophrenic Patients
Marie-Cecile Bralet, Nordin Mebtoul, Christian Koegel, Trang Ton

83. Do Patients with Schizophrenia Use Prosodic Focus Marking to Attribute Mental States in a Conversation Situation?
Maud Champagne-Lavau, Amandine Michelas, Catherine Faget, Cristel Portes, Anne-Sophie Lienhart, Laurent Boyer, Christophe Lançon

84. Reward Learning Impairment in Patients with First-episode Schizophrenia-spectrum Disorder

85. Verbal Episodic Memory Impairment along the Course of Schizophrenia and Bipolar Disorder
Leticia S. Czepielewski, Raffaella Massuda, Pedro Goi, Mireia Sulzbach, Mirela Vasconcelos-Moreno, Ramiro Reckziegel, Monice Costanzi, Paulo Belmonte-de-Abreu, Flavio Kapczinski, Clarissa Gama

86. Decreasing Paranoia Levels through Classical Conditioning: An Exploratory ESM Non Clinical Study
Filiberto Fuentenebro, Regina Espinosa, Carmen Valiente, Borja Paredes, Patricia Villavicencio, Jose Maria Prados, Filiberto Fuentenebro

87. Folate Pharmacogenomics, Endothelial Functioning, and Neurocognition in Schizophrenia Spectrum Disorders
Tyler Grove, Vicki Ellingrod, Stephan Taylor

88. Spreading Depolarization Effect on Behavioral Test of Schizophrenic Rat
Babak Khodaie, Ahmad Ali Lotfina, Milad Ahmadi, Mahmoud Lotfina

89. Psychosis Proneness, Anxiety, Depression and Interpretation Bias: The Twins Scan China Study
Phoebe Kar Yu Kong, Jenny Yiend, Shelly Leung, Cecilia Leung, Emma Li, Francesca A. Cotier, Winifred Mark, Lu Hua Chen, Jim van Os, Timothée Touloupiou

90. Calibration and Cross-validation of MCCB and CogState in Schizophrenia
Jane Lees, Eve Applegate, Richard Drake, Shon Lewis

91. The MATRICS Consensus Cognitive Battery (MCCB): Performance and Functional Correlates
June U. Lystad, Erik Falkum, Christine Mohn, Helen Bull, Stig Evensen, Bjørn Rund, Torill Ueland

92. Predicting Functional Capacity and Real-world Functioning in Schizophrenia: The Role of Cognition and Negative Symptoms
Lucas M. Mantovani, Rodrigo Ferrejans, João Vinicius Salgado

93. The Role of Cognition in Metabolic Disturbance in People with Psychotic Illness: Novel Data from a Large Population Prevalence Survey
Vera A. Morgan, Johanna Badcock, Anna Waterreus, Cherrie Galletly, Sonal Shah, Andrew Mackinnon

94. Are the Relationships of Cognitive Performance to Psychosocial Functioning at Five Year Outcome Mediated by Disorganization Symptoms?
Ross M. G. Norman, Rahul Manchanda, Raj Haricharan, Sandra Northcott

95. A Randomized Controlled Trial of Cognitive Remediation after a First Episode of Schizophrenia: Improving Cognition and Work/School Functioning
Keith H. Nuechterlein, Joseph Ventura, Kenneth L. Subotnik, Denise Gretchen-Doorley, Luana Turner, Laurie Casaus, John Luo, Morris D. Bell, Alice Medalia

96. Metacognitive Abilities in First Episode Psychosis: A Controlled Experimental Study
Emma C. Palmer, Anthony S. David, Stephen M. Fleming

97. Effects of Intimacy on the Social Decision in Patients with Schizophrenia
Sunyoung Park, Jungeun Shin, Kiwan Han, Yu-Bin Shin, Jae-Jin Kim

98. Optimising the Delivery of Cognitive Remediation for Schizophrenia – Results from a Feasibility Randomised Controlled Trial of a new Computerised Programme, CIRCuiTS
Clare Reeder, Matteo Cell, Vv Huddy, Sabine Landau, Til Wykes

99. An Examination of Auditory Processing and Affective Prosody in Relatives of Patients with Auditory Hallucinations
Susan Rossell, Rachel Tucker, John Farhall, Neil Thomas, Chris Groot

100. Investigating Facial Affect Processing in Psychosis: A Study Using the Comprehensive Affective Testing System
Susan Rossell, Tamsyn Van Rheenen, Nicki Joshua, Andrea Gogos, Alison O’Regan

101. Cognition among Schizophrenia in Supported Employment Program in Hospital Permai Malaysia
Marina Abd Rahman Sabri, Abdul Kadir Abu Bakar, Abdul Hamid Abd Rahman

102. Transcriptome Analysis Reveals Down-regulated Signal Transduction Pathways in Peripheral Blood Mononuclear Cells from Schizophrenia Patients with Cognitive Impairment
Jingqin Wu, Melissa J. Green, Erin Gardiner, Paul Tooney, Rodney Scott, Vaughan J. Carr, Murray J. Cairns
103. A New Method of Assessment of Thought Disorders (Schizophrenia Spectrum) Using the Standard for Clinicians’ Interview in Psychiatry (SCIP)

Ahmed Aboraya

104. Setting Psychopathology in Motion: A Network Perspective

P.R. Bakker, Marieke Wickers, Peter N. van Harten, Inez Myin-Germeys, Philippe Delespaul, Jim van Os

105. Schizotaxia Redux

Vaughan J. Carr, Jessica Bowen, Melissa J. Green

106. The Clinical Overlap between Autism and Psychosis

Katie E. Chisholm, Stephen Wood, Renate L. Reniers, Matthew Broome, Ashleigh Lin

107. Clinical Implications of Screening for NMDA Encephalitis in First Episode Psychosis

Eric Kelleher, Colin Doherty, Aiden Corvin

108. Measuring Stigma - An Overview of Available Instruments

Esther Sportel, Gerdina Pijnenborg, Stynke Castelein


Katherine C. Williams, Benjamin Lomas, Gillian Doody

110. P3 Abnormalities in Neuroleptic-naive First-episode Schizophrenia Patients and in Their Healthy Siblings

Müge Devrim-Üçok, Alp Üçok

111. Adolescent VTA Neurons Retain Neuronal Correlates of Reward Opportunity after Extinction

Nicholas Simon, YunBok Kim, Jesse Wood, Bita Moghaddam

112. Electrodermal Activity as Possible Neuropsychiatric Biomarker

Sergey Yagoda, Igor Boev

113. Threatening and Intrusive Life Events as Precursors to Psychotic Disorders

Stephanie Beards, Helen L. Fisher, Charlotte Gayer-Anderson, Kathryn Hubbard, Tjasa Velikonja, Adanna N. Onyejiaka, Valeria Mondelli, Carmine Pariante, Paola Dazzan, Rowena Handley, Craig Morgan

114. Shared Risk Factors between Schizophrenia and Other Neurodevelopmental Disorders

Mary C. Clarke, Antti Tanskanen, Matti Huttunen, David Cotter, Mary Cannon

115. Schizophrenia and Violence: A Comparison between Formerly and Never Violent Patients Living in Residential Facilities

Giovanni De Girolamo, Valentina Candini, Chiara Buizza, Clarissa Ferrari, Gian Marco Giobbio, Paolo Maggi, Stefania Greppo, Maria Elena Boero, Anna Melegari, Laura Iozzino

116. Social Inequality at Birth and Risk of First Episode Psychosis in Rural Ireland: A Case-control Study

Martha A. Finnegan, Sami Omer, Anthony Kinsella, Dennis Pringle, Paul Fearon, John L. Waddington

117. Evidence that Childhood Urban Environment is Associated with Blunted Stress Reactivity across Groups of Psychotic Patients, Relatives and Controls

Aleida Friessen, Ritsaert Lieverse, Marjan Drukker, Tineke Lataster, Philippe Delespaul, Inez Myin-Germeys, Jim van Os

118. A Population-based Longitudinal Study of Atopic Disorders and Inflammatory Markers in Childhood before Psychotic Experiences in Adolescence

Golam Khandaker, Stanley Zammit, Glynn Lewis, Peter B. Jones

119. Prenatal and Postnatal Exposures to Maximum Adversity among Holocaust Survivors and the Course of Schizophrenia: A Population-based Study

Stephen Z. Levine, Itzhak Levav, Rinat Yoffee, Inna Pugachova

120. Taxometric Analysis of Multilevel Multimodal Risk Data from Siblings of Probands with Nonaffective Psychotic Disorders

Richard J. Linscott, Inez Myin-Germeys, Jim van Os, G.R.O.U.P. Investigators

121. Incidence, Illness Characteristics and Early Outcome in an Irish First Episode Psychosis Service

John Paul Lyne, Laoise Renwick, Brian O’Donoghue, Kevin Madigan, Anthony Kinsella, Niall Turner, Eadbhard O’Callaghan, Mary Clarke

122. Prevalence of Infections in Patients with Schizophrenia: A Pilot Study

Monika E. Pankiewicz-Dulacz, Elsebeth Stenager, Egon Stenager, Ming Chen

123. Do Persons with Schizophrenia Selectively Migrate Towards City Areas?

Carsten B. Pedersen

124. Formal Thought Disorder: A Systematic Epidemiological Review

Eric Roche, Lisa Creed, Donagh McMahon, Daria Brennan, Brendan Kelly, Kevin Malone, Mary Clarke

125. The Effects of Cannabis on Relapse in Psychosis

Tabea Schoeler, Anna Monk, Musa Sami, Giulia Camuri, Ruth Brown, Sagnik Bhattacharyya
126. Attitudes towards Patients with Psychosis and Depression in the General Population: Effects of Labeling
Frauke Schultze-Lutter, Chantal Michel, Benno G. Schimmelmann

127. Characteristics of a Catchment Area in the State of São Paulo, Brazil, for Conducting an Incidence Study of Schizophrenia and Other Psychotic Disorders
Silvia H. Tenan, Maristela S. Schaufelberger, Rosana Shuhama, Juliana Souza, Jair Santos, Geraldo Busatto, Craig Morgan, Jim van Os, Cristina Del Ben, Paulo Menezes

128. Testing Ødegaard's Selective Migration Hypothesis: a Longitudinal Cohort Study of Risk Factors for Non-affective Psychotic Disorder among Prospective Emigrants
Elisie van der Ven, Christina Dalman, Susanne Wicks, Peter Allebeck, Jim van Os, Jean-Paul Selten

129. Genetic Variability in the FKBP5 and NTRK2 Genes and Clinical Response to Clozapine
Rosa Catalan Campos, Marina Mitjans, Bárbara Arias, Mireia Vázquez, Alexandre González, Rafael Penadés, Alexandre Pons, Guillem Masana, Janet Munro, Ma Jesús Arranz

130. Effects of Genetic Variations in NRG1 on Cognitive Domains in Patients with Schizophrenia and Healthy Subjects
Youngah Cho, Seunghyong Ryu, Iksoo Huh, Eun Young Cho, Hyeji Oh, Yu-Sang Lee, Taesung Park, Kyung Sue Hong

131. Epigenetic Signatures in IGF2 and Related Genes and their Link to Birth Weight, Working Memory and Psychotic Experiences: A Study Based on Informed MZ Twins
Aldo Cordova-Palomera, Silvia Alemany, José Ignacio Martín-Subero, Mar Patjó-Vilas, Ximena Goldberg, Igor Nenadic, Lourdes Faitanás

132. Stress and Variation in the Glucocorticoid Regulating Enzyme 11-β-hydroxysteroid-dehydrogenase Type 2 in Children who later Develop Schizophrenia
Henriksen, Preben Bo Mortensen

133. Association between Rs2267641 in the A2RE Sequence of the DDR1 Gene with Cognitive Processing Speed in Patients with Schizophrenia Spectrum Disorders
Maria Cinta Gas, Ana M. Gaviria, Marta de Castro-Catalá, Thomas R. Kwapił, Paula Cristóbal-Narváez, Neus Barrantes-Vidal

134. Association of Immune Gene Polymorphisms with Schizophrenia in a North Indian Cohort
Krithika Rajagopalan, Timothy Niecko, Andrei Pikalov, Mariam Hassan, Andrei Loebel

135. Investigation of the Relationship between Schizophrenia and KREMEN1 Gene
Dua Özsoylu, Banu Değirmencioglu, Çiğdem Eresen Yazıcıoğlu, Köksal Alptekin

136. Hypothesis-driven Genome-wide Association Study (GWAS) Analysis Highlights the Role of Immune Genes in the Extended Major Histocompatibility Complex in Schizophrenia
Jennie Pouget, Vanessa Gonçalves, Virginia Misener, James Kennedy, Jo Knight

137. P250GAP a New Candidate Gene for Schizophrenia and Psychosis-proneness?
Araceli Rosa, Elionora Peña, Marta de Castro-Catalá, Thomas R. Kwapił, Paula Cristóbal-Narváez, Neus Barrantes-Vidal

138. Investigation into an Association between Genetic Risk Factors for Schizophrenia and Bipolar Disorder and Dimension-specific Psychotic Experiences in Adolescence
Dominika Sieradzka, Robert A. Power, Daniel Freeman, Alastair Cardno, Philip McGuire, Robert Plomin, Emma Meaburn, Frank Dudbridge, Angelica Ronald

139. Cost Effectiveness of the Job Management Program (JUMP)
Stig Evensen, Torill Ueland, June U. Lystad, Helen Bull, Erik Falkum

140. Risk Reduction and Numbers Needed to Treat to Avoid Metabolic Syndrome: 12-month Cardiometabolic Parameters Changes among Schizophrenia Subjects Treated with Lurasidone or Quetiapine XR
Kritiika Rajagopalan, Timothy Niecko, Andrei Pikalov, Mariam Hassan, Andrei Loebel

141. Depression Disorders in Psychosis Risk Syndrome in a Child and Adolescent Sample
Xavier Alvarez, Marta Rodriguez, Marta Carulla, Jordina Tor, Elena De la Serna, Gisela Sugranyes, Bernardo Sánchez, Marta Espadas, Vanessa Sánchez-Gistau, Inmaculada Baexa, Montse Dolz

142. Psychosis Risk Syndrome in Children and Adolescents: Clinical Characteristics and Treatment in Help-seekers vs. Controls
Inmaculada Baexa, Elena De la Serna, Gisela Sugranyes, Olga Puig, Vanessa Sánchez-Gistau, Jordina Tor, Marta Carulla, Clara Espelt, Daniel Ilzarbe, Marta Espadas, Montserrat Dolz

143. Neuropsychological Characteristics of Child and Adolescent Offspring of Schizophrenia or Bipolar Disorder Patients
Elena De la Serna, Montse Vila, Dolores Moreno, Soledad Romero, Vanessa Sánchez-Gistau, Gisela Sugranyes, Inmaculada Baexa, Teresa Sánchez, Elisa Rodriguez, Josefa Castro-Fornieles

144. Focused Interventions in 258 Subjects at High Clinical Risk for Psychosis: Oasis 6-years Naturalistic Study
Mariana Frascarelli, Lucia Valmaggia, Majella Byrne, Louisa Codjoe, Laura Weinberg, Stefania Tognin, Xenaki Lida, Philip McGuire, Paolo Pusar-Poli
146. The Relationship between Positive Psychotic and Depressive Symptoms and Functioning in Young People with Mental Health Issues  
Karen Heinze, Ashleigh Lin, Stephen Wood

147. Gender Differences in Cognitive Functioning in At-risk Mental State for Psychosis, First-episode Psychosis and Healthy Control Subjects  
Sarah Ittig, Erich Studerus, Martina Pampmeyer, Martina Uttinger, Susan Koranyi, Avinash Ramyead

Tae Young Lee, Na Young Shin, Sang Bin Hong, Jun Soo Kwon

149. Are UHR Patients who Present with Hallucinations Alone at Lower Risk of Transition to Psychosis?  
Karen O’Connor, Barnaby Nelson, Ashleigh Lin, Stephen Wood, Alison Yung, Andrew Thompson

150. Cannabis Use in a Sample of Subjects at Risk for Developing Psychosis  
Marta Pardo, Jordin Tor, Daniel Muñoz, Marta Rodríguez, Bernardo Sánchez, Elena De la Serna, Josep Lluís Matalí, Vanesa Sánchez-Gistau, Marta Carulla, Inmaculada Baiza, Montserrat Dolz

151. A Multimodal Biomarker to Predict the Onset of Schizophrenia  
Diana Prata, Evangelos Vassos, Ceri Jones, Christopher Chaddock, Alice Egerton, Isabel Valli, James Stone, Lucía Valmaggia, Stefania Tognini, Andrea Marquand, Philip McGuire

152. Clinical Depression Predicts Paranoia in High-risk Patients. Results of the EPOS Study  
Raimo K.R. Salokangas, Markus Heinimaä, Tiina From, Jarmo Hietala, Heinrich Graf von Reventlow, Don Linszen, Max Birchwood, Stephan Ruhrmann, Joachim Klosterkötter

153. Environmental Risk Factors, Prodromal Psychotic Symptoms and Psychopathology of Child and Adolescent Offspring of Parents with Bipolar Disorder, Schizophrenia and Community Controls. The Bipolar and Schizophrenia Young Offspring Study (BASYS)  
Vanessa Sánchez-Gistau, Soledad Romero, Elena de la Serna, Gisela Sugranyes, Inmaculada Baiza, Dolores Moreno, Josefina Castro-Fornies

154. Prevalence of Psychosis-risk Criteria and Symptoms in an Inpatient and General Population Sample of Children and Adolescents  
Benno G. Schimmelmann, chantal Michel, Alexandra Martí-Irnagartinger, Frauke Schultz-Lutter

155. Mediation Models of the Relationship between Childhood Trauma and Depressiveness in Patients At-risk for Psychosis and in Help-Seeking Controls  
Stefanie J. Schmidt, Stephan Ruhrmann, Benno G. Schimmelmann, Joachim Klosterkötter, Frauke Schultz-Lutter

156. Understanding Social Functioning in “At-risk Mental State” Findings from the Zurich Early Recognition Program  
Anastasia Theodoridou, Karsten Heekeren, Nicolas Rüschi, Diane N. Dvorsky, Mario Müller, Sibylle Metzler, Susanna Walitza, Wulf Rössler

157. The Danish High Risk and Resilience Study - VIA 7-attachment Style, Home Environment and Emotional Climate among 7-year-old Children with Familiar High Risk of Developing Schizophrenia Spectrum Disorder or Bipolar Disorder  
Anne A.E. Thorup, Nicole Hemager, Jens Richard Jepsen, Camilla Jerlang Christiansen, Anne Ranning, Ditte Lou Ganttriis, Aja Greve, Mette Skærbæk, Niels Ole Mors, Merete Nordentoft, Kerstin Jessica Plessen

158. Neural Correlates of Reward Processing in Unmedicated Persons At-risk for Psychosis  
Diana Wotrub, Karsten Heekeren, Lars Michels, Buechler Roman, Joe J Simon, Ana Theodoridou, Spyros Kollas, Wulf Roessler, Stefan Kaiser

159. Symptomatic Outcome of Non-converters with At-risk Mental State Patients in Support for Wellness Programme, Institute of Mental Health, Singapore  
Spencer Yuen, Swapna Verma, Sujatha Rao, Lye Yin Poon, Helen Lee

160. Improved Individualised Prediction of Schizophrenia in Subjects at Genetic High Risk, Based on Neuroanatomical and Clinical Data  
Elii Zarojanni, Amos J. Storkey, Thomas W. J. Moorhead, Stephen M. Lawrie

161. The Brief Negative Symptom Scale: Psychometric Properties and Factor Analysis of the German Translation  
Martin Bischof, Stefan Kaiser, Matthias N. Hartmann, Oliver Hager, Matthias Kirschner, Kluge Agne, Oliver Matthes, Gregory P. Strauss

162. Which Negative Symptoms do Site Raters have the most Trouble Rating?  
David G. Daniel

163. Negative Symptom Subgroups have Different Effects on Clinical Course after First Episode of Schizophrenia: A 24 Months Follow-Up Study  
Ceylan Ergul, Alp Ucok

164. Improvement in Negative Symptoms in Patients Treated with Antipsychotics  
Diego Novick, William Montgomery, Tamas Treuer, Jordan Bertsch, Josep Maria Haro

165. Negative Symptoms of Schizophrenia Correlate Specifically with Deficits in Social Functioning  
Cedric O’Gorman, Philip D. Harvey
166. Evolution of Risk Factors for Late and Persistent Negative Symptoms over Time: Results from a 12-year Follow-up of First Episode Psychosis Patients
Hugh Ramsay, John Lyne, Michele Hill, Niall Crumlish, Niall Turner, Mary Clarke

167. Assessing Effort-based Decision-making in Schizophrenia with Two Novel Behavioral Paradigms
Felice Reddy, William Horan, Jonathan Wynn, Patricia Corey-Lisle, Gregory Maglinte, Deanna Barch, Robert W. Buchanan, James Gold, Jared Young, Michael Green

168. DNA Methylation of the 5-HT1A Receptor Gene Promoter is Associated with Negative Symptom Response to Antipsychotic Drug Treatment
Gavin Reynolds, Caroline Dalton, Hao Tang

169. Persistant Negative Symptoms after First-episode Schizophrenia; Results of 2 Years Follow-up
Alp Ucok, Ceylan Ergül

170. Negative Symptoms in the Early Course of Schizophrenia: Their Longitudinal Stability and Relationship to Early Cognitive Processes
Joseph Ventura, Kenneth L. Subotnik, Denise Grestchen-Dooryl, Michael J. Gitlin, Gerhard S. Hellemann, Keith H. Nuechterlein

171. Both Psychosis Patients and their Unaffected Siblings Show Increased Concentrations of Red Blood Cell Membrane Polyunsaturated Fatty Acids as Compared to Controls - for GROUP (Genetic Risk and Outcome of Psychosis)
Suzanne Medema, Roel J.T. Mocking, Nico J.M. van Beveren

172. Molecular Mechanisms Underlying Synaptic Pathology in Schizophrenia
Peter Penzes

173. Studying Heart Arrhythmias in Relation to Psychosis (SHARP). Increased Prevalence of Cardiac Arrhythmias in Recent Onset Schizophrenia
Arjen Sutterland, Marieke Blom, Lieuwe de Haan, Hanno Tan

174. Trauma may Induce Early Cognitive Deficits Antedating Schizophrenia in Children and Adolescents at High Genetic Risk
Michel Maziaed, Nicolas Berthelot, Elsa Gilbert, Thomas Paccalet, Isabel Moreau, Chantal Mérette, Joanne Lavoie, Valérie Beaupré-Monfette, Marco Battaglia, Nancie Rouleau

175. Gene Set Enrichment of Differential Expression and Splicing Analysis by RNA-Seq in Postmortem DLPPC and PBMCs in Schizophrenia
Murray J. Cairns, Xi Wang, Joshua R. Atkins, Stu G. Fillman, Paul Tooney, Rodney Scott, Cynthia Weickert, Vaughan Carr

176. Messenger RNA and MicroRNA Expression Profiling of Pyramidal Neurons, Parvalbumin-immunoreactive Neurons, Dopamine Neurons and Oligodendrocytes in Schizophrenia and Parkinson’s Disease
Tsung-Ung W. Woo, Sarah A. Maaney, Lindsey L. Wimberly, Kai-Christian Sonntag

177. Lack of Habituation of Mirror Neuron Activity: Study Using Transcranial Magnetic Stimulation Paradigms
Hulegar A. Abhishekh, Urvakhsh M. Mehta, Rakshathi Basavaraju, Jagadisha Thirthalli, Bangalore Gangadhar

Giorgio Di Lorenzo, Fabio Ciabattini, Andrea Daverio, Fabiola Ferrentino, Gianluca Coppola, Cherubino Di Lorenzo, Cinzia Nioli, Francesco Pierelli, Alberto Siracusano, Stefano Seri

179. Reduced Theta Band Response to Relevance in Schizophrenia
Alvaro Diez, Alejandro Bachiller, Manuel Martin-Loeches, Pilar Casado, Jesús Poza, Roberto Hornero, Vicente Molina

180. Behavioral Monitoring Deficits in Schizotypal Personality Disorder: Decreased ERN as a Trait Marker of Schizophrenia-spectrum Disorders
Eva M. Grasa, Mireia Rabella, Susanna Clos, Iluminada Corripio, Rosa M. Antonijoan, Victor Pérez, Jordi Riba

181. Sex-related Differences of EEG Coherence Between Patients with Schizophrenia and Healthy Controls
Yu Sang Lee, Hye Min Jung

182. EEG Coherence in Schizophrenia and Schizoaffective Disorder
Yulia Zaytseva, Zhanna Garakh

183. Thought Disorders and Family Liability in First Episode Psychosis
Esra Aydinli, Silay Sevilmis, Ahmet Ayer, Berna Yalincetin, Berna Binmer Akdade, Koksal Alptekin

184. Self-esteem and Psychopathology among Chinese Teenagers and University Students
Lu Hua Chen, Francesca A. Cotier, Winifred Mark, Kar Yu Phoebe Kong, Shelly Leung, Cecilia N.W. Leung, Emma Li, Jim van Os, Timothea Toulopoulou

185. Cognition, Self-esteem and Quality of Life in Schizophrenia: A 12 Month Follow-up Cognitive Remediation Clinical Trial
Gemma Garrido, Maite Barrios, Rafael Penadés
186. Neurocognitive Architecture of Schizophrenia  
Max Lam, Simon Collinson, Goh Khia Eng, Attilio Rapisarda, Michael Kraus, Jimmy Lee, Siow-Ann Chong, Richard S.E. Keefe

187. Neurocognitive Impairments in Adolescents with and without At-risk States of Psychosis  
Chantal Michel, Benno G. Schimmelmann, Alexandra Martz-Irngartinger, Frauke Schultze-Lutter

188. Implicit and Explicit Self-evaluation as Underlying Mechanisms of Impaired Insight in Patients with Schizophrenia  
L van der Meer, Annerieke De Vos, Marieke Pijnenborg, André Aleman

189. The Efficacy of Occupational Therapy in the Rehabilitation of Executive Functions in Patients with Treatment-resistant Schizophrenia: A Pilot Randomized Controlled Trial  
Adriana Dias Barbosa, Vizzotto, Diego Luis Celestino, Patricia Cardoso Buchain, Alexandra Martini de Oliveira, Graça Maria Ramos de Oliveira, Elaine Scapaticcio Di Sarno, Isabel Cristina Napolitano, Helio Elkins

190. Disorganization and Timing of Motor Behavior: Insight from Gesture Impairments and Movement Patterns in Schizophrenia  
Sebastian Walther, Fabian Ramseyer, Wolfgang Tschacher, Tim Vanbellingen, Stephan Bohlhalter

191. Keeping the Body in Mind for Young People with First Episode Psychosis  
Jackie Curtis, Andrew Watkins, Simon Rosenbaum, Scott Teasdale, Megan Kalucy, Katherine Samaras, Philip B. Ward

192. The DJ's Choices Approach Adapted for Families  
Marie-France Demers, Claudia Lévesque, Julie Bouchard, Julie Bourbeau, Marc-André Roy

193. The Impacts of Aerobic Exercise and Mind-body Exercise (Yoga) on Neuro-Cognition and Clinical Symptoms in Early Psychosis - A Single-blind Randomized Controlled Clinical Trial  

194. The Effect of Motivational Interviewing on Medication Adherence and Hospitalization Rates in Nonadherent Patients with Multi-episode Schizophrenia  
Carin Meijer, Emile Barkhof, Leo de Sonneville, Don Linszen, Lieuwe de Haan

195. Duration of Untreated Psychosis – Relation to Functional Outcome of Patients with Schizophrenia  
Roxana Ciungu, Anne-Marie Murgulescu, Victor Marinescu

196. Emotional Intelligence in Serious Mental Illness – Gender Differences in Patients with Schizophrenia and Bipolar I Disorder  
Beatrice Frajo-Apor, Moritz Mühlbacher, Irene Lehner-Adam, Alex Hofer

Riccardo Fusaroli, Arndis Simonsen, Ethan Weed, Vibeke Bliksted

198. Is the DINE Adequate for Capturing Dietary Patterns Among Patients with Severe Mental Illness?  
Poonam Gardner Sood, Fiona Gaughran, Zerrin Atakan, Khalida Ismail, John Lally

Ilanit Hasson-Ohayon, Michal Mashiaich--Eizenberg, Phil Yanos, Paul Lysaker, David Roe

200. Assessing Threat Responses towards the Symptoms and Diagnosis of Schizophrenia by Measuring Visual Perceptual Biases  
Adam Heenan, Michael Best, Sarah Ouellette, Erin Meiklejohn, Nikolaus Troje, Chris Bowie

201. Experience Sampling Method through a Smartphone App: The Case of City Living & Psychosis  
Georgina M. Hosang

202. Comparing Illness Presentation, Treatment and Functioning between Patients with Early- and Adult-onset Psychosis  

203. Schizophrenia “for Life” – A Registry and Interview Study Among Elderly with Lifelong Schizophrenia  
Maria Brink, Kjeld Andersen, Bent Nielsen, Anders Green

204. Outcomes of Patients with First-episode Schizophrenia at One-year Follow-up: Findings from the National Mental Health Registry in Malaysia  
Kok Yoon Chee, Norsiatul Azma Muhammad Dain, Salina Abdul Aziz, Sharifah Suziah Syed Mokhtar, Mazni Mat Junus, Ruzanna Zam Zam, Badiah Yahya, Yee Chuan Cheah

205. Performance on the UCSD Performance-based Skills Assessment (UPSA) and Real-world Outcomes in Severe Mental Illness: A Systematic Review of the Literature  
Amy Duhig, Julie Myers, Amber Pitts, Steven Hass, Robert Klein, Philip D. Harvey

206. Use of Reliable Change Index to Evaluate Clinical Significance in the Positive and Negative Syndrome Scale (PANSS): A CATIE Analysis  
Linda Gao, Anzalee Khan, Luka Lucic, Brian Rothman
208. Aging in Schizophrenia: A Systematic Review  
Matti Isohanni, David Cowling

209. The Longitudinal Course of Schizophrenia: A Systematic Review  
Adrian Preda, Robert Bota, Steven Potkin

Chiaka Sumiyoshi, Manabu Takaki, Yuko Okahisa, Thomas Patterson, Philip D. Harvey, Tomiki Sumiyoshi

211. The Three Faces of Schizophrenia: Sub-typing Schizophrenia Based on Response and Implications for Treatment  
Ofer Agid, Gagan Fervaha, George Foussias, Cynthia Siu, Krysta McDonald, Gary Remington

212. Ecological Validity of the Schizotypy Dimensions and Stress-reactivity Model of Psychotic-like Experiences  
Neus Barrantes-Vidal, Tamara Sheinbaum, Sergi Ballespi, Charlotte Chun, Inez Myin-Germeys, Thomas R. Kwapi

213. Prevalence and Predictors of Depressive Symptoms in Non-affective Psychosis Patients in Jockey Club Early Psychosis (JCEP) Project in Hong Kong  

Laura Galbusera

215. The Course of Obsessive-compulsive Symptoms in Patients with Non-affective Psychotic Disorders and in Un-aффected Sibling: A 3 years Follow-up Study  
Frederike Schirmbeck, Marije Swets, GROUP Investigators

216. Long-term Improvements in AVHs: Clinician vs. Patient Perspectives  
Yong Sik Kim, Sam Yi Shin, Samuel Suk-Hyun Hwang, Se Hyun Kim, Jae Seung Jang, Hee Yeon Jung, In Won Chung

217. A Network Approach to the Psychopathology of Psychosis  
Johanna Wigman, Jim van Os, Dina Collin, Catherine Derom, Evert Thiery, Nele Jacobs, Tineke Latater, Inez Myin-Germeys, Philippe Delespaul, Marieke Wichers

218. Pathways to Care for Young Individuals with a First-episode Psychosis in South London: Use of Prodromal Services  
Olesya Ajnakina, Craig Morgan, Sherifat Oduola, François Bourque, Lucia Valmaggia, Paola Dazzan, Robin M. Murray, Anthony S. David

219. The Association of Autistic Traits and Psychosis Proneness in Chinese Early Adults: The Twins Scan China Study  
Shelly Leung, Phoebe Kong, Cecilia Leung, Emma Li, Francesca A. Cotier, Winifred Mark, Lu Hua Chen, Jim van Os, Timothea Touloupoulou

220. Frequency and Duration of an At-risk Mental State (DUI-ARMS) in First-episode Psychosis Inpatients: Results from a Retrospective Assessment  
Jonas Rahman, Stephan Ruhrmann, Wolfgang Maier, Joachim Klosterkötter, Frauke Schultze-Lutter

221. Structural Brain Imaging Correlates of At-risk Mental State  
Ulrich Schall, Tim Ehlikes, Pat Michele, Rebekah Atkinson, Philip B. Ward, MinT Consortium

222. Psychosis Early Detection: Helpful or Stigmatizing Experience? - A Qualitative Pilot Study  
Martina Uttinger, Susan Koranyi, Martina Pampeyer, Erich Studerus, Fabienne Fend, Andor Simon, Anita Riecher-Rössler

223. A Follow-up of Functioning in At-risk Mental State  
Justine Xue, Lye Yin Poon, Helen Lee, Swapna Verma

224. Duration of Antipsychotic Medication Treatment is a Modifier for Weight Gain  
Maarten Bak, Jim van Os

225. Amisulpiride for Elderly Patients with Chronic Schizophrenia  
Yoram Barak, Shani Pridan, Yehuda Baruch, Manina Swartz

226. Compliance to Medicament Algorithm for First-episode Psychoses; Experiences from TIPS-2 Project  
Petros Drosos, Tor Ketil Larsen, Inge Joa

227. Safety and Tolerability of Cariprazine in the Long-term Treatment of Schizophrenia  
Suresh Durgam, Andrew J. Cutler, Yao Wang, Raafaele Migliore, Kaifeng Lu, István Laszlovszky, Krisztián Nagy

228. Flexibly Dosed Paliperidone Palmitate in Non-acute Patients with Schizophrenia Switched from Previously Unsuccessful Monotherapy with Oral Atypical Antipsychotics  
Ludger Hargarter, Paul Bergmans, Pierre Cherubin, Elmars Rancans, Yasin Bez, Eduardo Parelлада, Bernado Carpiniello, Pierre Vidalhel, Andreas Schreiner

229. Efficacy and Relevance of the Modulation of Kv3 Channels to Alleviate Cognitive Dysfunction in an Animal Model of Schizophrenia Symptomatology  
Michael K. Harte, Marianne Leger, Ben Grayson, Samuel Marsh, Charles Large, Jo Neill
230. QTc Prolongation in Children and Adolescents in Second-generation Antipsychotics Treatment: A Review
Karsten G. Jensen, Anne Katrine Pagsberg, Anders Fink-Jensen, Cristoph Correll

231. Two Novel KV3 Ion Channel Modulators Alleviate Cognitive Dysfunction and Social Behaviour Deficits of Relevance to Schizophrenia in an Animal Model
Marianne Leger, Mike Harte, Ben Grayson, Sam Marsh, Charles Large, Jo Neill

232. Neuroplastic Alterations in Rats Exposed to Prenatal Stress: Preventive Effect of Lurasidone Treatment during Adolescence
Alessia Luoni, Alessandra Berry, Francesca Calabrese, Francesca Cirulli, Marco A. Riva

233. A Rater-blinded, Randomized, Comparative Study of Aripiprazole versus Blonanserin in Japanese Patients with Schizophrenia
Tomohiko Mukai

234. Ketamine as a Model for Schizophrenia Deficits
Erica Neill, Susan L. Rossell, Celia J.A. Morgan, Olivia Carter, Nicole Joshua

235. The Effect of Blood Plasma Clozapine Levels on Specific Measures of Behavior in Childhood Onset Schizophrenia
Anna E. Ordóñez, David I. Driver, Mark Orloff, Scott R. Pennanz, Jerry Overman, Deanna Greenstein, Diane Dillard-Broadnax, Judith Rapoport, Nitin Gogtay

236. The Potential Beneficial Effects of Celecoxib or Omega-3 as Adjuvant Therapy in Schizophrenia Induced in Experimental Animals
Enass Y. Osman, Alaa Eldin Elisy, Samia Sokar, Magda Elsayad, Ehab Ramadan

237. Histamine H2 Blockers for Schizophrenia: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Kazuto Oya, Taro Kishi, Nakao Iwata

238. Effect of Lurasidone on Cognitive Impairment: From the Lab to the Clinic
Andrei Pikalov, Philip D. Harvey, Cynthia Siu, Josephine Cucchiari, Antony Loebel

239. Exploration of the Therapeutic Potential of Selective TAAR1 Agonists in Preclinical Paradigms
Eric Prinssen, Anja Harmemeir, Roger Norcross, Tanya Wallace, Celine Risterucci, Patrick Mortas, Jean-Luc Moreau, Joseph Wettstein, Marius Hoener

240. Behavioral Effects of the Novel Benzodiazepine Positive Allosteric Modulator SH-053-2’F-S-CH3 in an Immune-mediated Neurodevelopmental Disruption Model
Juliet Richetto, Marie A. Labouesse, Michael M. Poe, James M. Cook, Anthony A. Grace, Marco A. Riva, Urs Meyer

241. Description of the Impacts of Clozapine Use in an Early Stage Psychosis Population
Marc-André Roy, Brigitte Pelletier, Annie Liseau, Marie-Claude Harisson

242. Obsessive-compulsive Symptoms in Patients with Schizophrenia Comparing Treatment with Clozapine, Olanzapine, Risperidone and No Antipsychotics: A Longitudinal Study of 550 Patients after 3 Years of Treatment
Albertine Scheltenda Beduin, Carin Meijer, Lieuwe de Haan

243. Paliperidone Palmiate – Impact on Negative, Disorganized and Depressive Symptoms, Subjective Well-being and Patient Satisfaction in Patients with Schizophrenia Previously Unsuccessfully Treated with Oral Antipsychotics
Andreas Schreiner, Ludger Hargarter, Paul Bergmans, Pierre Cherubin, Elmars Rancans, Yasin Bez, Eduardo Pareda, Bernardo Carpiello, Pierre Vidalhe

244. The Use of Mirtazapine as Add-on Therapy in the Treatment of Schizophrenia
Gaurav Singh, Klara Sputova, Eric Hecht

245. Positive Results with ITI-007 for the Treatment of Schizophrenia: A Randomized, Double-blind, Placebo- and Active-controlled Phase 2 Study
Kimberly Vanover, Robert E. Davis, Larry Ereshefsky, Sharon Mates

246. Social Anxiety as a Treatment Target to Improve Social Adjustment and Quality of Life in Schizophrenia
Sayaka Aikawa, Takahiro Nemoto, Naohisa Tsujino, Yoko Baba, Yuko Yorozuya, Miki Tobe, Kiyoeaki Takeshi, Taiju Yamaguchi, Naoyuki Katagiri, Masafumi Mizuno

247. Can Work History at Baseline Predict Work Behavior Within the First Four Weeks of Vocational Rehabilitation?
Helen Bull, Torill Ueland, June U. Lystad, Stig Evensen, Erik Falkum

248. Improving Social Functioning in Schizophrenia through Social Cognitive Remediation
Linda K. Byrne

249. Helping People with Psychotic Disorders Back to Work – The JUMP Study
Erik Falkum, June U. Lystad, Helen Bull, Stig Evensen, Torill Ueland

250. The Role of Gender and Symptoms in Predicting Functioning in Early Episode Psychosis
Maya Gupta, Michael Grossman, Michael Best, Emma Ayukawa, Christopher Bowie

251. Methodological Considerations in the Implementation of the US MOSAIC Registry: A Large-Scale, Long Term Study of People with Schizophrenia
Philip D. Harvey, Cedric O’Gorman
252. Patients’ Opinions on Key Issues of Psychosocial Functioning Among Non-psychotics, Psychotic Responders and Non-Responders: Correlation with Clinical Variables and Symptom Domains Relevant to Remission from Psychosis
Felice Iasevoli, Sara Giordano, Raffaele Balletta, Elisabetta F. Buonaguro, Carmine Tomasetti, Rodolfo Rossi, Valentina Gillardi, Claudia Cucciniello, Cristina Elce, Roberto Acampora, Andrea de Bartolomeis

253. Vocational Recovery in First Episode Psychosis: Preliminary Results from a Large Randomised Controlled Trial of Individual Placement and Support
Eoin Killackey, Henry Jackson, Kelly Allott, Susan Cotton

254. Differential Effects of Antipsychotics on Quality of Life and Functioning in Chinese Patients with First-episode Psychosis
Edwin Lee, Christy L.M. Hui, Wing Chung Chang, Sherry K.W. Chan, Elaine Ching, Eric Y.H. Chen

255. Interpersonal Trauma and the Social Functioning of Adults with First Episode Psychosis
Helen J. Stain, Kolbjorn Bronnick, Wenche ten velden Hegelstad, Inge Joa, Jan Olav Johannessen, Johannes Langeveld, Lauren Mawn, Tor Ketil Larsen

256. The Effects of Self-stigma Content and Process on Subjective Quality of Life in People with Schizophrenia
Kevin K.S. Chan, Winnie W.S. Mak

257. Variables Influencing Subjective Well-being in Patients with Schizophrenia
Seung-Hyun Kim, Changsu Han, Young-Hoon Ko, Jong-Woo Paik, Moon-Soo Lee, Hyun-Ghang Jeong, Jinseung Oh, Jung Jin Kim

258. Quality of Life and Depression among Caregivers of Schizophrenics
Priyanka Rawat

259. Social Support, Quality of Life, Psychotic Symptoms, and Depression in Schizophrenia
Srijit Suttajit, Sutrak Pilakanta

260. The Role of Consumer Feedback in Shaping Recovery Services for Agitated Psychotic People
David Ash, Shuichi Suetani, Matt Halpin, Cassandra Burton

261. Health Service and Resource Use at 12 Years in First Episode Psychosis
Caragh L. Behan, David Moloney, Michele Hill, Anthony Kinsella, John Waddington, Mary Clarke

262. Acute Medical Care Utilisation in Psychiatric Inpatients
John Lally, Emma Wong, Hitesh Shetty, Anita Patel, Vivek Srivastava, Matthew TM Broadbent, Fiona Gaughran

263. Clozapine Prescription to Treatment-resistant Schizophrenia Patients in Community Mental Health Services in São Paulo, Brazil
Rodrigo Bressan, Devis Rocha, Ana Silveira, Cecilia Attu, Claudiane Daltio, Leticia Silva, Helio Elkis, John Kane

264. Differences in Cannabis-related Experiences between Patients with a First Episode of Psychosis and Healthy Controls
Matteo Bonomo, Francesca Bianconi, Marta Di Forti, Arianna Marconi, Anna Kolliakou, Simona A. Stilo, Valeria Mondelli, Pedro Gurillo Muñoz, Craig Morgan, Michael T. Lynskey, Robin M. Murray

265. The Importance of Pharmacological and Non-pharmacological Factors for the Development of Organ Lesions and Occurrence of “Sudden Cardiac Death” in Patients with Schizophrenia. A PhD project as part of SURVIVE
Anne Bugge, C.B. Hoyer, L.W. Boel, G.L. Ottesen, J. Banner, J.I. Thomsen

266. Clinical Characteristics in Early Onset First-episode Psychosis with Cannabis Use
Radhika Patel, Maria-de-Gracia Dominguez, Helen Fisher, Sonia Johnson, Matthew Hodes

267. Does Substance Abuse Increase the Risk of Schizophrenia?
Nanna G. Toftdahl, Carsten Rygaard Hjorthøj
POSTERS, TUESDAY 08 APRIL

12:00 PM - 2:00 PM
Location: Cavaniglia

1. Prevalence and Correlates of HIV Risk Behaviour among Persons with Schizophrenia in Southwestern Nigeria
   Olukayode Abayomi

2. Perspective-taking Abilities in the Balance between Autism Tendencies and Psychosis Proneness
   Ahmad Abu-Akel, Stephen Wood, Peter Hansen, Ian Apperly

3. Predictors of Theory of Mind and Social Functioning Impairments in Patients with Recent-onset of Psychosis
   Amelie M. Achim, Marc-André Roy, Marie-Audrey Lavoie, Philip Jackson

4. Value Recalibration in First-episode Schizophrenia
   Ofer Agid, Gagan Fervaha, Krysta McDonald, Romie Littrell, Jessica Thoma, George Foussias, Eli Remington, Cynthia Siu, Gary Remington

5. Escalated Social Aggression and Extracellular Synaptic Activity after Blockage of NMDA and mGlur1 Receptors in Central Nucleus of Amygdala in Developmental Schizophrenic Model
   Milad Ahmadi, Babak Khodaie, Ahmadali Lotfina, Mahmoud Lotfina, Ali Gorji

6. Childhood Trauma, FKBP5 Gene and Psychotic Experiences in General Population
   Silvia Alemany, Bárbara Arias, Helena Villa, Jorge Moya, Manuel I. Ibáñez, Generós Ortet, Lourdes Fàñanás

7. Familial Liability, the BDNF-Val66Met Polymorphism and Psychotic-like Experiences
   Koşkal Alptekin, Tolga Binbay, Hayriye Elbi, Nesli Zagli, Huseyin Onay, Ferda Özkanay, İmam Öztürk, İhsan Polat

8. Efficacy and Safety of Olanzapine Long-acting Injection in Patients with Schizophrenia: A Post-hoc Analysis of a 6-year, Multinational, Single-arm, Open-label Study
   Ernie Anand, Lovisa Berggren, Agoston Toth, David McDonnell

9. The Gothenburg Research and Investigation in Psychosis – GRIP – An Interdisciplinary Naturalistic Study with the Major Aims to Improve Diagnostics and Predict Outcome in Patients Believed to be Suffering from a Psychotic Illness
   Kristina Annerbrink, Irma Ryno, Anneli Goulding, David Berg, Christian Øhrn, Mats Gustafsson, Mikael Landén

10. Acceptability and Feasibility of Extended Use of Mobile Phone Technology to Assess Psychotic Symptoms in DSM-IV Schizophrenia Patients
    Eve Applegate, Jasper Palmier-Claus, Matthew Machin, Caroline Sanders, John Ainsworth, Shôn Lewis

11. Reduction in the Use of Seclusion with the Introduction of Recovery Principles in an Acute Psychiatric Unit
    David Ash, Peter Metcalfe, Cassandra Burton

12. Lifetime Symptom Dimensions and their Correlation with Cognitive Function, Functional Level, and Treatment Response in Chronic Schizophrenia Patients
    Moonoh Bae, Youngah Cho, Seunghyong Ryu, Hyeji Oh, Sohee Oh, Taesung Park, Kyung Sue Hong

13. The Effect of Previous Dose or Oral Aripiprazole (10 or 30 mg/day) on the Efficacy and Tolerability of Aripiprazole Once-monthly: Results from Post-hoc Analyses from Two Double-blind, Randomized, Controlled Trials
    Ross A. Baker, Anna Eramo, Anna-Greta Nylander, Lan-Feng Tsai, Timothy S. Peters-Strickland, Dusan Kostic, Raymond Sanchez

    Sophie I. Barkl, Suncica Lah, Anthony W. Harris, Leanne Williams

15. Postnatal mGlur5 Ablation from Parvalbumin-positive Interneurons Alters the Responsivity to Psychotomimetic Drugs
    Samuel A. Barnes, Terrence J. Sejnowski, M. Margarita Behrens, Athina Markou

16. Relatives’ Expressed Emotion, Attractions and Emotional State in Clinical High-risk and Onset Stages of Psychosis
    Neus Barrantes-Vidal, Tecelli Domínguez-Martínez, Thomas R. Kwapil

17. Prevalence of Disease Relevant NMDA Receptor Autoantibodies in Refractory Psychosis
    Katherine Beck, John Lally, Sukhwinder Shergill, James H. MacCabe, Fiona Gaughran, Oliver Howes

18. Estimating the Cost and Effect of Early Intervention on In-patient Admission in First Episode Psychosis
    Caragh L. Behan, Niall Turner, Elizabeth Owens, Adam Lau, Anthony Kinsella, John Cullinan, Brendan Kennelly, Mary Clarke

19. Animal Models of Schizophrenia Symptoms: Polydipsia Following Subchronic MK-801, Post-weaning Social Isolation or Amphetamine Sensitization in Rats
    Richard J. Beninger, Emily R. Hawken

20. The Association between Infections and General Cognitive Ability in Young Men – A Danish Nationwide Study
    Michael E. Benros, Holger Sørensen, Philip Nielsen, Merete Nordentoft, Preben Bo Mortensen, Liselotte Petersen
21. Maternal Smoking during Pregnancy and Symptom Severity among Offspring During Their First Episode of Psychosis
Francesco Bernardini, Michael T. Compton

22. Exploring the Impact of Family Interventions for Patients Presenting a First Episode Psychosis and their Families
Séverine Bessero, Fabrice Chantraine, Manuel Tettamanti, Logos Curtis

23. Affective Prosody in Remitted and Non-remitted Schizophrenia Patients Compared to Healthy Controls
Falk Biedermann, Baumgartner Susanne, Alexandra Kaufmann, Georg Kemmler, Christine Hoertnagl, Christian Widschwendter, Nursen Yalcin, W. Wolfgang Fleischhacker, Alex Hofer

24. The Impact of Consanguinity on Risk of Extended Psychosis Phenotype
Tolga Binbay, Köksal Alptekin, Hayriye Elbi, Halis Ulaş, Marjan Drukker, Jim van Os

25. Anomalies in the Fabric of the Perineuronal Net and Schizophrenia Pathophysiology
Byron K.Y. Bitanihirwe, Charmaine Pietersen, Tsung-Ung W.

Catherine L. Bois, Liat Levita, Lisa Ronan, Stephen Lawrie

27. Altered Hippocampal Glutamate Function in People at Ultra High Risk for Psychosis
Matthijs G. Bossong, Paul Allen, Carly Samson, Haleema Rasheed, Beverly Quinn, Ilaria Bonoldi, Gemma Modinos, James Stone, Oliver Howes, Philip McGuire

28. Obsessive Compulsive Symptoms and Premorbid Adjustment as Predictors of Transition to Psychosis in Ultra-high Risk Subjects
Julie Bourgin, Emilie Magaud, Anne Gut, Mathilde Kazes, Marie-Odile Krebs

29. How to Predict and Measure Medication Adherence in Schizophrenia: Twelve Months of Electronic Monitoring (MEMS®) in the Swedish COAST-study
Cecilia Brain, Katarina Allerby, Lisbeth Barnes, Margda Waern

30. Link between Neurological Soft Signs and Poor Outcome Schizophrenia (Krapelinian Sub-type): Preliminary Results
Marie-Cécile Bralet, Nordine Mebtoul, Trang Ton, Christian Koegel, Isabelle Amado, Marie-Odile Krebs

31. Proteomic Investigation and Characterisation of Post-translational Modifications of Histone Proteins Purified from Prenatally Stressed Mouse Brain Tissue
Elizabeth Brindley, Melanie Foeking, Daniel van den Hove, Jos Prickaerts, Gerard Cagney, David Cotter

32. “People with Schizophrenia Sometimes Talk to themselves, and that’s Okay:” Community-partnered Development of Anti-stigma Messages
Beth Broussard, Michael T. Compton

33. Criminal Justice Settings as a Potential Site for Early Detection of Psychotic Disorders and Reducing Treatment Delay
Beth Broussard, Michael T. Compton

34. Increased Stability of Microtubules in Cultured Olfactory Neuroepithelial Cells from Individuals with Schizophrenia
Alan Brown, Karin Borgmann-Winter, Chang-Gyu Hahn, Lorna Role, David Talmage, Raquel Gur, Jacky Chow, Patric Prado, Thelma McCluskey, J. Chloe Bulinski, Andrew Dwork

35. The Effect of Lifestyle Treatments on Bodyweight, Cardiometabolic Risk and Depression in People with Severe Mental Illness - A Meta-analysis
Joanneke Bruins, Frederike Jörg, Richard Bruggeman, Cees Slooff, Eva Corpeleijn, Marieke Pijnenborg

36. Global Methylation Levels of Schizophrenia Subjects Supplemented with Folate: A Pilot Study
Kyle J. Burghardt, Vicki Ellingrod

37. Facial Affect Recognition: The Impact of Culture and Schizotypal Traits
Linda K. Byrne, Richard Zhang, Xiaoyan Xu, Renati Solomon, Eugenia Vinet, Jose Luis Saiz, David Mellor

38. Prediction of Symptom Outcome in Clinical High Risk Subjects Using the Acoustic Startle Paradigm
Kristin Cadence, Jean Addington, Carrie E. Bearden, Tyrone Cannon, Tom McGlashan, Daniel Mathalon, Diana Perkins, Larry J. Seidman, Ming Tsuang, Elaine Walker, Scott Woods

39. An Association Study of RGS4 Polymorphisms with Clinical and Neurocognitive Profiles of Schizophrenia Patients
Günes Can, Emre Gülsu, Banu Değirmencioğlu, Ahmet Topuzoğlu, Çiğdem Eresen Yazıcıoğlu, Berna Binnur Akdede, Köksal Alptekin

40. Theory of Mind and Personality Pathology in Schizophrenia Patients and First-degree Relatives
Briana D. Cassetta, Vina Goghari

41. Do Reward-processing Deficits in Schizophrenia Promote Cannabis Use? An Investigation of Response to Natural Rewards and Drug Cues
Clifford M. Cassidy, Mathieu Brodeur, Martin Lepage, Ashok Malla

42. Durability of Reinforcement Learning Changes after Cognitive Remediation
Matteo Cella, Anthony Bishara, Clare Reeder, Til Wykes
43. Automatic Self-stigma-relevant Associations in People with Schizophrenia Experiencing Habitual Self-stigma: Evidence from the Brief Implicit Association Tests
   Kevin K.S. Chan, Winnie W.S. Mak

44. Three-year Outcome Comparison between Patients Presenting with First-episode Psychotic Mania and Schizophrenia to EASY Program in Hong Kong

45. Changes in Body Mass and Metabolic Profiles over 12 Months in Patients with First-episode Schizophrenia with Assured Antipsychotic Adherence
   Bonginkosi Chiliza, Laila Asmal, Piet Oosthuizen, Yvette van Niekerk, Rajiv Erasmus, Martin Kidd, Anil K. Malhotra, Robin Emsley

46. Comparison of the Rorschach Performance between Schizophrenia and Bipolar I Disorder with Psychotic Features
   Booyeol Choi, Minkyung Koh, Yeon Ho Joo, Eun Ah Noh

47. Similar Age-related Decline in Cortical Activity over Frontotemporal Regions in Schizophrenia and Healthy Individuals: A Multi-channel Near-infrared Spectroscopy Study
   Po Han Chou, Koike Shinsuke, Yukioka Nishimura, Yoshihiro Satomura, Akihide Kinoshita, Ryu Takizawa, Chin Hong Chan, Tsuo Hung Lan, Kiyou Kasai

48. Investigation of the Pro-melanin-concentrating Hormone Gene in Antipsychotic-Induced Weight Gain
   Nabilah Chowdhury, Arun Tiwari, Eva Brandl, Jeffrey Lieberman, Herbert Y. Meltzer, James Kennedy

49. Hypothetical of Mind in Children with Psychotic Experiences
   Lars Clemmensen, Jim van Os, Anne Mette Skovgaard, Mette Vaever, Els M.A. Blijd-Hoogewys, Agna A. Bartels-Velthuis, Pia Jeppesen

50. Is Cognitive Remediation Therapy an Effective Intervention in Enhancing Vocational Outcomes for People with Severe Mental Illness?
   Natalia Contreras, Susan Rossell, David J. Castle, Carol Harvey, Ellie Fossey, Caroline Crosse, Dea Morgan

51. Birth Weight and IQ Are Associated with Adult Cortical Surface Area: Additional Evidences Based on a Twin Study
   Aldo Cordova-Palomera, Silvia Alemany, Carles Falcón, Nuria Bargalló, Ximena Goldberg, Benedicto Crespo-Facorro, Igor Nenadic, Lourdes Fañanás

52. COMT Moderation of the Association between Momentary Stress and Psychotic-like Experiences in Daily Life
   Paula Cristóbal-Narváez, Araceli Rosa, Marta de Castro-Catalá, Tamara Sheinbaum, Thomas R. Kwapi, Neus Barrantes-Vidal

53. The Kamon Method for Cognitive Remediation of Individuals with Schizophrenia: A Randomized, Placebo-controlled Trial
   Marisa M. Crivelaro, Paula Martins, Monia Musskopf, Suely Ayuso, Silvia Arcury, Paula Martins, Zilda Celidonio, Rosa Bertinho, Mario Louzã

54. Increasing Therapeutic Activities on Acute Psychiatric Wards
   Emese Csipke, Diana Rose, Paul McCrone, Tom Craig, Til Wykes

55. Effect of Lurasidone on Depressive Symptoms in Patients with Schizophrenia Josephine Cucchiara, Jay Hsu, Antony Loebel

56. Learn Before You Burn: THC Impairs Encoding but not Retrieval of Verbal Information
   Deepak Cyril D’Souza, Mohini Ranganathan, Peter Addy, Halle Thurnauer, Ashley Schnakenberg, Brian Pittman, Rajiv Radhakrishnan, Patrick Skosnik, Richard Andrew Sewell

   Nataliya Andreevna Daeva, Elizaveta Fedotova

58. Lower Anterior Cingulate Volume in Seriously Violent Men with Antisocial Personality Disorder or Schizophrenia and a History of Childhood Abuse
   Mirjandra Das, Veena Kumari

59. Relationship between the BDNF Val66Met Polymorphism, Childhood Trauma, Schizotypy and Psychotic-like Experiences
   Marta de Castro-Catalá, Neus Barrantes-Vidal, Thomas R. Kwapi, Paula Cristóbal-Narváez, Araceli Rosa

60. Service Satisfaction and Spiritual Well-being as Predictors of Quality of Life among Patients with Schizophrenia: A Longitudinal Study Using a Structural Equation Model Approach
   Giovanni De Girolamo, Mariangela Lanfredi, Valentina Candini, Chiara Buizza, Clarissa Ferrari, Maria Elena Boero, Gian Marco Giobbio, Laura Iozzino

61. Patterns of Habituation to Novelty in First Episode Schizophrenia and Control Subjects
   Elisabetta C. del Re, Margaret Niznikiewicz, Tracey Petryshen, Robert McCarley, Kevin Spencer

62. Distinct Effects of Lithium Chloride and Clozapine in Preventing Suicide-related Behaviors in a Two-hit Model of Schizophrenia
   Jessica Deslauriers, Karine Belleville, Nicolas Beaudet, Philippe Sarret, Sylvain Grignon
63. The Impact of a NCAN Gene Polymorphism on Memory and White Matter Microstructure in Healthy Individuals: A Diffusion Tensor Imaging Study
Bruno Dietche, Thomas Weikert, Davide Laneri, Heidelore Backes, Stephanie Witt, Marcella Rietzschel, Jens Sommer, Tilo Kircher, Axel Krug

64. Spectral Entropy Modulation Decrease in Patients with Schizophrenia during P300 Evocation
Alvaro Diez, Vanessa Suazo, Alejandro Bachiller, Marta Ayuso, Cristina Domínguez, Roberto Hornero, Jesús Poza, Vicente Molina

65. Image-based Automated Detection of First-episode Schizophrenia: The Importance of Spatial Resolution of Morphological Features and Ensemble Learning
Petr Dluhos, Daniel Schwarz, Tomas Kasparek

66. Premorbid Impairments in Childhood-onset Schizophrenia
David I. Driver, Deanna Greenstein, Judith Rapoport, Nitin Gogtay

67. Are Patients with Schizophrenia Abnormally Sensitive to Pain?
Céline Z. Duval, André Dufour, Pierre Vidalhiet, Kemmel Véronique, Yannick Goumon, Guy Mensah-Nyagan, Catherine Schmidt-Mutter, André Muller, Anne Giersch

68. Brain Systems Regulating Food-intake and Body Mass Changes during Acute Antipsychotic Treatment in First-episode Schizophrenia
Robin Emsley, Laila Asmal, Bonginkosi Ciliza, Stefan du Plessis, Jonathan Carr, Martin Kidd, Matthias Vink, René Kahn

69. Negative Symptom Subgroups have Different Effects on Clinical Course after First Episode of Schizophrenia: A 24-month Follow-up Study
Cevlan Ergul, Alp Uçok

70. The Effects of Psychosocial Stress Induction on the Jumping to Conclusions Bias in People with Clinical Risk for Psychosis
Anna O. Ermakova, Graham Murray, Ian Goodyer, Paul Fletcher, Veronika Dobler

71. Oxidative Stress is Related toNeuropsychological Functioning, and Delusional Beliefs in First Episode Psychosis
Aysem Esen-Danaci, Cristina Gonzalez-Lienecres, Cumhur Tas, Elliot C. Brown, Soner Erdin, Ece Onur, Zeynep Cubukcoglu, Omerr Aydemir, Aysem Esen-Danaci, Martin Brüne

72. DNA Methylation and GABAergic Pathology of Schizophrenia
Helene Aparecida Fachim, Umarat Srisawat, Michael K. Harte, Caroline Dalton, Gavin Reynolds

73. Jumping to Conclusions, Neuropsychological Functioning, and Delusional Beliefs in First Episode Psychosis
M. Aurora Falcone, Benjamin Wiffen, Robin M. Murray, Marta Di Forti, Suzanne Jolley, Daniel Freeman

74. Engagement with Psycho-social Interventions Within and an EI Psychosis Service
Felicity Fanning, Roisin Doyle, Patrick Egan, Niall Turner, Elizabeth Lawlor, Mary Clarke

75. Prenatal Exposure to Maternal Immune Stimulation Leads to Changes in Myelin Proteins in the Adult Rat Prefrontal Cortex Which can be Prevented by Risperidone in Adolescence
Lorna Farrelly, Melanie Föcking, Yael Piontkewitz, Patrick Dicker, Jane English, Kieran Wynne, Mary Cannon, Ina Weiner, Gerard Cagney, David Cotter

76. Behavioural Economics of Effort-based Reward-driven Choice in Schizophrenia
Gagan Fervaha, Ofer Agid, George Foussias, Ariel Graff-Guerrero, Konstantine Zakzanis, Gary Remington

77. Perceived Stress is Associated with the Risk of Hospitalization in Early Psychosis: 1-year Prospective Study
Rosa Maria Gabernet Florensa, Rosa Monseny, Laura Ortega, Itziar Montalvo, Oscar Reáitia, Marta Creus, Javier Labad

78. Determinants of Poor Diet among a Large Sample of People Living with a Psychotic Illness
Cherie Galletly, Lisa Hahn, Debra Foley, Andrew Mckinnon, Gerald Watts, David Castle, Dennis Liu, Anna Waterreus, Vera A. Morgan

79. Cognitive Biases, Personality and Dimension of Psychotic-like Experiences in the General Population
Lukasz Gaweda, Katarzyna Prochowicz, Matteo Celli

80. Investigation of the Relationship between Cognition and Anatomical Networks in Schizophrenia
Suzanne Geier, Nelson Brent, Kelvin O. Lim, S. Charles Schulz

81. Frequency and Characteristics of the Attenuated Psychosis Syndrome and Delineation to Other Risk Profiles in a Sample of Help-seeking Individuals
Miriam Gerstenberg, Anastasia Theoeridou, Nina Traber-Walker, Maurizia Franscini, Diana Wotruba, Sibylle Metzler, Diane Dvorsky, Christoph U. Correll, Susanne Walitza, Wulf Rössler, Karsten Heekeren

82. Social Stress and Psychotic Symptoms in the Daily Life of Young Adults with Hearing Impairment
Martin Gevonden, Inez Myin-Germeys, Jan Booij, Wim van den Brink, Jim van Os, Jean-Paul Selten

83. Genetic Variation in Arrb2 Is Associated with B-arrestin2 Expression and Striatal Activity during Working Memory
Giulia M. Giordano, Antonio Rampino, Gianluca Ursini, Leonardo Fazio, Laura Ferranti, Rita Maselli, Mariateresa Attrotto, Ilaria Bitetti, Pasquale Di Carlo, Giuseppe Blasi, Alessandro Bertolino
84. Semaphorins and Plexins Gene Expression is Altered in the Prefrontal Cortex of Schizophrenia Patients with and without Auditory Hallucinations
Rocio Gonzalez-Martinez, Javier Gilabert-Juan, Ana Rosa Saez, Guillermo Lopez-Campos, Noelia Sebastiá, Juan Nacher, Julio Sanjuán, María Dolores Moltó

85. The Effects of Motivational Incentives on Cognition in Patients with Schizophrenia and Negative Symptoms – A Functional Magnetic Resonance Imaging Study
Oliver M. Hager, Matthias Kirschner, Matthias N. Hartmann, Agne Kluge, Martin Bischof, Philippe N. Tobler, Stefan Kaiser

86. Structural MRI in First Episode Psychosis: An International Collaborative Mega-analysis of Individual Adult Patient Data
Brian Hallahan, Colm McDonald, Anne Gallagher, Cathy Scanlon, Aengus O’Conghaille

87. Once Monthly Paliperidone Palmitate – Tolerability and Treatment Response in Recently Diagnosed versus Chronic Non-acute Schizophrenia Patients Switched from Previously Unsuccessful Treatment with Oral Antipsychotics
Ludger Harertger, Paul Bergmans, Pierre Cherubin, Elmars Rancans, Yasin Bez, Eduardo Parellada, Bernardo Carpinello, Pierre Vidalhet, Andreas Schreiner

88. The Effects of Maternal Immune Activation and MK-801 on Mismatch Responses in Awake, Freely Moving Rats
Lauren R. Harms, Deborah Hodgson, William Fulham, Michael Hunter, Markku Penttonen, Ulrich Schall, Juanita Todd, Cyndi Shannon-Weickert, Katerina Zavitsanou, Patricia Michie

89. Do Community Treatment Orders Keep People Out of Hospital? The Influence of the Level of Community Care
Anthony W. Harris, Joe Garside, Grant Sara

90. Effect of Lifetime Stress on Resistance to Antipsychotic Treatment
Ahmed Hassan, Vincenzo De Luca

91. Childhood Abuse and Brief Life Events in Postpartum Psychosis
Katie M. Hazelgrove, Carmine M. Pariante, Astrid M. Pauls, Susan Pawlby, Costanza Vecchio, Paola Dazzan

92. N-acetylcysteine Prevents Increased Sensitivity to Amphetamine in Social Isolation-reared Mice
Ana P Herrmann, Radharani Benvenutti, Luisa Pilz, Elaine Elisabethsky

93. Concordance Rates and Heritability in Schizophrenia, Data from a Danish Twin Study
Rikke Hilt, Dorthe Helenius, Birgitte Fagerlund, Axel Skythte, Merete Nordentoft, Birte Glenthoj

94. Optimizing Treatment and Signal Detection with EVP-6124 in a CIAS Phase 2b Study
Dana Hill, Ilise Lombardo, Maria Gawryl, Nancy Dgetluck, Richard Keefe
105. Prevalence and Profile of Cognitive Deficits in a Cohort of First-episode Antipsychotic-naïve Schizophrenia Patients
   Maria H. Jensen, Birte Glenthøj, Mette Ødegaard Nielsen, Sanne Wulff, Birgitte Fagerlund

106. Psychopathology, Level of Functioning and Socioeconomic Status: A Descriptive Study of 42 Subjects from an Ultra High-risk Cohort
   Helle K. Jessen, Dorte Nordholm, Lasse Randers, Kristine Krakauer, Merete Nordentoft

107. Cigarette Smoking is Associated with Reduced Cingulate and Insular Thickness among Patients with Psychosis and Bipolar Spectrum Disorders
   Kjetil N. Irgensen, Ingeborg Skjærmo, March-Johnsen Lynn, Unn Kristin Hauvkiv, Elisabeth Heffermehl Lange, Melle Ingrid, Ole Andreas Andreassen, Ingrid Agartz

108. The Relationship between Language Ability and Cognitive Function in People with Schizophrenia
   Do Un Jung, Sung Jin Kim, Jo Cheol Shim, Bo Geum Kong, Jung Joon Moon

109. Association of Family History of Psychosis to Social, Occupational and Global Outcome in Schizophrenia: Systematic Review and Meta-analysis
   Juha P. Käkelä, Joni Panula, Eetu Oinas, Noora Hirvonen, Erika Jääskeläinen, Jouko Miettunen

110. Classifying Schizophrenia Using Joint Multivariate Pattern Recognition Analysis of Brain Function and Structure
   Lana Marija Kambeitz-Ilankovic, Nikolaos Koutsouleris, Sebastian von Saldern, Peter Falkai, Carlos Cabral

111. Association Study Between Antipsychotics-induced Restless Legs Syndrome and Polymorphisms of MEIS1 Genes in Schizophrenia
   Seung-Gul Kang, Ho-Kyoung Yoon, Young-Min Park, Heon-Jeong Lee, Leen Kim

112. Identical Pattern of Hedonic and Affective Reactivity to Daily-life Social Stress among Patients with Psychotic Disorder and Healthy Individuals
   Zuzana Kasanova, Dina Collip, Johan Lataster, Jim van Os, Inez Myin-Germeys

113. Salience Attribution in Schizophrenia Patients and Delusion-prone Subjects
   Teresa Katthagen, Anne Pankow, Sarah Diner, Stefan Koch, Andreas Heinz, Florian Schlagenhauf

114. Early Detection and Intervention Project for Young People at Risk for Developing Psychosis in Uchinada
   Yasuhiro Kawasaki, Reiko Hashimoto, Sachiko Ono, Takamito Shimada, Hiromasa Kihara, Masahiko Tunoda

115. Kanizsa Shape Perception and Contour Integration in Schizophrenia: What Is the Role of Spatial Frequency?
   Brian P. Keane, Danielle Paterno, Genna Erlichman, Sabine Kastner, Steven Silverstein

116. Interaction between Parental Psychosis and Delays on Early Motor Developmental Milestones in Schizophrenia - The Northern Finland 1966 Birth Cohort Study

117. Childhood Neurodevelopmental Disorders, IQ and Subsequent Risk of Psychotic Experiences in Adolescence: A Population-based Longitudinal Study
   Golam Khandaker, Jan Stochl, Stanley Zammit, Glyn Lewis, Peter B. Jones

118. Histological Response on Different Model of Schizophrenia
   Babak Khodaei, Ahmad Ali Lotfiania, Milad Ahmadi, Mahmoud Lotfiania

119. Reward System Dysfunction and Negative Symptom Dimensions in Schizophrenia
   Matthias Kirschner, Oliver Hager, Matthias Hartmann, Agne Kluge, Martin Bischof, Erich Seifritz, Philippe Tobler, Stefan Kaiser

120. Does rTMS Help to Improve Negative Symptoms in Schizophrenia? Results from a Randomized Controlled Trial in the Netherlands
   H. Kneutinger, Jozarni Dlabac-de Lange, Leonie Bais, Bert Visser, Frank Van Es, Els Reinink, Bertil Bakker, Edwin van den Heuvel, André Aleman

121. Social Cognition Dysfunction and Abnormality of the Brain Structure
   Minkyung Koh, Yangsik Kim, Jung-Sun Lee, Yeon Ho Jo, Changyouon Kim

122. White Matter Structure in Subjects with Familial Risk for Psychosis – The Oulu Brain and Mind Study
   Jenni Koivukangas, Lassi Björnholm, Jouko Miettunen, Tanja Nordström, Pirjo H. Mäki, Erika Jääskeläinen, Jennifer Barnett, Vesa Kiviniemi, Osmo Tervonen, Juha Nikkinen, Juha Veijola

123. A Transgenic Rat Model of DISC1opathies: Brain Disorders Characterized by DISC1 Aggregates and Aberrant Dopamine Homeostasis
   Carsten Korth, Svenja Trossbach, Verian Bader, Ingrid Priklis, Sandra Schäble, Angelica de Souza Silva, Zoe A. Hughes, Nick Brandon, Joseph Huston

124. Clinical and Brain Structural Predictors of ‘Transition to Psychosis’ or ‘Risk Remission’ in Individuals at Ultra High-risk for Schizophrenia
   Kristine Krakauer, Egil Rostrup, Bjørn H. Edbrub, Lasse Randers, Dorte Nordholm, Louise Birkedal Glenthøj, Christina Wenneberg, Birte Y. Glenthøj, Merete Nordentoft

125. Effects of Urban Uprising on Brain Structure and Neuropsychological Functioning – A Multimodal DTI and VBM Study
   Axel Krug, Bruno Dietsche, Heidelore Backes, Davide Laneri, Henriette Schneider-Haßlof, Tilo Kircher
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>126.</td>
<td>Head Movement Synchrony in Social Interactions of Patients with Schizophrenia Indicates Symptoms, Cognition and Social Functioning</td>
<td>Zeno Kupper, Fabian Ramseyer, Holger Hoffmann, Wolfgang Tschacher</td>
</tr>
<tr>
<td>128.</td>
<td>Multitasking Capacities in Persons Diagnosed with Schizophrenia: A Preliminary Examination of their Neurocognitive Underpinnings and Ability to Predict Real World Functioning</td>
<td>Julien Laloyaux, Martial Van der Linden, Marie-Noëlle Levaux, Haitham Mourad, Anthony Pirri, Hervé Bertrand, Marc-André Domken, Stéphane Adam, Frank Laroï</td>
</tr>
<tr>
<td>130.</td>
<td>Neural Mediator of Schizotypy-antisocial Behaviors Relationship: Prefrontal and Orbitofrontal Gray</td>
<td>Yin Hung Lam, Adrian Raine, Tatia M.C. Lee</td>
</tr>
<tr>
<td>131.</td>
<td>Autobiographical Memory Deficits in Patients with Chronic Schizophrenia</td>
<td>Marc M. Lüscher, Christina J. Herold, Lena Schmid, Johannes Jodrherd</td>
</tr>
<tr>
<td>134.</td>
<td>Persistence of Psychotic-like Experiences (PLEs) in the General Population of Hong Kong</td>
<td>Kit Wai Lee, Sherry Chan, WC Chang, Edwin Lee, Christy Hui, Eric Chen</td>
</tr>
<tr>
<td>135.</td>
<td>Reduction in Hospital Stay of Patients with Schizophrenia after the Long-term Psychosocial Intervention</td>
<td>Kyuyeong Lee, Heejin Oh, Minjeong Kang, Minyoung Kwon, Eunjeong Joo</td>
</tr>
<tr>
<td>138.</td>
<td>Capacities for Theory of Mind, Metacognition, and Neurocognitive Function as Independently Related to Performance on a Test of Emotional Recognition</td>
<td>Bethany L. Leonard, Paul Lysaker, Martin Brune, Kelly Buck, Jamie Ringer, Jen Vohs, Michael Francis, Jay Hamm, Giampaolo Salvatore, Giancarlo Dimaggio</td>
</tr>
<tr>
<td>139.</td>
<td>Genotypic Variation, Childhood Literacy Skills and Risk of Psychotic Experiences in Early Adolescence: Findings from the ALSPAC Study</td>
<td>Andrew J. Lewis, Mohajer Abbass Hameed, Sarah Sullivan, Stanley Zammit</td>
</tr>
<tr>
<td>140.</td>
<td>The Roles of Victimization Experiences, Paranoia and Salience Misattribution in Predicting Psychosis Proneness: The TwinsScan China Study</td>
<td>Emma K. Li, Cecilia Leung, Francesca A. Cotier, Winifred Mark, Pearl Chen, Jim van Os, Timothea Touloupoulou</td>
</tr>
<tr>
<td>141.</td>
<td>Sensitivity to Minor Stressors Mediates the Relationship between Environmental Risk Exposures and Psychometric Risk for Schizophrenia</td>
<td>Richard J. Linscott, Rebecca Grattan</td>
</tr>
<tr>
<td>142.</td>
<td>Social Cognition and Interaction Training - Tablet for Outpatients with Schizophrenia: A Preliminary Study</td>
<td>Philip Y.T. Liu, David Roberts, Heather Carr</td>
</tr>
<tr>
<td>144.</td>
<td>Integrated Genomic and Proteomic Evidence for the Postsynaptic Density in Schizophrenia</td>
<td>Lorna M. Lopez, Jane English, Melanie Focking, David Cotter</td>
</tr>
<tr>
<td>145.</td>
<td>“I Am Here Because the Voices Came Back…” Narrative Exploration of the Function of Concept Formation in Adults Hospitalized Due to Symptoms of Schizophrenia</td>
<td>Luca Lucic, Anzalee Khan, Daiute Colette</td>
</tr>
</tbody>
</table>
146. Delays to Treatment Predict Persistent Negative Symptom Domains
John Paul Lyne, Laoise Renwick, Brian O'Donoghue, Kevin Madigan, Tim Grant, Anthony Kinsella, Patricia McCarthy, Kevin Malone, Niall Turner, Eadbhard O'Callaghan, Mary Clarke

147. Deconstructing Negative Symptom Prevalence in First Episode Psychosis
John Paul Lyne, Laoise Renwick, Brian O'Donoghue, Kevin Madigan, Tim Grant, Anthony Kinsella, Patricia McCarthy, Kevin Malone, Niall Turner, Eadbhard O'Callaghan, Mary Clarke

148. Risk of Psychotic Disorder in Offspring of Parents with Schizophrenia: A Meta-analysis
Angus M. MacBeth, Andrew Gumley, Susanne Harder, Helen Beaumont

149. LINE1 Polymorphic Retrotranspositions in Schizophrenia
Fabio Macciardi, Guia Guffanti, James Fallon, Theo G.M. Van Erp, Michele Pato, Steven G. Potkin, James A. Knowles, Steven A. McCarroll, Carlos N. Pato, Simona Gaudi

150. Depersonalization in the Schizophrenia Spectrum: Lack of Sense of Agency at the Current Time of Action Due to Impaired Prediction
Takaki Maeda, Keisuke Takahata, Tsukasa Okimura, Akihiro Koreki, Sho Moriguchi, Masaru Mimura, Motoichiro Kato

151. Childhood and Adolescence Symptoms Preceding First Episode Psychosis in a General Population Based Northern Finland 1986 Birth Cohort
Pirjo H. Mäki, Tatu-Pekka Laakso, Marika Kaakinen, Graham Murray, Irma Målen, Tuula Hurtig, Matti Joukamaa, Markus Heinimaa, Sebastian Therman, Juha M. Veijola

152. Phenotypic Features of Patients with Schizophrenia Carrying De Novo Gene Mutations
Pierre J. Malherbe, J. Louis Roos, J. Louw Roos, Maria Karayiorgou, René Ehlers

153. Aberrant Affective Salience Attribution as a Risk Factor for Psychosis-proneness: Insights from the Twinscan China Study
Winifred Mark, Francesca Alice Cotier, Lu Hua Chen, Kar Yu Phoebe Kong, Shelly Leung, Cecilia N.W. Leung, Emma Li, Jim van Os, Timothea Touloupoulou

Pamela Marsh, Robyn Langdon, Anthony W. Harris

155. Factors Related to Employability of Outpatients with Schizophrenia and Schizoaffective Disorders
Larissa C. Martiní, Beatriz Petreche, Fernanda Vieira Lima, Patrícia Barbosa, Ana Olivia Silva, Gisela Moraes, Carlos Antônio Ferreira, Cecília Attux, Rodrigo Bressan

156. Decreased Cortical and Right Prefrontal Cortex Volumes Are Correlated with an Inflammatory Marker (IL-6) in Patients with Schizophrenia
Raffael Massuda, Mariana Pedrini, Bruna Panizzutti, Juliana Duarte, Sandra Polita, Leonardo Sodre, Pedro Goi, Mineia Vianna-Sulzbach, Leticia Czepielewski, Antonio L. Teixeira, Clarissa S. Gama

157. Progressive Reduction of Visual P300 Amplitude in Patients with First Episode Schizophrenia
Robert McCarley, Naoya Oribe, Yoji Hirano, Elisabetta C. del Re, Kevin Spencer, Margaret Niznikiewicz

158. A Comparison of Long-acting Injected Medications for Schizophrenia
Joseph P. McEvoy, Matt Byerly, Robert M. Hamer, Scott Stroup, Rosalie Dominik

159. “It Is Hard Work to Become Educated in One’s Vulnerability.” Patients’ Conceptualization of Treatment for First Episode Psychosis: A Qualitative Study
Marianne Melau, Charlotte Bredahl Jacobsen, Anne A. E. Thorup, Merete Nordentoft

160. A Stratified Model for Psychosis Prediction in Clinical Practice
Chantal Michel, Stephan Ruhrmann, Benno G. Schimmelmann, Joachim Klosterkötter, Frauke Schultze-Lutter

161. An Open-label Trial of Adjunctive Tocilizumab in Schizophrenia
Brian J. Miller, James Dias, Peter Buckley

162. CAARMS in the Community: Assessing the Prevalence of Ultra-high Risk Symptoms in the General Population
John G. Mills, Craig Morgan, Philip McGuire

163. Altered Connectivity in the Hippocampal Network and Heightened Coupling with the Salience Network in People at Ultra-high Risk for Psychosis
Jun Miyata, Toby Winton-Brown, Nicolas Crossley, Shitij Kapur, Philip McGuire

164. Emotion Processing in Schizophrenia is State-dependent
Simone van Montfort, Arija Maat

165. Ethnicity, Social Disadvantage and the Long-term Course and Outcome of Psychosis
Craig Morgan, Julia Lappin, Margaret Heslin, Tim Croudace, Gillian Doody, Kim Donoghue, Peter B. Jones, Robin M. Murray, Paul Fearon, Paola Dazzan

166. Can the Motor Threshold Be Predictive to Response to rTMS Treatment in Schizophrenic Patients with Auditory Hallucinations?
Céleste Nathou, Olivier Etard, Grégory Simon, Sonia Dollfus

167. Ketamine as a Model for Schizophrenia Deficits
Erica Neill, Celia J.A Morgan, Nicole Joshua, Olivia Carter, Susan L. Rossell
168. **Brain Structure in Subgroups of Persons at Ultra High-risk (UHR) Compared to First-episode Schizophrenia and Healthy Persons**
Igor Nenadic, Raka Maitra, Soumyajit Basu, Maren Dietzek, Nils Schoenfeld, Carsten Lorenz, Heinrich Sauer, Christian Gaser, Stefan Smesny

169. **Effect of Long-term Treatment with Lurasidone or Risperidone on Metabolic Syndrome Status in Patients with Schizophrenia**
John W. Newcomer, Andrei Pikalov, Kei Watabe, Josephine Cucchiaro, Krithika Rajagopalan, Antony Loebel

170. **Could Reward-disturbances Caused by Antipsychotic Medication Lead to Weight Gain?**
Mette Ødegaard Nielsen, Egill Rostrup, Henrik Norbak-Emig, Sanne Wulff, Birte Grønholdt

Lars Siersbæk Nilsson, Kristina Milting, Igor Petrov, René Sjelland, Annick Urfer Parnas

172. **Project CHANGE: It is about Life. A Randomised Clinical Trial Investigating the Effect of a Systematic Intervention for Improving the Physical Health of Patients with Schizophrenia**
Merete Nordenfelt, Helene Speyer, Ole Mors, Hans Christian Noergaard

173. **The Prognostic Significance of Early Remission of Positive Symptoms in First Episode Psychosis**
Ross M.G. Norman, Rahul Manchanda, Raj Harricharan, Sandra Northcott

174. **Gender Differences in the Course of Schizophrenia across Diverse Regions of the World**
Diego Novick, William Montgomery, Tamás Treuer, Maria Victoria Moneta, Magdy Gado, Josep Maria Haro

175. **NPAS3: New Genetic and Biological Findings with Implications for Protein Aggregation and Schizophrenia**
Frederick Nucifora Jr., Leslie Nucifora, Nicolas Arbez, Elaine Roby, Lan Yu, Dong Wei, Lynn DeLisi, Akira Saw, Christopher Ross, Russell Margolis

176. **The Increased Number of Phospholipid Abnormalities Observed in the Erythrocyte Membrane of Schizophrenia Patients is Associated with Increased Psychopathology**
Philippe Nuss, Haifa Bergaoui, Cédric Tessier, Ariel Fragman, Antonin Lamaziere, Kim Sweers, Marc De Hert

177. **Relationship between Psychotic Symptoms and Jumping to Conclusions: Are there Differences by Gender?**
Susana Ochoa, Christian Stephan-Otto, Judith Usall, Jorge Cuevas, Elena Huerta-Ramos, Josep Maria Haro

178. **Lifetime Exposure to Severe Trauma, Stress Sensitivity and Psychosis in a UK Sample**
Adanna N. Onyejiaka, Charlotte Gayer-Anderson, Stephanie Beards, Kathryn Hubbard, Inez Myin-Germeys, Robin M. Murray, Carmine Pariente, Paolo Dazzan, Til Wykes, Craig Morgan, Ulrich Reininghaus

179. **Atypical Antipsychotics Normalize Gamma Evoked Oscillations in Patients with Schizophrenia**
Felipe Ortuño, Patricio Molero, Manuel Alegre

180. **The Course of Cognitive Functioning in Clinical High Risk and First-episode Psychosis Individuals**
Marta Pardó, Montserrat Dolz, Anna Sintes, Olga Puig, Clara Espelt, Marta Pardó, Daniel Muñoz, Xavier Alvarez, Elena de la Serna, Luis San, Immaculada Baizas

181. **Clinical Predictors of the Diagnostic Stability of Brief Psychotic Disorder**
Sooyeon Park, Saejeong Lee, Sung Sun Lee, Yeon Ho Joo

182. **Vagal Nerve Stimulation as a Novel Therapy for the Treatment of Schizophrenia**
Stephanie M. Perez, Flavia Carreno, Alan Frazer, Daniel Lodge

Maxine X. Patel, Delia Bishara, Simone Jayakumar, Krysia Zalewska, David Shiers, Mike Crawford, Stephen Cooper

184. **REFLEX: Results of a Metacognitive Group Treatment to Improve Insight in Psychosis**
Gerdina Pijnenborg, Annerieke De Vos, Liset Van der Meer, Esther Sportel, Claudio Bockting, Mark van der Gaag, Andre Aleman

185. **Efficacy of Lurasidone in the Treatment of Schizophrenia with Prominent Negative Symptoms: A Post-hoc Analysis of Short-term Trials**
Andrei Pikalov, Jonathan Meyer, Yongcai Mao, Josephine Cucchiaro, Antony Loebel

186. **Comparing Changes in Functional Activation and Neural Connectivity from Cognitive Remediation in Schizophrenia**
Ian S. Ramsay, Angus MacDonald, Matthew Marggraf, Tasha Nienow
189. Deviant Neural Oscillations and Lagged Phase Synchronicity in Patients with an At-risk Mental State for Psychosis
Avinash Ramyead, Michael Kometer, Erich Studerus, Martina Papmeyer, Sarah Ittig, Ute Gschwandtner, Peter Fuhr, Anita Riecher-Rössler

190. Effective Connectivity in Schizophrenia – Dynamic Causal Modelling of the Mismatch Negativity
Siri M. Ranlund, Alvaro Diez, Rick A. Adams, Harriet Brown, Muriel Walshe, Robin M. Murray, Karl Friston, Dimitris Pinotsis, Elvira Bramon

191. Sources of Clinical Distress in Young People at Ultra High Risk of Psychosis
Marta Rapado-Castro, Ana Calvo, Patrick McGorry, Alison Yung, Barnaby Nelson

192. Functional Neuroanatomy of the ‘Jumping to Conclusions’-task in Patients with Schizophrenia, Anorexia, Depression and in Healthy Subjects
Alexander M. Rapp, Larissa Wolkenstein, Katrin E. Giel, Andreas Wittorf, Michael Erb, Karin Langohr, Phöbe Schmierer, Dorothee E. Mutschler, Martin Hautzinger, Stephan Zipfel, Stefan Klingberg

193. Sex-differences in the Relationship between Cannabis Use and Risk of Admission in Young Subjects with an Early Psychosis: A 1-year Follow-up Study
Oscar Reatiga, Rosa Monseny, Laura Ortega, Rosa Gubernet, Itziar Montalvo, Marta Creus, Javier Labad

194. Improving Functional Outcomes for Schizophrenia Patients in the Netherlands using Cognitive Adaptation Training as a Nursing Intervention – A Pilot Study
Jeroen Redmeijer, Piotr Quee, Annemarie Stiekema, Johanna Wigman, Harald Schneider, Lisette van der Meer, Natalie Maples, Durk Wiersma, Dawn Velligan, Richard Bruggeman

195. Psychological Mechanisms Underlying the Association between Childhood Adversity and Psychosis: An Experience Sampling Study
Ulrich Reininghaus, Matthew Kempton, Tom Craig, Lucia Valmaggia, Adanna N. Onyejiaka, Charlotte Geyer-Anderson, Jim van Os, Til Wykes, Robin Murray, Inez Myin-Germeys, Craig Morgan

196. Impact of Psychiatric Comorbidity in Individuals at Ultra High Risk (UHR) of Psychosis
Gurpreet Rekhi, Jimmy Lee, Jeanette Lim, Max Lam, Attilio Rapisarda

197. Antipsychotics and Antidepressants and their Associations with Suicidal Ideation – The Northern Finland Birth Cohort 1966
Ina Rissanen, Erika Jäskeläinen, Matti Isohanni, Hannu Koponen, Matti Joukamaa, Antti Alaräisäinen, Jouko Miettunen

198. The Factor Structure and Associated Clinical Variables of Formal Thought Disorder in First Episode Psychosis
Eric Roche, John Lyne, Laoise Renwick, Lisa Creed, Anthony Kinsella, Mary Clarke

199. Working Memory and Visual Memory Deficit in Children Offspring of Schizophrenia Patients
Elisa Rodríguez-Toscano, Teresa Sánchez-Gutiérrez, Ángel Del rey-Mejías, Laura Roldán, David Fraguas, Mara Parellada, Celso Arango, Dolores Moreno

200. Subgroup Analysis in a Randomized Clinical Trial of Long-acting Injectable Risperidone and Oral Antipsychotics in Unstable Chronic Schizophrenia
Robert Rosenheck, Sarah Leatherman, John Krystal, Matthew Liang

201. Behavioural and fMRI Evidence of Semantic Categorisation Deficits in Schizophrenia
Susan Rossell, Matthew Hughes

202. Social Cognition in Neurocognitive Subtypes of Psychotic Disorders
Jessica E. Rowland, Nicole O’Reilly, Leah Girshkin, Philip B. Mitchell, Vaughan J. Carr, Melissa J. Green

203. Using Personalised Computer Modelling to Classify People with Treatment-resistant or Ultra-treatment-resistant Schizophrenia Based on Cognitive Measures
Bruce Russell, Reggio Hartono, Meghan Mcllwain, Valerie Anderson, Nikola Kasabov, Rob Kydd, Carolyn McNabb

204. Studying Relationship between Schizophrenia and PAI-1 4G/5G Polymorphism in Iranian Patients
Vida Sadeghifard, Seyed Mehdi Sadat, Ahmad Ebrahimi, Mohammad Reza Aghasadeghi, Abas Gharagouzloo, Elham Sadeghi, Fozieh Javadi

205. Trajectories of Neurocognitive Functioning According to Cannabis Use Pattern in Children and Adolescents with First Episode Psychosis: A 2-year Follow-up Study
Teresa Sánchez-Gutiérrez, Celso Arango, Ana Calvo, Jessica Merchán-Naranjo, Dolores Moreno, Mara Parellada, Laura Roldán, Elisa Rodríguez, Marta Rapado-Castro

206. Possible Association between ITIH3 Gene Polymorphism and Schizophrenia in a Japanese Population
Daimei Sasayama, Hiroaki Hori, Toshiya Teraishi, Masahiko Tatsumi, Kotaro Hattori, Miho Ota, Teruhiko Higuchi, Hiroshi Kunugi

207. A Novel Digital Health Approach to Treating Negative Symptoms Using a Personalized Real-time Intervention for Motivational Enhancement (PRIME)
Danielle Schlosser, Silvia Vergani, Daniel Kim, Tim Campbellone, Charlie Ward, Sophia Vinogradov
142 143

Tuesday Posters

4th Schizophrenia International Research Society Conference
Fostering Collaboration in Schizophrenia Research

208. PROACTIVE: Exploring Longitudinal Symptom Course to Understand Outcomes in LAI-oral Comparisons
Nina Schooler, Peter Buckley, Jim Mintz

209. Flexibly Dosed Paliperidone Palmitate in Non-acute but Symptomatic Patients with Schizophrenia Previously Unsuccessfully Treated with Long-acting Injectable Risperidone
Andreas Schreiner, Paul Bergmans, Pierre-Michel Llorca, Giulio Corrivetti, Behcet Cosar, Pierre Cherubin, Ludger Hargarter

210. Paliperidone Palmitate in Acute Patients with Schizophrenia – Treatment Response, Safety and Tolerability: A Prospective Flexible Dose Study in Patients Previously Unsuccessfully Treated with Oral Antipsychotics
Andreas Schreiner, Paul Bergmans, Pierre Cherubin, Elmars Rancans, Yasin Bez, Eduardo Parellada, Bernardo Carpinelli, Pierre Vidalilhet, Ludger Hargarter

211. Glutamatergic Dysfunction Associated with Focal Brain Cortical Thickness in Antipsychotic – Naive Patients with Schizophrenia

212. Mental Health Literacy on Psychosis and Depression: Do Labeling and Causal Attribution Affect Treatment Recommendations?
Frauke Schultze-Lutter, Chantal Michel, Benno G. Schimmelmann

213. The Course of At-risk Symptoms for Psychosis in the General Population: 2-year Follow-up of the Bern Epidemiological At-risk (BEAR) Study
Frauke Schultze-Lutter, Chantal Michel, Caroline Linder, Benno G. Schimmelmann

Kyra-Verena Sendt, Derek Kenneth Tracy, Sagnik Bhattacharyya


216. Association of Vitamin-D with Hippocampal Gray Matter Volume in Antipsychotic - Naive Schizophrenia Patients
Venkataram Shivakumar, Sunil V. Kalmady, Amaresh C. Anekal, Janardhanan C. Narayanaswamy, Dania Jose, Boban Joseph, Ganesan Venkatasubramanian, Vasanthapuram Ravi, Bangalore N. Gangadhar

217. Preliminary Sample Description of First Episode Psychosis in a Brazilian Large Catchment Area
Rosana Shuhama, Silvia Tenan, Juliana Souza, Mariestela S. Schauffeberger, Paulo Louzada-Junior, Antonio Santos, Craig Morgan, Jim van Os, Paulo Menezes, Cristina Del-Ben

218. The Third National Survey about Prescription Patterns of Psychotropic Drug for Three Mental Disorders in China
Tianmei Si, Nan Li

219. Pitfall of Using Absolute Risk Score for Risk Assessment and Prevention
Cynthia Siu, Carla Brambilla

220. Transition and Psychosis Related Hemodynamic Correlates of Motivational Salience Processing
Renata Smieskova, Jonathan Roiser, Christopher Chaddock, André Schmidt, Andor Simon, Anna Walter, Paolo Fusar-Poli, Undine Lang, Anita Riecher-Rössler, Stefan Borgwardt

221. Mechanism of Action of ITI-007: A Novel Therapy for the Treatment of Schizophrenia and Related Psychoses
Gretchen L. Snyder, Kimberly Vanover, Joseph Hendick, Wei Yao, Peng Li, Robert E. Davis, Lawrence P. Wennogle, Sharon Mates

222. Abnormal Hyperactive Self-awareness Processing in Schizophrenia
Injung Sohn, Jung Suk Lee, Sang Woo Cho, Jae Jin Kim

223. Axis I and Axis II Disorders in Young People at Ultra-high Risk of Developing a Psychotic Disorder: A Long-term Follow-up Study
Anneliese E. Sperli-Staines, Alison R. Yung, Paul G. Amminger, Stephen J. Wood, Ashleigh Lin, Emily Li, Barnaby Nelson

224. Tackling Stigma: Developing Neighbourhood Interventions by Means of Focus Groups
Esther Sportel, Gerdina Pijnenborg, Johan Arends

225. Failure to Find Additive Interaction between Social Adversity in Childhood and Family Risk of Psychosis
Simona A. Stilo, Matteo Bonomo, Francesca Bianconi, Conrad Iyegbe, Charlotte Gaye-Anderson, Kathryn Hubbard, Stephanie Beards, Helen Fisher, Marta Di Forti, Robin M. Murray, Craig Morgan

226. Social Anxiety Disorder in Recent-onset Schizophrenia Spectrum Disorders: The Relation with Symptomology, Anxiety, and Social Rank
Stephanie A. Sutliff, Marc-André Roy, Amélie Achim

227. Transdiagnostic Exploration of the Association of Toxoplasma Gondii with Psychiatric Disorders: A Systematic Review and Meta-analysis
Arjen Sutterland, Guillaume Fond, Anne Kuin, René Lutter, Tom van Gool, Andrei Szoke, Marion Leboyer, Lieuwe de Haan
228. Reduced Anterior Cingulate Gray Matter Volume and Thickness in Subjects with Deficit Schizophrenia
Michio Suzuki, Mizuho Takayanagi, Jacqueline Wentz, Yoichiro Takayanagi, David Schretlen, Elvan Ceyhan, Akira Sawa, Patrick Bartha, Tilak Ratnavather, Nicola Cascella

229. Sexual Side Effects in Patients Using Long-acting Depot Antipsychotics
Marte Swart, Marrit de Boer, Durk Wiersma, Robert Schoevers, Henderikus Knegtering

230. Effects on Cognition of Clozapine in Treatment-naïve First-episode Schizophrenia (FES): Preliminary Results
Diana Taboada Denia, Javier Sanz-Fuentenebro, Tomás Palomo Álvarez, Vicente Molina Rodríguez

231. Anti-psychotic Treatment Decreased iPLA2 Activity in First Episode Drug Naive Patients
Leda L. Talib, Helena P.G. Joaquim, Mauricio Serpa, Geraldo Busatto, Martinus van de Bilt, Marcus Zanetti, Wagner Gattaz

232. Assessing Theories of Semantic Memory Function in Schizophrenia Thought Disorder at Two Levels
Eric Tan, Susan Rossell

233. A Double-blind, Placebo-Controlled, Randomized Withdrawal Study of Lurasidone for the Maintenance of Efficacy in Patients with Schizophrenia
Rajiv Tandon, Antony Loebel, Debra Phillips, Andrei Pikalov, David Hernandez, Yongcai Mao, Josephine Cichiaro

234. Sleep Disruption in Children and Adolescents At-risk for Psychosis: A Preliminary Study
Leila Tarokh, Chantal Michel, Benno G. Schimmelmann, Frauke Schultze-Lutter

235. Deficient Cortical Activity during Motor Inhibition in Schizophrenia
Maxime Térémetz, Caroline Malherbe, Marie-Odile Krebs, Catherine Oppenheim, Pavel Lindberg, Isabelle Amado

236. Environmental Influences on Symptomatology of a First Episode Psychosis
Manuel Tettamanti, Paolo Ghisletta, Adriano Zanello, Panteleimon Giannakopoulos, Marco C.G. Merlo, Logos Curtis

237. Using Structural Neuroimaging to Make Quantitative Predictions of Symptom Progression in Individuals at Ultra-high Risk for Psychosis
Stefania Tognin, William Petterson-Yeo, Isabel Valli, Chloe Hutton, James Woolley, Paul Allen, Philip McGuire, Andrea Mechelli

238. Relation Between Psychotic-like Experiences and Major Depression in the Community Based Sample
Ahmet Topuzoğlu, Tolga Binbay, Hayriye Elbi, Nesli Zاغ، Huseyin Onay, Feriştah Ferda Özkınay, Jim Van Os, Köksal Alptekin

239. Dimensional Exploration of Personality Disorders in Schizophrenic Patients and their First-degree Relatives Using the Shedler-Westen Assessment Procedure
Maria Chiara Torti, Antonino Buzzanca, Fabio Di Fabio, Marianna Frascarelli, Alessia Mirigiani, Chiara Squarcione, Massimo Biondi

240. Can Childhood Adversity Predict Onset and Clinical Outcomes of Psychotic Disorders?
Antonella Trotta, Jennifer O’Connor, Anna Kolliakou, Marta Di Forti, Paola Dazzan, Carmine Pariante, Anthony S. David, Robin M. Murray, Helen Fisher

241. Dose and Dosing Frequency of Long-acting Injectable Antipsychotics: A Systematic Review of PET and SPECT Data and Clinical Implications
Hiroyuki Uchida, Takefumi Suzuki

242. Exceptional Experiences in Healthy People - Early Warning Signals of Psychosis?
Lui Unterrassner, Thomas A. Wyss, Peter Krummenacher, Diana Wotruba, Peter Brugger, Helene Haker Rössler, Gerd Folkers, Wulf Rösler

243. [11C]GMOM as New Potential PET Radiotracer to Image the NMDA Receptor in Vivo
Thalia F. van der Doef, Sandeep (SVS) Golla, Pieter (PJ) Klein, Robert (RC) Schuit, Bert (AD) Windhorst, Adriaan (AA) Lammertsma, Bart (BNM) van Berckel, Ronald (R) Boellaard

244. Testing the Estrogen Hypothesis of Schizophrenia: Associations between Cumulative Estrogen Exposure and Cerebral Structural Measures
Christine van der Leeuw, Petra Habets, Ed Gronenschild, Patrick A.E. Domen, Stijn Michielse, Martinus van Kroonenburgh, Jim van Os, Machteld Marcelis

245. Cognitive Functioning Associated with Stimulant Use in Patients with Non-affective Psychosis, their Unaffected Siblings and Healthy Controls
Floor J. van der Meer, Julia Meijer, Carin Meijer, Wim van den Brink, Eva Velthorst

246. Plasma Oxytocin and Testosterone Levels in Patients with Psychotic Disorder, their Unaffected Siblings and Healthy Controls: Results from the EU-GEI Project
Elishe van der Ven, Daniella S. van Dam, Floor J. van der Meer, Elles Messchaert, Eva Velthorst, Lieuwe de Haan, Jean-Paul Selten

247. Subtle Movement Disorders in Individuals at Risk of Schizophrenia
Peter van Harten, Thierry Q. Mentzel, Ritsaert Lieverse, Jeroen P. Koning, P. Roberto Bakker, Diederik E. Tenback

Anja Vaskinn, Ole A. Andreassen, Ingrid Melle, Kjetil Sundet
249. Psychosis Liability, Paranoia and Distress in Experimental Virtual Reality Social Environments
   Wim Veling, Roos Pot-Kolder, Jacqueline Counotte, Mark van der Gaag

250. Theory of Mind in First Episode Schizophrenia: Clinical and Neurocognitive Correlates, State vs Trait, Relationship to Daily Functioning
   Joseph Ventura, Kenneth L. Subotnik, Arielle Ered, Denise Gretchen-Doody, Gerhard S. Hellemann, Keith H. Nuechterlein

251. Interaction between GSK-3β rs12630592 and HTR2A rs6314 Polymorphisms on Cerebral Activity and Behavior during Attention
   Rosa Vitale, Paolo Taurisano, Linda A. Antonucci, Barbara Gelao, Rita Masellis, Raffaella Romano, Apostolos Papazacharias, Annabella Di Giorgio, Grazia Caforio, Giuseppe Blasi, Alessandro Bertolino

252. Is Aerobic Exercise Effective in Improving Negative Symptoms in Patients with Schizophrenia? The Results of a Meta-analysis
   Sjoerd J. Vogel, Mark van der Gaag, Henderikus Kneegtering, Stynke Castelein

253. Differential Diagnosis of Schizophrenia vs. Borderline Personality Disorder Using Pattern Classification Methods in Structural MRI Images
   Sebastian von Saldern, Eva Meisenzahl-Lechner, Lana Kambeitz-Ilankovic, Carlos Cabral, Nikolaos Koutsouleris

254. Dynamic Causal Modeling of fMRI Data Reveals Disordered Frontal-hippocampal-striatal Interactions during Associative Learning in Schizophrenia Patients
   Sunali Wadehra, Patrick Pruitt, Eric Murphy, Vaibhav Diwadkar

255. Tissue-specific DNA Methylation across Blood and Brain and its Application to Schizophrenia
   Esther Walton, Johanna Hass, Jingyu Liu, Matthias Kirsch, Gabriele Schackert, Veit Roessner, Randy L. Gollub, Vince Calhoun, Stefan Ehrlich

256. Age of Onset and Prevalence of Substance Use in Help-seeking Ultra-high Risk Youth are Linked to Current Psychopathology
   Philip B. Ward, Shanna Logan, Alana Scully, Danielle Mathersul, Celia Loneragan, Jackie Curtis, Helen Stain, Patricia Michie, Juanita Todd, Ulrich Schall, Robyn Landon, Rebekah Atkinson

257. Perceptions of Participating in a Lifestyle Intervention From the Perspective of Patients with Psychosis
   Rikard E. Wärdig, Margareta Bachrach-Lindström, Sally Hultsjö, Torbjörn Lindström, Anniqa Foldemo

258. Metabolic Syndrome in People with Psychosis: Is Cannabis Protective?
   Anna Waterreus, Patsy Di Prinzio, Cherrie Galletly, David J. Castle, Gerald Watts, Vera A. Morgan

259. High False Positive Rate of a Putative Biomarker Test to Aid in the Diagnosis of Schizophrenia
   Cheryl Wehley, Sheldon H. Preskorn

260. Object Pattern Separation Performance in Schizophrenics Is Consistent with Disrupted Hippocampal Dentate Gyrus Activity and Compromised Neurogenesis
   Keith Wesnes, Lawrence Brownstein, Howard Hassman

261. Schizophrenia: Bilirubin Levels Correlate with Positive Symptoms
   Christian G. Widschwendter, Maria Rettenbacher, Georg Kemmler, Monika Edlinger, Susanne Baumgartner, W. Wolfgang Fleischhacker, Alex Hofer

262. The Effects of Dopaminergic Manipulation in Healthy Controls Compared to Patients with Schizophrenia during Social Decision-making
   Rebekah Wigton, Thomas White, Sukhi Shergill

263. OTX2 Expression in Human Prefrontal Cortex Development and in Subjects with Schizophrenia
   Tsung-Ung W. Woo, Katina M. Athanas, Sarah A. Mauney

264. Increased Pattern Detection in Meaningless Noise of Healthy People with Exceptional Experiences
   Thomas A. Wyss, Lui Unterrassner, Peter Krummenacher, Diana Wotruna, Peter Brugger, Helene Haker, Gerd Folkers, Wulf Rössler

265. A Treatable Cause of Catatonia: Anti-NMDA Receptor Encephalitis in a Young Woman
   Woon Yoon, Saejeong Lee, Jungsun Lee, Yeonho Joo, Changyoon Kim

266. Tardive Dyskinesia in Relation to Estimated Dopamine D2 Receptor Occupancy in Patients with Schizophrenia: Analysis of the CATIE data
   Kazumari Yoshida, Robert Bies, Takefumi Suzuki, Gary Remington, Bruce Pollock, Yuya Mizuno, Masaru Mimura, Hiroyuki Uchida

267. Prefrontal Cortex Thickness in PTSD and Schizophrenia and the Role of Childhood Trauma
   Andre Zugman, Elson Asevedo, Rodrigo Mansur, Graccielle Asevedo, Ary Ararpe, Lara Faria, Vitor Tardelli, Rodrigo Bressan, Andrea Jackowski, Elisa Brietzke
<table>
<thead>
<tr>
<th>Name</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aas M. 51</td>
<td></td>
</tr>
<tr>
<td>Abayomi O. 4, 122</td>
<td></td>
</tr>
<tr>
<td>Abhishekh H. 113</td>
<td></td>
</tr>
<tr>
<td>Abi-Dargham A. 16, 44, 66</td>
<td></td>
</tr>
<tr>
<td>Aboraya A. 106</td>
<td></td>
</tr>
<tr>
<td>Abu-Akel A. 122</td>
<td></td>
</tr>
<tr>
<td>Achim A. 122</td>
<td></td>
</tr>
<tr>
<td>Adams C. 131</td>
<td></td>
</tr>
<tr>
<td>Adams R.A. 104</td>
<td></td>
</tr>
<tr>
<td>Adcock R.A. 46</td>
<td></td>
</tr>
<tr>
<td>Agid O. 45, 90, 116, 122</td>
<td></td>
</tr>
<tr>
<td>Ahmadi M. 122</td>
<td></td>
</tr>
<tr>
<td>Akbarian S. 42</td>
<td></td>
</tr>
<tr>
<td>Akil H. 13, 26</td>
<td></td>
</tr>
<tr>
<td>Alameda L. 90</td>
<td></td>
</tr>
<tr>
<td>Alberati D. 56</td>
<td></td>
</tr>
<tr>
<td>Aleman A. 5, 84</td>
<td></td>
</tr>
<tr>
<td>Alonso-Solis A. 98</td>
<td></td>
</tr>
<tr>
<td>Alptekin K. 122</td>
<td></td>
</tr>
<tr>
<td>Alveraz X. 109</td>
<td></td>
</tr>
<tr>
<td>Amato D. 4, 60, 71</td>
<td></td>
</tr>
<tr>
<td>Amminger P. 67</td>
<td></td>
</tr>
<tr>
<td>Anand E. 122</td>
<td></td>
</tr>
<tr>
<td>Anderson K. 52</td>
<td></td>
</tr>
<tr>
<td>Anhoj S. J. 98</td>
<td></td>
</tr>
<tr>
<td>Anil Yagcioglu A. 96</td>
<td></td>
</tr>
<tr>
<td>Annerbrink K. 122</td>
<td></td>
</tr>
<tr>
<td>Anticevic A. 54, 69</td>
<td></td>
</tr>
<tr>
<td>Antonucci L.A. 98</td>
<td></td>
</tr>
<tr>
<td>Appelbaum P. 35</td>
<td></td>
</tr>
<tr>
<td>Applegate E. 122</td>
<td></td>
</tr>
<tr>
<td>Arango C. 3, 5, 31, 37</td>
<td></td>
</tr>
<tr>
<td>Armando M. 102, 70</td>
<td></td>
</tr>
<tr>
<td>Ash D. 120, 123</td>
<td></td>
</tr>
<tr>
<td>Atkins J. 82</td>
<td></td>
</tr>
<tr>
<td>Aydinli E. 113</td>
<td></td>
</tr>
<tr>
<td>Ayer A. 103</td>
<td></td>
</tr>
<tr>
<td>Bacon E. 104</td>
<td></td>
</tr>
<tr>
<td>Bae M. 123</td>
<td></td>
</tr>
<tr>
<td>Baeza I. 109</td>
<td></td>
</tr>
<tr>
<td>Bagalkot T. 87</td>
<td></td>
</tr>
<tr>
<td>Bahn S. 36</td>
<td></td>
</tr>
<tr>
<td>Bai Y.M. 91</td>
<td></td>
</tr>
<tr>
<td>Bailey C. 4</td>
<td></td>
</tr>
<tr>
<td>Bainbridge E. 89</td>
<td></td>
</tr>
<tr>
<td>Bais L. 73</td>
<td></td>
</tr>
<tr>
<td>Bak M. 117</td>
<td></td>
</tr>
<tr>
<td>Baker R.A. 123</td>
<td></td>
</tr>
<tr>
<td>Bakker P. R. 70, 106</td>
<td></td>
</tr>
<tr>
<td>Bales K. 14, 39</td>
<td></td>
</tr>
<tr>
<td>Balu D.T. 96</td>
<td></td>
</tr>
<tr>
<td>Barak Y. 117</td>
<td></td>
</tr>
<tr>
<td>Barch D.M. 14, 30, 35, 46</td>
<td></td>
</tr>
<tr>
<td>Barkl S. 123</td>
<td></td>
</tr>
<tr>
<td>Barnes S.A. 123</td>
<td></td>
</tr>
<tr>
<td>Barrantes-Vidal N. 70, 116, 123</td>
<td></td>
</tr>
<tr>
<td>Bartels-Velthuis A. 91</td>
<td></td>
</tr>
<tr>
<td>Bartokzis G. 97</td>
<td></td>
</tr>
<tr>
<td>Barilay R. 72</td>
<td></td>
</tr>
<tr>
<td>Bastett A. 62</td>
<td></td>
</tr>
<tr>
<td>Bearden C. 62</td>
<td></td>
</tr>
<tr>
<td>Beards S. 106</td>
<td></td>
</tr>
<tr>
<td>Beck K. 123</td>
<td></td>
</tr>
<tr>
<td>Behan C.L. 120, 123</td>
<td></td>
</tr>
<tr>
<td>Ben-Mabrouk F. 80</td>
<td></td>
</tr>
<tr>
<td>Bendlall S. 89</td>
<td></td>
</tr>
<tr>
<td>Beninger R. 123</td>
<td></td>
</tr>
<tr>
<td>Benros M. 123</td>
<td></td>
</tr>
<tr>
<td>Berg A. 70</td>
<td></td>
</tr>
<tr>
<td>Bergen S. 57</td>
<td></td>
</tr>
<tr>
<td>Bernardini F. 124</td>
<td></td>
</tr>
<tr>
<td>Bessero S. 124</td>
<td></td>
</tr>
<tr>
<td>Bestheur B. 74</td>
<td></td>
</tr>
<tr>
<td>Biagianti B. 73</td>
<td></td>
</tr>
<tr>
<td>Biedermann F. 124</td>
<td></td>
</tr>
<tr>
<td>Binbay T. 124</td>
<td></td>
</tr>
<tr>
<td>Birchwood M. 52, 62</td>
<td></td>
</tr>
<tr>
<td>Birnbaum M. 52</td>
<td></td>
</tr>
<tr>
<td>Bischof M. 111</td>
<td></td>
</tr>
<tr>
<td>Bisoglio J. 87</td>
<td></td>
</tr>
<tr>
<td>Bitanbirwe B.K.Y. 4, 124</td>
<td></td>
</tr>
<tr>
<td>Blomstrom A. 41</td>
<td></td>
</tr>
<tr>
<td>Blumberger D. 61</td>
<td></td>
</tr>
<tr>
<td>Bohlenk M. 100</td>
<td></td>
</tr>
<tr>
<td>Bois C.L. 124</td>
<td></td>
</tr>
<tr>
<td>Boks M. 32</td>
<td></td>
</tr>
<tr>
<td>Bonomo M. 121</td>
<td></td>
</tr>
<tr>
<td>Bonvino A. 98</td>
<td></td>
</tr>
<tr>
<td>Boonstra N. 85</td>
<td></td>
</tr>
<tr>
<td>Bosch S. 84</td>
<td></td>
</tr>
<tr>
<td>Bossong M.G. 124</td>
<td></td>
</tr>
<tr>
<td>Bourgin J. 124</td>
<td></td>
</tr>
<tr>
<td>Brain C. 124</td>
<td></td>
</tr>
<tr>
<td>Bralet M.C. 104, 124</td>
<td></td>
</tr>
<tr>
<td>Brennand K. 51</td>
<td></td>
</tr>
<tr>
<td>Bressan R. 121</td>
<td></td>
</tr>
<tr>
<td>Brindley E. 124</td>
<td></td>
</tr>
<tr>
<td>Brinka M. 115</td>
<td></td>
</tr>
<tr>
<td>Broussard B. 125</td>
<td></td>
</tr>
<tr>
<td>Brown A. 41, 125</td>
<td></td>
</tr>
<tr>
<td>Brown D. 91</td>
<td></td>
</tr>
<tr>
<td>Bruins J. 125</td>
<td></td>
</tr>
<tr>
<td>Brunelin J. 61</td>
<td></td>
</tr>
<tr>
<td>Bryant E. 78</td>
<td></td>
</tr>
<tr>
<td>Buchanan R. 31, 68</td>
<td></td>
</tr>
<tr>
<td>Buckley P. 12, 26, 67</td>
<td></td>
</tr>
<tr>
<td>Bugarski-Kirola D. 34</td>
<td></td>
</tr>
<tr>
<td>Bugge A. 121</td>
<td></td>
</tr>
<tr>
<td>Bull H. 119</td>
<td></td>
</tr>
<tr>
<td>Bullmore E. 14, 30, 36</td>
<td></td>
</tr>
<tr>
<td>Burdick K. 32</td>
<td></td>
</tr>
<tr>
<td>Burghart K.J. 125</td>
<td></td>
</tr>
<tr>
<td>Burshtein S. 77</td>
<td></td>
</tr>
<tr>
<td>Byrne L.K. 119, 125</td>
<td></td>
</tr>
<tr>
<td>Cadenhead K. 125</td>
<td></td>
</tr>
<tr>
<td>Cahn W. 78</td>
<td></td>
</tr>
<tr>
<td>Cairns M.J. 112</td>
<td></td>
</tr>
<tr>
<td>Calem M. 70</td>
<td></td>
</tr>
<tr>
<td>Calhoun V. 35</td>
<td></td>
</tr>
<tr>
<td>Callaghan R. 16, 66</td>
<td></td>
</tr>
<tr>
<td>Campos R.C. 108</td>
<td></td>
</tr>
<tr>
<td>Can G. 125</td>
<td></td>
</tr>
<tr>
<td>Cannon M. 4, 12, 16, 65</td>
<td></td>
</tr>
<tr>
<td>Cannon T. 36</td>
<td></td>
</tr>
<tr>
<td>Cantillon M. 34</td>
<td></td>
</tr>
<tr>
<td>Carpenter W.T. 4, 12, 35, 40, 69</td>
<td></td>
</tr>
<tr>
<td>Carr V. 106</td>
<td></td>
</tr>
<tr>
<td>Cassetta B.D. 125</td>
<td></td>
</tr>
<tr>
<td>Cassidy C.M. 82</td>
<td></td>
</tr>
<tr>
<td>Castelein S. 95</td>
<td></td>
</tr>
<tr>
<td>Castle D. 4, 40</td>
<td></td>
</tr>
<tr>
<td>Castro M. 98</td>
<td></td>
</tr>
<tr>
<td>Cella M. 88, 125</td>
<td></td>
</tr>
<tr>
<td>Champagne-Lavau M. 87, 104</td>
<td></td>
</tr>
<tr>
<td>Chan R.C.K. 78</td>
<td></td>
</tr>
<tr>
<td>Chan K.K.S. 78, 120, 126</td>
<td></td>
</tr>
<tr>
<td>Chan T.C.W. 104</td>
<td></td>
</tr>
<tr>
<td>Chang C.W. 95, 116, 126</td>
<td></td>
</tr>
<tr>
<td>Charles S. 87</td>
<td></td>
</tr>
<tr>
<td>Chaumette B. 91</td>
<td></td>
</tr>
<tr>
<td>Chee K. Y. 115</td>
<td></td>
</tr>
<tr>
<td>Chen E.Y.H. 41</td>
<td></td>
</tr>
<tr>
<td>Chen L.H. 113</td>
<td></td>
</tr>
<tr>
<td>Chen S.M. 96</td>
<td></td>
</tr>
<tr>
<td>Chiliza B. 126</td>
<td></td>
</tr>
<tr>
<td>Chisholm K.E. 106</td>
<td></td>
</tr>
<tr>
<td>Cho Y. 108</td>
<td></td>
</tr>
<tr>
<td>Choi B. 126</td>
<td></td>
</tr>
<tr>
<td>Choi J. 94</td>
<td></td>
</tr>
<tr>
<td>Chou PH. 126</td>
<td></td>
</tr>
<tr>
<td>Chowdhury N. 108, 126</td>
<td></td>
</tr>
<tr>
<td>Christiani C.A.J. 84</td>
<td></td>
</tr>
<tr>
<td>Christoffersen C.T. 89</td>
<td></td>
</tr>
<tr>
<td>Ciolfolini S. 100</td>
<td></td>
</tr>
<tr>
<td>Cuingu R. 115</td>
<td></td>
</tr>
<tr>
<td>Clamor A. 89</td>
<td></td>
</tr>
<tr>
<td>Clarke M.C. 106</td>
<td></td>
</tr>
<tr>
<td>Clementi N. 90</td>
<td></td>
</tr>
<tr>
<td>Clemmensen L. 126</td>
<td></td>
</tr>
<tr>
<td>Colibazzi T. 44</td>
<td></td>
</tr>
<tr>
<td>Colizzi M. 114</td>
<td></td>
</tr>
<tr>
<td>Compton M.T. 52, 90</td>
<td></td>
</tr>
<tr>
<td>Conley R. 35</td>
<td></td>
</tr>
<tr>
<td>Contreras G.N. 126</td>
<td></td>
</tr>
<tr>
<td>Cordova-Palomera A. 75, 108, 126</td>
<td></td>
</tr>
<tr>
<td>Correll C. 16, 37, 66</td>
<td></td>
</tr>
</tbody>
</table>

* “The Index of Authors and Presenters includes only First Authors of Posters, Speakers of Plenary Sessions, Symposia, and Workshops.”
Corvin A. 57, 61
Cotier F. 84
Cotter D. 51
Coughlan H. 103
Craig T. 62
Cristóbal-Narváez P. 127
Crivelaro M. 127
Csiipke E. 127
Cucchiaro J. 127
Cullen A. 4, 84
Ćurčić-Blake B. 98
Curtis J. 114
Curtis L. 78
Czepielewski L. 104
D’Souza D.C. 44, 54, 95, 127
Daeva N.A. 127
Dalman C. 4, 41
Daniel D.G. 77, 111
Das M. 127
David A. 5, 12, 35
Davidson M. 5, 53
Davis R.E. 77
Dawson N. 96
Dazzan P. 4, 5, 51
de Castro-Català M. 82, 127
De Girolamo G. 43, 107, 127
de la Fuente-Sandoval C. 44
De la Serna E. 109
de Leeuw M. 58
de Nijs J. 78, 97
de Vos A. 73
Debost J.C. 108
Değirmencioglu B. 78
del Re E.C. 127
Del Rey-Mejias A. 94
DeLisi L. 2, 3, 12, 14, 26, 29
de Luca V. 81
Demers M.F. 88, 114
Demjaha A. 58
Deserno L. 99
Deslauriers J. 127
Devrim-Uçok M. 106
Di Forti M. 32, 44, 90
di Giacomo E. 89
di Lorenzo G. 113
Dias Barbosa A. 114
Dickerson F. 36
Dietche B. 128
Dier A. 87, 128
Dionisio B. 73
Dluhos P. 128
Dodd S. 67
Dold M. 92
Dollfus S. 100
Domen P.A.E. 55
Dorpf-Petersen K.A. 69
Drakesmith M. 55, 101
Driver D.I. 128
Drosos P. 117
Duhig A. 115
Durgam S. 117
During S.W. 81
Dutta R. 33
Duval C.Z. 128
Dvorsky D. 88
Earls L. 62
Ebreup B. 70
Edwards C. 57
Egerton A. 36
Ehrenreich H. 45
Elingrod V. 67
Emsey R. 4, 5, 45, 80, 103, 128
English J. 51
Englund A. 44
Eramo A. 92
Ergul C. 111, 128
Ermakova A.O. 128
Esen-Danaci A. 128
Etain B. 51
Evensen S. 109
Fachim H.A. 71, 128
Falcone M.A. 128
Falckai P. 4, 41
Falkenberg I. 99
Falkum E. 119
Fanning F. 129
Farrelly L. 129
Fatjó-Vilas M. 82
Fazel S. 43
Fervaha G. 129
Fillman S. 72
Finnegan M.A. 107
Fleischhacker W.W. 35
Fowling M. 87
Foussias G. 78
Frajo-Apor B. 114
Frangou S. 60
Frascarelli M. 75, 109
Frissen A. 107
Fuentenebro F. 104
Fusar-Poli P. 40
Fusaroli R. 115
Fusté M. 4, 75
Gabernet Florensa R.M. 129
Gadelha A. 56
Gaebel W. 45, 60
Gage S. 32
Galbusera L. 116
Gelderis S. 26
Galletly C. 37, 79, 129
Gama C. 75
Ganguli R. 5, 88
Gao L. 115
Garay I. 94
Gardner Sood P. 115
Gardner R.M. 72
Gardner Sood R. 3
Garrido G. 113
Gas M.C. 108
Gass P. 131
Gaughran F. 16, 66
Gawęda L. 129
Gayer-Anderson C. 59
Geerts H. 79
Geier S. 129
Gerstenberg M. 129
Gevonden M. 42, 129
Geyer M.A. 46
Ghosh A.K. 87
Gilbert-Juan J. 97
Gillis J. 61
Giordano A. 72
Giordano G.M. 129
Giovanoli S. 71
Girgis R. 34
Giuffrida A. 52
Glenthøj B. 45, 69
Gogharri V. 101
Gold J. 14, 39
González-Martínez R. 97, 130
Goozee R. 92
Gottfredsen D. 59
Grace A. 3, 14, 39
Grajek G. 103
Graea E. 113
Green M. 4, 5, 9, 14, 31, 39, 46
Green M. 97
Grilli-Tissot M.C. 96
Grove T. 104
Gruber O. 99
Gulsu E. 83
Gupta M. 119
Gur R. 62
Gurillo Muñoz P. 32
Gurvich C. 83
Hager O. 130
Hahn L. 129
Hahn M. 60
Hallahan B. 130
Hallak J. 67
Hamaie Y. 94
Hargarter L. 117, 130
Harms L.R. 130
Haroutunian V. 33
Harris A.W. 130
Harrisberger F. 75
Harrison P. 51
Harte M.K. 117
Hartmann M. N. 86
Harvey P.D. 12, 86, 119
Hassan A. 130
Hassan S. 90
Hasson-Ohayon I. 115
Hattori K. 72
Hatzelgrove K.M. 130
Hecher L. 72
Heenan A. 115
Heinez K. 110
Hemager N. 84
Index of Presenters and Authors

4th Schizophrenia International Research Society Conference
Fostering Collaboration in Schizophrenia Research

FLORENCE, ITALY
05 - 09 APRIL 2014

Hernaus D. 54
Herold C.J. 101
Herrmann A.P. 130
Hilker R. 130
Hilt D. 130
Hirnstein M. 58
Hjortsoe C. 131
Holllins S. 57
Holshausen K. 131
Homan P. 61
Honer W. 41
Hosang G. 115
Hosford D. 34
Howes O. 10, 36, 42, 44
Huang W. 88
Hughes M. 141
Hughes Z.A. 131
Hui C.L.M. 115
Humpston C. 73
Husa A. 92
Iakoucheva L.M. 83
Inta D. 42, 131
Iasevoli F. 94, 120, 131
Ihalainen J. 71
Ilzarbe D. 84
Itohanna M. 53, 116
Ivorra J.L. 131
Iwata K. 86
Jacob R. 95
Janssens M. 131
Jardri R. 54
Jensen A. 131
Jensen K.G. 118
Jensen M.H. 132
Jessen H.K. 132
Ji E. 73
Joaquim H. 97
Johnsen E. 79
Jones P.B. 53
Jørgensen K.N. 132
Joyce E. 68
Jukuri T. 99
Jung D.U. 132

Kahn R. 3, 14, 29, 32, 46, 53, 62, 69
Kääkelä J. 132
Kamboldt J. 101
Kamberts - I. 130
Kanbayashi T. 45
Kane J. 3, 15, 26, 34, 49
Kane J. M. 52, 69
Kang S.G. 132
Kapur S. 60, 68
Kasanova Z. 132
Katsura M. 84
Katthagen T. 132
Kellendonk C. 60
Kelly D. 67
Kerr D. 83
Keshavan M. 69
Keskinen E.S.J. 133
Khandaiker G. 41, 57, 107, 133
Khodaei B. 4, 104, 133
Kikuchi Y. S. 96
Kilian S. 82
Killackey E. 120
Kim E. 92
Kim J.J. 83, 143
Kim N. 84
Kim S.H. 83, 120
Kim Y. S. 97, 116
Kinnon B. 15, 49
Kircher T. 12, 60
Kirschner M. 133
Kishi T. 96
Kiss B. 71
Kjellberg E. 91
Klaassen N. 73
Knegtering H. 133
Koenig J. 31, 68

Koh M. 133
Koivukangas J. 133
Kollaiakou A. 90
Kondrup R.E. 56
Kong P.K.Y. 104
Koops S. 55
Korth C. 133
Koutsouleris N. 55
Krakauer K. 133
Krug A. 71, 101, 133
Kubota M. 101
Kukhal P. 108
Kumar J. 101
Kupper Z. 134
Kwapil T.R. 85
Labouesse M.A. 71, 97
Lally J. 90, 120, 134
Laloyaux J. 134
Lam M. 114, 134
Lam Y.H. 134
Lammers Vernal D. 77
Large C. 92
Larsen J.T. 81
Laruelle M. 59
Lässer M.M. 134
Latorre S. 134
Laurens K. 58
Lavin A. 81
Lawrie S. 36
Law E. 90, 120
Lee K. 134
Lee K.W. 134
Lee S.H. 99, 135
Lee T.Y. 110
Lee Y. 113, 135
Lee T.M. 134
Lees J. 104
Leger M. 118
Legge S. 59
Lennox B. 45
Leonhardt B. 135
Leroux E. 100, 101
Leung C.N.W. 85, 117
Leung S. 117
Levine S.Z. 107

Leweke F.M. 46, 52
Lewis A. 135
Li E.K. 135
Liem C. 55, 81
Lim K. 35
Lin A. 103
Lin IJ. 114
Lin S.H. 98
Lindgren M. 91
Linscott R.J. 79, 107, 135
Litman R.E. 92
Liu C.C. 88
Liu P.Y.T 135
Llorca B.C. 135
Lodge D. 52
Lopez L. 135
Lotfínia M. 72
Louzada-Junior P. 73
Lucic L. 94, 135
Luoni A. 118
Lyne J.P. 86, 107, 136
Lystad J.U. 104
Maat A. 75
MacBeth A.M. 92, 136
MacCabe J. 5, 32, 68
Maccardi F. 136
Mackay-Sim A. 51
Maeda T. 136
Maalbing C. 77
Mailman R. 32
Mäki P.H. 136
Malherbe P.J. 136
Malhotra A. 5, 31
Mane Santacana A. 86
Manning E.E. 97
Mantovani L.M. 105
Mäntylä T. 75
Marcelis M. 75
Marder S. 3, 5, 68
Mark W. 136
Markou A. 46
Marsh P. 136
Marsman A. 55, 100
Martínez G. 79
Martini L.C. 136
Martins-de-Souza D. 86
Maruff P. 88
Marvulli D. 74
Massuda R. 4, 137
Matsuda Y. 92
Mazzia M. 56, 112
McCann T. 103
McCarley R. 5, 12, 26, 137
McCombie D. 61
McEvoy J.P. M. 137
McGorry P. 3, 50, 67
McGrath J. 3, 5, 16, 25, 32, 43, 65
McGuire P. 4, 36, 46
McMahon F. 14, 30
McNabb C. 98
Medalia A. 88
Medema S. 112
Meijer C. 94, 114
Melau M. 95, 137
Melle I. 51
Mentzel T. 70
Merritt K.S. 74
Mervis J. 94
Metzler S. 85
Meyer U. 31
Meyer-Lindenberg A. 42, 68
Mezquida G. 86
Michalopoulou P. 103
Michel C. 81, 114, 137
Miettunen J. 81
Mikels J. 81
Miller B. J. 137
Mills J. G. 137
Mitta Raghava J. 75
Miyata J. 137
Mizrahi R. 42
Mizuno Y. 4, 71
Moghaddam B. 42, 44, 46
Mondelli V. 51
Montfort S. 137
Moore H. 14, 30, 39
Mørch-Johnsen L. 101
Morgan C. 137
Morgan VA. 5, 105
Morilak D. 52
Moriwaki M. 93
Morrison A. 50, 62
Mortensen P. 4, 16, 31, 66
Mouchlianitis E. 55
Mukai T. 118
Müller B.W. 81
Müller D. R. 77
Müller D. J. 108
Murray G. 14, 39, 68
Murray R. 16, 25, 26, 32, 40, 44, 53, 65, 66
Na E. J. 99
Najjar S. 45
Nathou C. 137
Neill E. 118, 137
Nelson B. 51
Nelson B. G. 74
Nenadic I. 5, 75, 76, 99, 138
Nesvág R. 81, 101
Newcomer J. N. 37, 138
Newell K. 86
Nielsen J. 72
Nielsen M. Ø. 54, 138
Nielsen J. 72
Nielsen O. 43
Nieman D. 50
Nilsson L. S. 138
Nordentoft M. 5, 81, 138
Nordholm D. 85
Norman R. G. M. 89, 105, 138
Novick D. 111, 138
Nucifora Jr. E. 138
Nuechterlein K. 88, 105
Nurjono M. 4, 95
Nuss P. 86, 138
Nyboe L. 91
O’Connor K. 110
O’Donnell P. 5, 32, 42
O’Donoghue B. 82
O’Gorman C. 111
O’Hanlon E. 101
Ochoa S. 138
Onyejiaka A. 139
Ondziej A. E. 93, 118
Ortuño F. 79, 139
Osman E. 118
Oya K. 118
Özsoyolu D. 109
Pandharpan J. 83
Palmer E. 105
Pani L. 35
Pankiewicz-Dulacz M. 107
Pankow A. 99
Pantelis C. 4, 67
Papmeyer M. 139
Pardo M. 85, 110, 139
Parente F. 74
Park K. 91
Park S. 105, 139
Patel M. X. 5, 12, 93, 139
Patel Rash 86
Patel Rad 121
Patterson P. 41
Paunio T. 14, 30
Pearlson G. 35
Pedersen C. B. 107
Peeters S. 99
Penalés R. 89
Penzes P. 112
Pereira F. A. 97
Perez S. M. 139
Peters E. 62
Petryshen T. 83
Picchioni M. M. 5, 54, 102
Pijnenborg G. 89, 139
Pijnenborg M. 73, 102, 114, 125
Pikalov A. 93, 118, 139
Piskulic D. 103
Poteous D. 61
Posporelis S. 74
Potkin S. 57
Pouget J. 109
Prata D. 110
Preda A. 116
Premkumar P. 87
Prinssen E. 118
Pruessner M. 76
Puig O. 85
Rabiner I. 69
Rabinowitz J. 5, 15, 34, 49
Rahman J. 117
Rajagopalan K. 83, 109
Ramsay H. 112
Ramsay I. S. 139
Rameyad A. 140
Randers L. 91
Ranlund S. 140
Rao S. 85
Rapado-Castro M. 67, 93, 140
Rapisarda A. 91
Rapp A. M. 140
Raudivo A. 56, 83
Rawat P. 120
Reattig O. 140
Reddy F. 112
Redmeier J. 140
Reeder C. 105
Reichenberg A. 5
Reichenberg A. B. 68
Reininghaus U. 140
Reis Marques T. 102
Rekhi G. 140
Reniers R. 76, 102
Reynolds G. 112
Richetto J. 118
Reicher-Rössler A. 25, 52, 80
Rinaldi R. 88
Rissanen I. 140
Rosa M. 31, 72
Roberts D. L. 77
Robinson J. 33
Roche E. 107, 141
Rodríguez-Toscano E. 141
Roffman J. 67
Rosa A. 109
Rosenbrock H. 97
Rosenheck R. 141
Rossel S. 79, 105, 141, 144
Rowland J. E. 141
Roy M. A 119
Rubino T. 44
Ruggeri M. 26
Ruhmann S. 50
Rusjes D. 18, 57
Rund B. 68
# 4th Schizophrenia International Research Society Conference

**Fostering Collaboration in Schizophrenia Research**

**FLORENCE, ITALY**

**05 - 09 APRIL 2014**

<table>
<thead>
<tr>
<th>Presenter</th>
<th>Author(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Russell B.</td>
<td>141</td>
</tr>
<tr>
<td>Sabri M.A.R.</td>
<td>105</td>
</tr>
<tr>
<td>Sadeghifard V.</td>
<td>141</td>
</tr>
<tr>
<td>Sahakian B.</td>
<td>14, 39</td>
</tr>
<tr>
<td>Salokangas R.K.R.</td>
<td>110</td>
</tr>
<tr>
<td>Salum C.</td>
<td>97</td>
</tr>
<tr>
<td>Sanchez-Gistau V.</td>
<td>110</td>
</tr>
<tr>
<td>Sanchez-Gutierrez T.</td>
<td>141</td>
</tr>
<tr>
<td>Santoro M.L.</td>
<td>83</td>
</tr>
<tr>
<td>Sanz-Fuentenebro F.I.</td>
<td>77</td>
</tr>
<tr>
<td>Saracco-Alvarez R.</td>
<td>78</td>
</tr>
<tr>
<td>Sasayama D.</td>
<td>141</td>
</tr>
<tr>
<td>Sawa A.</td>
<td>9, 31, 51</td>
</tr>
<tr>
<td>Sawada K.</td>
<td>41</td>
</tr>
<tr>
<td>Scanlon C.</td>
<td>102</td>
</tr>
<tr>
<td>Schall U.</td>
<td>117</td>
</tr>
<tr>
<td>Schaufelberger M.S.</td>
<td>102</td>
</tr>
<tr>
<td>Scheltema Beduin A.</td>
<td>119</td>
</tr>
<tr>
<td>Schimmelmann B.G.</td>
<td>37, 110</td>
</tr>
<tr>
<td>Schirmbeck F.</td>
<td>116</td>
</tr>
<tr>
<td>Schlosser D.</td>
<td>141</td>
</tr>
<tr>
<td>Schmidt A.</td>
<td>33, 75, 100, 143</td>
</tr>
<tr>
<td>Schmidt C.</td>
<td>15, 49</td>
</tr>
<tr>
<td>Schmidt S.J.</td>
<td>85</td>
</tr>
<tr>
<td>Schnack H.G.</td>
<td>76</td>
</tr>
<tr>
<td>Schobel S.</td>
<td>100</td>
</tr>
<tr>
<td>Schoeler T.</td>
<td>107</td>
</tr>
<tr>
<td>Schoeller N.</td>
<td>5, 12, 18, 58, 142</td>
</tr>
<tr>
<td>Schreiner A.</td>
<td>93, 119, 142</td>
</tr>
<tr>
<td>Schulte P.F.J.</td>
<td>89</td>
</tr>
<tr>
<td>Schuch W.</td>
<td>60</td>
</tr>
<tr>
<td>Schulz C.C.</td>
<td>102, 142</td>
</tr>
<tr>
<td>Schulze-Lutter F.</td>
<td>82, 108, 142</td>
</tr>
<tr>
<td>Schulz S.C.</td>
<td>35, 45</td>
</tr>
<tr>
<td>Sebat J.</td>
<td>14, 29, 30</td>
</tr>
<tr>
<td>Seidman L.</td>
<td>5, 68</td>
</tr>
<tr>
<td>Selten J.</td>
<td>26, 42</td>
</tr>
<tr>
<td>Selvaggi P.</td>
<td>74</td>
</tr>
<tr>
<td>Sendt K.V.</td>
<td>142</td>
</tr>
<tr>
<td>Sevilmiş Demir Ş.</td>
<td>79</td>
</tr>
<tr>
<td>Shah S.</td>
<td>59</td>
</tr>
<tr>
<td>Shakoor S.</td>
<td>142</td>
</tr>
<tr>
<td>Shannon-Weickert C.</td>
<td>3, 4, 5, 18, 36, 42, 56</td>
</tr>
<tr>
<td>Sheinbaum T.</td>
<td>4, 70, 96</td>
</tr>
<tr>
<td>Shi C.</td>
<td>78</td>
</tr>
<tr>
<td>Shivakumar V.</td>
<td>4, 142</td>
</tr>
<tr>
<td>Shuhama R.</td>
<td>143</td>
</tr>
<tr>
<td>St T.</td>
<td>4, 103, 143</td>
</tr>
<tr>
<td>Sieradzka D.</td>
<td>109</td>
</tr>
<tr>
<td>Siever L.</td>
<td>39</td>
</tr>
<tr>
<td>Silberberg C.</td>
<td>82</td>
</tr>
<tr>
<td>Simon N.</td>
<td>4, 106</td>
</tr>
<tr>
<td>Simons C.</td>
<td>79</td>
</tr>
<tr>
<td>Simonsen A.</td>
<td>79</td>
</tr>
<tr>
<td>Simpson E.</td>
<td>46, 72</td>
</tr>
<tr>
<td>Singh G.</td>
<td>119</td>
</tr>
<tr>
<td>Siu C.</td>
<td>79, 143</td>
</tr>
<tr>
<td>Smesny S.</td>
<td>74, 100</td>
</tr>
<tr>
<td>Smieskova R.</td>
<td>143</td>
</tr>
<tr>
<td>Smith M.J.</td>
<td>95</td>
</tr>
<tr>
<td>So S.H.</td>
<td>80</td>
</tr>
<tr>
<td>Soguel-dit-Piquard F.</td>
<td>85</td>
</tr>
<tr>
<td>Sohn I.</td>
<td>143</td>
</tr>
<tr>
<td>Sommer I.</td>
<td>4, 5, 36</td>
</tr>
<tr>
<td>Sommer J.</td>
<td>61</td>
</tr>
<tr>
<td>Spilka M.J.</td>
<td>100</td>
</tr>
<tr>
<td>Spitteri-Staines A.E.</td>
<td>4, 143</td>
</tr>
<tr>
<td>Squarcina L.</td>
<td>54</td>
</tr>
<tr>
<td>Stain H.</td>
<td>120</td>
</tr>
<tr>
<td>Stefani N.</td>
<td>16, 65</td>
</tr>
<tr>
<td>Steiner J.</td>
<td>33, 45</td>
</tr>
<tr>
<td>Stepiak B.</td>
<td>89</td>
</tr>
<tr>
<td>Stewart R.</td>
<td>16, 66</td>
</tr>
<tr>
<td>Stiekema A.P.M.</td>
<td>78</td>
</tr>
<tr>
<td>Stillo S.A.</td>
<td>71, 143</td>
</tr>
<tr>
<td>Strauss G.</td>
<td>100</td>
</tr>
<tr>
<td>Strik W.</td>
<td>60</td>
</tr>
<tr>
<td>Sugranyes G.</td>
<td>102</td>
</tr>
<tr>
<td>Sullivan P.</td>
<td>14, 30</td>
</tr>
<tr>
<td>Sumiyoshi C.</td>
<td>116</td>
</tr>
<tr>
<td>Sutliff S.A.</td>
<td>143</td>
</tr>
<tr>
<td>Suttajat S.</td>
<td>4, 120</td>
</tr>
<tr>
<td>Sutterland A.</td>
<td>112, 143</td>
</tr>
<tr>
<td>Suvisaari J.</td>
<td>56</td>
</tr>
<tr>
<td>Suzuki M.</td>
<td>76, 144</td>
</tr>
<tr>
<td>Swaminathan V.</td>
<td>56</td>
</tr>
<tr>
<td>Swanson J.</td>
<td>43</td>
</tr>
<tr>
<td>Swart M.</td>
<td>144</td>
</tr>
<tr>
<td>Taboada Denia D.</td>
<td>144</td>
</tr>
<tr>
<td>Takayanagi Y.</td>
<td>82</td>
</tr>
<tr>
<td>Takeuchi H.</td>
<td>93</td>
</tr>
<tr>
<td>Talib L.L.</td>
<td>97, 144</td>
</tr>
<tr>
<td>Tamagnan G.D.</td>
<td>76</td>
</tr>
<tr>
<td>Tan E.</td>
<td>88, 144</td>
</tr>
<tr>
<td>Tanoue C.</td>
<td>80</td>
</tr>
<tr>
<td>Tandon R.</td>
<td>144</td>
</tr>
<tr>
<td>Tang C.</td>
<td>93</td>
</tr>
<tr>
<td>Tarokh L.</td>
<td>144</td>
</tr>
<tr>
<td>Tenan S.H.</td>
<td>108</td>
</tr>
<tr>
<td>Térémetz M.</td>
<td>144</td>
</tr>
<tr>
<td>Tettamanti M.</td>
<td>144</td>
</tr>
<tr>
<td>Theodoridou A.</td>
<td>111</td>
</tr>
<tr>
<td>Thiabaut B.</td>
<td>80</td>
</tr>
<tr>
<td>Thompson A.</td>
<td>58</td>
</tr>
<tr>
<td>Thomson P.</td>
<td>61</td>
</tr>
<tr>
<td>Thorup A.A.E.</td>
<td>111</td>
</tr>
<tr>
<td>Tofthedahl N.G.</td>
<td>95, 121</td>
</tr>
<tr>
<td>Tognin S.</td>
<td>144</td>
</tr>
<tr>
<td>Topuzoglu A.</td>
<td>144</td>
</tr>
<tr>
<td>Torgalsboen A.K.</td>
<td>90</td>
</tr>
<tr>
<td>Torti M.C.</td>
<td>145</td>
</tr>
<tr>
<td>Trifillieff P.</td>
<td>14, 39</td>
</tr>
<tr>
<td>Trizio S.</td>
<td>76</td>
</tr>
<tr>
<td>Trotta A.</td>
<td>145</td>
</tr>
<tr>
<td>Truong W.</td>
<td>76</td>
</tr>
<tr>
<td>Tseng K.</td>
<td>52</td>
</tr>
<tr>
<td>Tsjurio N.</td>
<td>100</td>
</tr>
<tr>
<td>Uhida H.</td>
<td>145</td>
</tr>
<tr>
<td>Ucok A.</td>
<td>112</td>
</tr>
<tr>
<td>Ulhais P.</td>
<td>69</td>
</tr>
<tr>
<td>Unnassasser L.</td>
<td>145</td>
</tr>
<tr>
<td>Upthegrove R.</td>
<td>33</td>
</tr>
<tr>
<td>Urano N.</td>
<td>33</td>
</tr>
<tr>
<td>Uttinger M.</td>
<td>117</td>
</tr>
<tr>
<td>van Berckel B.</td>
<td>36</td>
</tr>
<tr>
<td>van Dael F.</td>
<td>82</td>
</tr>
<tr>
<td>van den Heuvel M.</td>
<td>55</td>
</tr>
<tr>
<td>van der Doef T.</td>
<td>145</td>
</tr>
<tr>
<td>van der Gaag M.</td>
<td>50, 69</td>
</tr>
<tr>
<td>van der Leeuw C.</td>
<td>145</td>
</tr>
<tr>
<td>van Os J.</td>
<td>4, 12, 25, 26, 40, 60, 66</td>
</tr>
<tr>
<td>van Tol M.J.</td>
<td>102</td>
</tr>
<tr>
<td>van Harten P.</td>
<td>145</td>
</tr>
<tr>
<td>van Hasselt F.M.</td>
<td>95</td>
</tr>
<tr>
<td>van Lutterveld R.</td>
<td>61</td>
</tr>
<tr>
<td>van Nieker M.</td>
<td>59</td>
</tr>
<tr>
<td>van Vledder J.</td>
<td>4, 12, 16, 25, 26, 40, 60, 66</td>
</tr>
<tr>
<td>Vaskinn A.</td>
<td>145</td>
</tr>
<tr>
<td>Veiljola J.</td>
<td>58</td>
</tr>
<tr>
<td>Velings W.</td>
<td>146</td>
</tr>
<tr>
<td>Velthorst E.</td>
<td>80</td>
</tr>
<tr>
<td>Venture J.</td>
<td>80, 105, 112, 146</td>
</tr>
<tr>
<td>Vernon A.</td>
<td>60</td>
</tr>
<tr>
<td>Vialou V.</td>
<td>42</td>
</tr>
<tr>
<td>Vink M.</td>
<td>103</td>
</tr>
<tr>
<td>Vinogradov S.</td>
<td>5, 18, 31, 41</td>
</tr>
<tr>
<td>Visconti G.</td>
<td>100</td>
</tr>
<tr>
<td>Vital E.</td>
<td>146</td>
</tr>
<tr>
<td>Vogel S.J.</td>
<td>146</td>
</tr>
<tr>
<td>Voineskos A.</td>
<td>31</td>
</tr>
<tr>
<td>von Salderen S.</td>
<td>146</td>
</tr>
<tr>
<td>Vorstman J.</td>
<td>62</td>
</tr>
<tr>
<td>Vreeker A.</td>
<td>80</td>
</tr>
<tr>
<td>Waddington J.</td>
<td>4, 12, 32</td>
</tr>
<tr>
<td>Wadehra S.</td>
<td>4, 146</td>
</tr>
<tr>
<td>Walters J.</td>
<td>57</td>
</tr>
<tr>
<td>Walther S.</td>
<td>114</td>
</tr>
<tr>
<td>Walton E.</td>
<td>146</td>
</tr>
<tr>
<td>Wang M.</td>
<td>90</td>
</tr>
<tr>
<td>Wang Y.</td>
<td>4, 77</td>
</tr>
<tr>
<td>Ward M.K.</td>
<td>74</td>
</tr>
<tr>
<td>Ward PB.</td>
<td>146</td>
</tr>
<tr>
<td>Wärdig R.E.</td>
<td>146</td>
</tr>
<tr>
<td>Waterreus A.</td>
<td>146</td>
</tr>
<tr>
<td>Webster M.</td>
<td>56</td>
</tr>
<tr>
<td>Wehler C.</td>
<td>147</td>
</tr>
<tr>
<td>Wieckert C.S.</td>
<td>3, 5, 18, 36, 42, 56</td>
</tr>
<tr>
<td>Wieckert T.</td>
<td>5, 58, 73</td>
</tr>
<tr>
<td>Weiser M.</td>
<td>4, 5, 53, 67</td>
</tr>
<tr>
<td>Wennogle L.P.</td>
<td>87</td>
</tr>
<tr>
<td>Werbeloff N.</td>
<td>57, 82</td>
</tr>
<tr>
<td>Wenning T.</td>
<td>146</td>
</tr>
<tr>
<td>Widschwendter C.</td>
<td>147</td>
</tr>
<tr>
<td>Wigman J.</td>
<td>77, 116</td>
</tr>
<tr>
<td>Name</td>
<td>Page Numbers</td>
</tr>
<tr>
<td>------------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Wigton R.</td>
<td>4, 147</td>
</tr>
<tr>
<td>Willems A.</td>
<td>91</td>
</tr>
<tr>
<td>Williams J.B.W.</td>
<td>69, 103</td>
</tr>
<tr>
<td>Williams K.C.</td>
<td>106</td>
</tr>
<tr>
<td>Wimberley T.</td>
<td>93</td>
</tr>
<tr>
<td>Witten L.M.</td>
<td>87</td>
</tr>
<tr>
<td>Won S.</td>
<td>80</td>
</tr>
<tr>
<td>Woo T. U.</td>
<td>87, 113, 147</td>
</tr>
<tr>
<td>Wotrub A. D.</td>
<td>111</td>
</tr>
<tr>
<td>Wright S.</td>
<td>74</td>
</tr>
<tr>
<td>Wu C.</td>
<td>80</td>
</tr>
<tr>
<td>Wu J.</td>
<td>105</td>
</tr>
<tr>
<td>Wunderink L.</td>
<td>59</td>
</tr>
<tr>
<td>Wykes T.</td>
<td>3, 4, 62</td>
</tr>
<tr>
<td>Wyss T.A.</td>
<td>147</td>
</tr>
<tr>
<td>Xiao L.</td>
<td>33</td>
</tr>
<tr>
<td>Xue J.</td>
<td>117</td>
</tr>
<tr>
<td>Yagoda S.</td>
<td>4, 106</td>
</tr>
<tr>
<td>Yakovenko I.</td>
<td>95</td>
</tr>
<tr>
<td>Yalcin-Siedentopf N.</td>
<td>94</td>
</tr>
<tr>
<td>Yan C.</td>
<td>86</td>
</tr>
<tr>
<td>Yolken R.</td>
<td>36, 41</td>
</tr>
<tr>
<td>Yoon W.</td>
<td>147</td>
</tr>
<tr>
<td>Yoshida K.</td>
<td>147</td>
</tr>
<tr>
<td>Young J.</td>
<td>46</td>
</tr>
<tr>
<td>Yu A.</td>
<td>34</td>
</tr>
<tr>
<td>Yu X.</td>
<td>3</td>
</tr>
<tr>
<td>Yuan Y.</td>
<td>103</td>
</tr>
<tr>
<td>Yuen S.</td>
<td>111</td>
</tr>
<tr>
<td>Yun J. Y.</td>
<td>85</td>
</tr>
<tr>
<td>Yung A.</td>
<td>3</td>
</tr>
<tr>
<td>Zarogianni E.</td>
<td>111</td>
</tr>
<tr>
<td>Zaytseva Y.</td>
<td>4, 113</td>
</tr>
<tr>
<td>Zhang L.W.</td>
<td>74</td>
</tr>
<tr>
<td>Zimmerman E.</td>
<td>72</td>
</tr>
<tr>
<td>Zipursky R.</td>
<td>5, 18, 45, 59</td>
</tr>
<tr>
<td>Zugman A.</td>
<td>147</td>
</tr>
</tbody>
</table>
Schizophrenia
International Research Society Conference